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ABSTRACT 
Cannabinoids cause both acute and time-dependent 
vasodilation!vasorelaxation in a range of vascular beds. The vascular 
effect of cannabinoids is dependent on the cannabinoid ligand, the 
species studied and the vascular bed used. To date, there have been 
four studies that have characterised the effects of cannabinoids in 
humans. Therefore, the aim of this thesis was to characterise the 
pharmacological effects of cannabinoids in the human mesenteric 
artery. 
Written Informed consent was granted for the use of mesenteric 
arteries collected from patients at the Royal Derby Hospital. Arteries 
were dissected from mesenteric tissue and mounted on a Mulvany-
Halpern myograph. Arteries were contracted using U46619 and 
endothelin-l. Concentration-response curves were carried out to the 
phytocannabinoids THC and CBD; the endocannabinoids AEA and 2-AG; 
the synthetic cannabinolds CP55,940 and HU-30S. The underlying 
mechanisms of action were assessed using receptor antagonism, 
enzyme inhibition, endothelium denudation and ion channel 
manipulation. Experiments to probe the potential for cannabinoids to 
cause time-dependent vasorelaxation of human mesenteric arteries 
were also carried out. Post-hoc analysis was conducted on all acute 
vasorelaxation responses to assess the potential influence of patient 
characteristics/disease state on cannabinoid responses. 
All cannabinoids tested, with the exception of HU-30S, caused 
concentration-dependent vasorelaxation of human mesenteric arteries. 
The synthetic cannabinoid CP55,940 had the greatest Rmax of all the 
cannabinoids tested. 2-AG had the greatest Rmax of the 
endocannabinolds tested and CBO had the greatest Rmax of the 
phytocannablnolds tested. Compared to animal models, cannabinoid 
efficacy was reduced in human mesenteric arteries. The vasorelaxant 
effects of 2-AG were mediated through COX-l metabolism, prostanoid 
receptor activation (EP4 and IP) and Ion channel modulation. The 
mechanisms underpinning CBD-induced vasorelaxation were CB l and 
TRPVl receptor activation, NO release, the endothelium and ion 
channel modulation. Vasorelaxant responses to AEA were inhibited by 
antagonism of the CB l receptor and a putative cannabinoid receptor 
located on the endothelium (CBe), nitriC oxide synthase inhibition and 
endothelium denudation. Cannabinoid responses were reduced in 
patients with cardiovascular diseases/disease risk factors Including 
Ischaemic heart disease, type-2 diabetes and hypercholesterolemia. 
Endocannabinoid responses were reduced In patients taking NSAID 
medication, with some reductions in responses seen to other 
medication Including statlns and beta-blockers. CBD and AEA were 
tested for time-dependent vasorelaxation. Both CBD and AEA were able 
to cause vasorelaxatlon that gradually increased over time, this was 
not mediated by the PPARy receptor. 
This thesis concludes that cannabinoids are able to modulate 
vascular tone In Isolated human mesenteric arteries, and this may be 
blunted In patients with cardiovascular disease. Furthermore, this 
thesis presents data suggesting that differences exist between human 
and animal arterial responses to cannabinolds. 
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1. INTRODUCTION 
1.1. Cannabinoid Ligands and Receptors 
The therapeutic history of Cannabis sativa is well reviewed by Zuardi 
(2006). In brief, since the BC era, cannabis has been used as a 
medicinal plant treating pain, constipation, malaria, convulsions and 
inflammation (Zuardi 2006). For several years, it was thought that the 
chemical constituents of Cannabis sativa (cannabinoids) caused their 
effects through non-specific actions on the body (Lawrence and Gill 
1975). However, breakthroughs In cannabinoid pharmacology started 
to occur as early as 1930 (see Pertwee 2006 for review). The most 
notable discoveries being the isolation and stereochemistry of the 
plant-derived cannabinold l\9-THC (Gaoni and Mechoulam 1964) and 
the isolation of the Internally synthesised cannabinoid 
(endocannabinoid), N-arachldonoylethanolamine (anandamide, AEA) 
(Devane et al., 1992). Alongside this, two seven transmembrane 
G protein-coupled receptors (GPCRs) with cannabinoid specificity have 
been discovered and fully characterised. The cannabinoid receptor one 
(CB l ) was first cloned in 1990 and the cannabinoid receptor two (CB2) 
was cloned In 1993 (see Pertwee 2006). CBl receptors are present in 
the central nervous system and a range of peripheral tissues, while CB2 
expression is seen in a variety of immune cells and under some 
conditions In neurons (reviewed in Mackie 2008). To date, over 60 
cannabinoid ligands have been isolated from the cannabis plant and 
there have been many endogenous cannabinoids or cannabinoid-like 
mediators discovered. There Is also speculation of the existence of as 
yet uncharacterised receptors or subtypes of existing cannabinoid 
receptors. 
1.1.1. Cannablnold Ligands 
A summary of cannabinold ligands In order of their affinity for CB l and 
CB2 receptors and cannablnoid chemical structures can be seen In table 
1.1 and figure 1.1 respectively. 
Phytocannabinoids and Synthetic Cannabinoids 
Plant-derived cannabinoids (phytocannabinoids) and synthetic 
cannablnoids are divided Into several groups based on their chemical 
structures, these Include; classical, non-classical, aminoalkylindoles, 
diarylpyrazoles (for review see Howlett et al., 2002; Pertwee 2005) and 
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bicyclic sesquiterpene compounds that are part of the essential oil 
groups found in cannabis sativa (Gertsch et aI., 2008). Classical 
phytocannabinoids such as f19-THC and cannabidiol (CBO) are 
ABC-terpenoid compounds with a functional benzopyran group. 
Non-classical cannabinoids such as CP55,940 and HU-308 (both 
synthetic ligands) are either AO-bicyclic or ACO-tricyclic compounds 
that lack the pyran Bring. Aminoalkylindole cannabinoids are 
structurally very different to all other groups of cannabinoids and 
include the synthetic compounds WIN55,212-2 and AM630 (CB2 
antagonists/inverse agonist). AM251, rimonabant and SR144528 are 
part of the diarylpyrazole family of cannabinoids and are classified as 
cannabinoid antagonists/inverse agonists due to their reported ability 
to inhibit endocannabinoid tone or produce effects inverse to 
cannabinoid receptor agonists (Howlett et al., 2002; Pertwee 2005). 
The bicyclic sesquiterpene group of cannabinoids Include a-humulene 
and (E)-(3-caryophyllene «(3-CP) or its isomers (Gertsch et al., 2008). 
a-humulene has been shown to be void of CB l and CB2 activity, whilst 
(3-CP is considered a natural agonist at the CB2 receptor (Gertsch et al., 
2008). 
Several pharmacophores have been identified in determining 
cannabinoid ligand affinity for cannabinoid receptors. For example, 
alterations in the C-3 lipophilic alkyl side chain (Huffman et al., 2003), 
the northern aliphatiC hydroxyl group (Mechoulam et al., 1988) and the 
phenolic hydroxyl group (Huffman et al., 2002) are all capable of 
altering classical and non-claSSical cannabinoid receptor affinity. 
Similarly, alterations in the Indole ring of the aminoalkylindole group 
have been shown to affect cannabinoid receptor specificity of AM630 
(Pertwee et al., 1995), and the N-l and C-5 substituent of the 
diarylpyrazoles, rimonabant and AM251 (both CBl receptor 
antagonists/inverse agonists), are. integral to their ability to bind to 
cannabinoid receptors (Lan et al., 1999). 
Cannabinold ligand affinity and efficacy at cannabinoid receptors 
has been reviewed In depth elsewhere (Pertwee 2005; Razdan 2009; 
Vemurl and Makriyannis 2009). However in brief, CP55,940 and 
WIN55,212-2 are considered full agonists at both CB l and CB2 
receptors. HU-308 Is a full agonist at CB2 receptors, whilst THC Is a 
partial agonist at both CB l and CB2 receptors and cannabidiol displays 
low affinity for both CB l and CB2 receptors. However, these findings 
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often depend on the assay or preparation used, for example in some 
preparations, ~ 9 - T H C , , CBO and ~ 9 - t e t r a h y d r o c a n n a b i v a r i n n have been 
shown to have altered activity at CBl receptors depending on ligand 
concentration (reviewed by Pertwee 2008). The cannabinoid receptor 
antagonists rimonabant, SR144528, AM251 and AM630 bind to and 
antagonise cannabinoid receptors at nanomolar concentrations, whilst 
at higher concentrations they have been shown to have off target 
effects (discussed section 2.7) 
Endocannabinoids 
Since the isolation of AEA, several other endocannabinoid ligands have 
been discovered. Shortly after the isolation of AEA it was discovered 
that a known endogenous metabolite, 2-arachidonoylglycerol (2-AG), 
displayed affinity for cannabinoid receptors (Mechoulam et al., 1995; 
Sugiura et al., 1995). AEA and 2-AG are considered to be the main 
endocannabinoids, however a range of endocannabinoids or 
endocannabinoid-like ligands have been discovered, including noladin 
ether, virodhamine, N-arachidonoyl-dopamine (NAOA), 
oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) (see 
Bradshaw and Walker 2005; 01 Marzo 2009 for review). AEA and 2-AG 
are thought to be biosynthesised on demand from a series of 
phospholipid metabolic reactions (for review see Matias and Oi Marzo 
2007; Muccioli 2010). 
The synthesis of AEA requires N-arachidonoyl 
phosphatidylethanolamine (NAPE), a lipid membrane derivative, formed 
through Ca2+ -dependent and Ca2+ -Independent N-acyltransferase 
(NAT/INAT) (Astarita et al., 2008; Jin et al., 2009). NAPE is then 
hydrolysed to N-acylethanolamine through either NAPE-PLD (Wang et 
al., 2008), GP-NAE (Simon and Cravatt 2006) or a phospholipase 
C-dependent pAEA pathway (Uu et al., 2006). The major synthetic 
pathway of 2-AG Is through phospholipase C (PLC) hydrolysing 
arachidonic acid to form diacylglycerol (OAG). OAG is then hydrolysed 
via DAG lipase alpha and beta (OAGLa/p) forming 2-AG (Stella et al., 
1997; Bisogno et al., 2003). Other pathways have been shown to exist 
In the formation of 2-AG including Gq-receptor-dependent activation of 
PLCPl (Hashlmotodanl et al., 2005) and phospholipase Al leading to 
Iysophosphatldylinosltol (LysoPI) being hydrolysed by a LysoPI-specific 
PLC (Suglura et al., 1995) (Figure 2). The endocannabinoids OEA and 
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PEA are also N-acylethanolamine derivatives and therefore follow 
similar synthetic pathways as AEA (Hansen and Diep 2009). However, 
the endogenous synthesis of the cannabinoid and vanilloid receptor 
agonist NADA is speculated to involve condensation of dopamine with 
arachidonic acid (AA) (Huang et a/., 2002). 
Once formed, endocannabinoids are chemically similar to 
eicosanoids based on their four non-conjugated cis double bonds 
(Khanolkar and Makriyannis 1999). Endocannabinoids have two 
pharmacophores; a polar head region and a hydrophobic arachidonoyl 
side chain (Vemurl and Makriyannis 2009) (Figure 1). AEA and 2-AG 
levels are reported at low nM concentrations in human plasma 
(Quercioli et a/. f 2011), and have been suggested to modulate receptor 
and target site activity in an autocrine or paracrine manner (Howlett et 
a/. f 2011). 
Table 2.1. Cannabinoid ligands in order of CBdCB2 affinity 
Cannabinoid ligands CP55,940>AM251>Rimonabant>WIN55212-2>THC 
in order of affinity > A E A > 2 - A G > C B D > A M 6 3 0 > H U - 3 0 8 ~ f 3 - C P P
for CB1 receptor 
Cannabinoid ligands CP55,940>WIN55212-2>HU-308>AM630> 
in order of affinity THC>AEA>f3-CP>Rimonabant>2-AG>AM251>CBD 
for CB2 receptor 
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Figure 2.1. Cannabinoid chemical structures 
Chemical structures of classical cannabinoids (THC and CBO), 
non-classical cannabinoids (CPSS,940 and HU-308), aminoalkylindoles 
(WIN55,212-2 and AM630), diarylpyrazoles (Rimonabant and AM251), 
two endogenous cannablnoids (AEA and 2-AG) and a bicyclic 
sesqulterpene (J3-CP). Chemical structure taken from www.Tocris.com 
and www.sigmaaldrlch.com. 
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Figure 2.2. Endocannabinoid synthesis. 
AEA (a) and 2-AG (b) synthetic pathways adapted from Muccioli 
(2010). PC, phosphatidylcholine; Iyso-PLC, 
Iysophosphatidylinositol-selective phospholipase C; PE, 
phosphatidylethanolamine; NAT, N-acyltransferase; NAPE, 
N-arachidonoyl phosphatidylethanolamine; sPLA2, secreted 
phospholipase A2; pLC, phospholipase C; NAPE-PLO, 
N-acylphosphatidylethanolamine-selective phospholipase 0; Iyso-NAPE, 
Iysophosphatidyl-NAPE; pNAE, phospho-NAE; NAE, 
N- acylethanolamine; OAG, diacylglycerol; PA, phosphatidic acid; PI, 
phosphatidylinositol; PLA1, phospholipase A1; PTPN22, phosphatase 
protein tyrosine phosphatase 22. 
1.1.2. Cannabinoid Metabolism 
Metabolism of phytocannablnoids has primarily focused on the 
metabolism of the three main constituents of cannabis, THC, 
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cannabinol (CBN) and CBD. These compounds are primarily 
metabolised in the liver via the cytochrome P450 family of enzymes 
(Yamamoto et al., 1995; Watanabe et al., 2007). Other sites of 
metabolism have also been reported including the intestine, brain and 
lung (for review see Pertwee and Huestis 2005). The effect of phase 
one metabolism on THC, but not other phytocannabinoids, has been 
well studied. THC undergoes phase one metabolism to produce several 
metabolites, the main being an ll-hydroxy derivative of THC 
(ll-OH-THC) (Glaz-Sandberg et al., 2007; Ferreiros et al., 2013). 
ll-OH-THC retains pyschoactivity but Is oxldised to 
11-nor-Ll9-carboxy-tetrahydrocannabinol, a non-psychoactive 
cannabinoid metabolite, and then undergoes phase two metabolism 
(Glaz-Sandberg et al., 2007). However, the systemic effect of 
phytocannabinoid metabolites remains to be studied. 
Intracellularly, AEA is rapidly degraded by the enzyme fatty acid 
amide hydrolase (FAAH) (Deutsch and Chin 1993; Cravatt et al., 1996). 
AEA (and other NEA-derived endocannabinoids) are raised 15- fold in 
FAAH knockouts compared to wild type controls (Cravatt et al., 2001), 
suggesting FAAH as a primary enzyme involved in AEA (and potentially 
other NEA-derived endocannabinolds) metabolism. A second FAAH, 
FAAH-2 has also been identified in cystolic lipid droplets with a similar 
catalytic ability to that of FAAH (Wei et al., 2006; Kaczocha et al., 
2010). Other pathways for the degradation of NEAs have also been 
shown through N-acylethanolamine-hydrolysing acid amidase (NAAA) 
(Tsubol et al., 2005), however this pathway is pH-dependent and may 
be more important in the metabolism of other endocannabinoids 
(Ueda et al., 2010). In all the aforementioned pathways, metabolism of 
AEA ultimately leads to the production of arachidonic acid and 
subsequent metabolism through cyclooxygenase (COX), lipoxygenase 
(LOX) or cytochrome P450 (CYP450). However, direct metabolism of 
AEA through these pathways has also been reported to form 
prostamides, hydroxyeicosatetraenoic (HETE-ethanolamides) and 
epoxyelcosatrienoic (EET -ethanolamides) acid-ethanolamides 
(Bornheim et al., 1995; Ueda et al., 1995; Yu et al., 1997; Snider et 
al., 2007). 
Monoacylglycerol lipase (MAGL) was first suggested to be 
Involved In 2-AG metabolism by Goparaju et al., (1998). This was later 
confirmed when increases In 2-AG were seen when the genes that code 
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for MAGL were silenced, confirming MAGL as the primary pathway for 
degradation of 2-AG (Dinh et al., 2004). However, there is also a role 
for FAAH metabolism of 2-AG. In cells, Di Marzo et al. (1998) have 
shown, that 2-AG metabolism can be inhibited by 
methylarachidonylfluorophosphonate (MAFP) and AEA suggesting 
competition for the same enzyme. In the rodent brain, it has also been 
shown that a-f3-hydrolase domain 6 (ABHD6) and a-f3-hydrolase 
domain 12 (ABHD12) are responsible for a small proportion of 2-AG 
degradation (Blankman et al., 2007). There is potential for ABHD6 and 
ABHD12 enzymes to playa role in 2-AG degradation in the periphery, 
however as yet the research focus Is centred upon their role In brain 
tissue (Savinainen et al., 2012). Metabolism of 2-AG through the 
aforementioned pathways liberates arachidonic acid and glycerol, of 
which the arachidonic acid is subsequently metabolised by COX, LOX or 
CYP450. However, as with AEA, 2-AG can also be directly metabolised 
through these pathways to produce prostanoids glycerol esters, 
HETE-glycerol esters and EET-glycerol esters (Kozak et al., 2002; 
Awumey et al., 2008). 
1.1.3. Cannabinoid Target Sites 
Cannabinoid Receptors (CB1) 
CB l receptors are GPCRs that predominantly signal through GI/o protein 
coupling and subsequent inhibition of adenyl ate cyclase (Howlett and 
Fleming 1984; Howlett et al., 1986), cyclic adenosine monophosphate 
(cAMP) (Felder et al., 1995), protein kinase A (PKA) (Hampson et al., 
1995), Ca 2+ influx through L-, N-, P/Q-, T- and R-type voltage-sensitive 
channels (Caulfield and Brown 1992; Mackie and Hille 1992; Mackie et 
al., 1995; Ross et al., 2008) and intracellular calcium release from 
ryanodine receptors (RyR) (Zhuang et al., 2005). Stimulatory effects 
through CB l Gilo can also be seen to include membrane 
hyperpolarisations through potassium channel opening (Deadwyler et 
al., 1995; Hampson et al., 1995; McAllister et al., 1999) and activation 
of the mitogen-activated protein kinase (MAPK)/extracellular regulated 
kinase (ERK) pathway through a range of Intracellular actions 
(Bouaboula et al., 1995; Galve-Roperh et al., 2002; Davis et al., 2003; 
Derkinderen et al., 2003). However, under some circumstances, such 
as in the presence of the dopamine D2 receptor, the CB l receptor can 
couple to Gs proteins to stimulate cAMP production (Glass and Felder 
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1997). Also, WIN55212-2 activation of the CB1 receptor has been 
shown to increase intracellular calcium through Gq/ ll, coupling 
(Lauckner et al., 2005). 
CB1 receptors are found in high concentrations in various brain 
tissues including interneurons, pre-terminal axonal segment and the 
axons themselves (reviewed Mackie 2008). CB1 receptors have also be 
shown to be expressed in the periphery including in adipocytes, liver, 
pancreas, skeletal muscles (reviewed Mackie 2008) and In human 
smooth muscle and endothelial cells (Sugiura et al., 1998; Llu et al., 
2000). 
Cannabinoid Receptors (CB2) 
CB2 receptors are also GPCRs which are negatively coupled to cAMP 
through GI/a proteins and inhibition of adenylate cyclase (Felder et al., 
1995). Also, inhibition of tumour necrosis factor (TNF), Nuclear 
Factor-KB (NF-KF) and ras homolog family member A (RhoA) pathways 
have been observed (Rajesh et al., 2007; Rajesh et al., 2008). The CB2 
receptor has stimulatory actions on MAPK, protein kinase B (PKB), 
protein kinase C (PKC), phosphoinositide 3-kinase (PI3K), Raf-l/Erk 
and Krox 24 (Bouaboula et al., 1996; Sanchez et al., 2003). The CB2 
receptor is not coupled to Gs subunits (Glass and Felder 1997), 
phospholipase A2, C or D, calcium (Q-type and lea) or 
G protein-coupled Inward rectifying potassium (GIRK) channels (Felder 
et al., 1995). However, In endothelial cells, CB2 antagonism attenuates 
Increased PLC-mediated mobilisation of intracellular Ca2+ (Zoratti et al., 
2003). CB2 receptors have been shown to be expressed predominantly 
in Immune cells (reviewed Mackie 2008), in some neurons (reviewed 
Atwood and Mackie 2010) and In vascular smooth muscle and 
endothelial cells (Rajesh et al., 2007; Rajesh et al., 2008) 
Putative Cannabinoid Receptor Located on the Endothelium (CBe) 
There Is also evidence Implicating a role for a PTX sensitive non-CB1 0r 
CB2 receptor in the cardiovascular system (Jaral et al., 1999). Reported 
agonlsts include AEA, methanandamide (synthetic stable analogue of 
AEA) and Abn-CBD. There has been one reported antagonist at this 
receptor (0-1918). However, little is known about this receptor and the 
evidence for its existence will be discussed in section 1.3. 
G Protein-coupled Receptors Proposed to be Cannabinoid Receptors 
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GPR55 is an orphan G protein-coupled receptor widely expressed In 
human tissues including brain, spleen, adipose and several endothelial 
cell lines (Godlewski et al., 2009). GPR55 was first cloned in 1999 
(Sawzdargo et al., 1999), and since then, several studies have debated 
whether various cannabinoid ligands bind to and activate GPR55. 
Ryberg et al. (2007) showed, in GPR55-transfected human embryonic 
kidney (HEK) cells, that 2-AG, CP55,940, THC, AM251 and PEA were 
able to stimulate GTPyS binding. Lauckner et al., (2008), also observed 
THC, JWH-01S, AEA and methanandamide activated GPRSS in 
GPR55-transfected HEK cells. Finally, in endothelial cell lines 
transfected with GPRSS, AEA and methanandamide increase calcium 
signalling (Waldeck-Weiermair et al., 2008). However, contention 
exists as WIN55,212-2, CP5S,940, 2-AG, virodhamine and Abn-CBD 
were not observed to bind to GPRSS-transfected HEK cells by Lauckner 
et al. (2008). A further study in GPRSS-transfected HEK cells revealed 
that although AEA and 2-AG were not able to stimulate calcium 
signalling, AM2S1 stimulated calcium signalling and CP55,940 
competitively antagonised L-a-Iyso-phosphatidylinositol (LPI) induced 
calcium signalling (Henstridge et al., 2009). 
GPRSS Is not coupled to Gi/a proteins, instead strong evidence 
points towards either Ga13 (Ryberg et al., 2007; Henstridge et al., 2009) 
or Gq (Lauckner et al., 2008; Waldeck-Weiermair et al., 2008) coupling. 
Activation of this receptor releases intracellular calcium from 
Intracellular stores Involving RhoA kinase and PLC, ultimately having 
nuclear affects through ERK 1/2 and/or nuclear factor of activated T 
cells (NFAT) (Ryberg et al., 2007; Lauckner et al., 2008; Waldeck-
Weiermair et al., 2008; Henstridge et al., 2009). GPRSS has also been 
reported to Inhibit potassium M type current, with this effect speculated 
to be through activation of Gq receptor coupling (Lauckner et al., 
2008). 
It is now widely accepted that the main endogenous agonist of 
GPRSS is LPI and that synthetic cannabinolds cause greater activation 
of GPRSS than that of endogenous cannabinoids (Henstridge 2012). 
Some studies also suggest that cannabinolds may act as allosteric 
modulators of GPRS5 (Anavi-Goffer et al., 2012) or that heteromers 
may form between GPR5S and cannabinold receptors (Kargl et al., 
2012). Interestingly, it has also been reported that GPR55 signalling 
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may be inhibited by CB l signal transduction (Waldeck-Weiermair et al., 
2008). 
GPR119 was first Identified using bioinformatics (Fredriksson et 
al., 2003). Human expression of GPR119 is predominantly in pancreatic 
and Intestinal tissues (Soga et al., 2005). Yeast cells transfected with 
human GPR119 have shown that oleoylethanolamide, 
palmitoylethanolamide, stearoylethanolamide and AEA bind to GPR119 
(Overton et al., 2006). However, the synthetic cannabinoids CP55,940, 
WIN 55,212-2, methanandamide and JWH-133 have shown no affinity 
to the receptor. Overexpression of the receptor in HEK cells has been 
associated with Increased levels of cAMP through Gs proteins (Chu et 
al., 2008). There is evidence for modulation of ATP sensitive potassium 
(KATP) channels and voltage-dependent Ca2+ channels in 
GPR119-mediated Insulin release (Ning et al., 2008). 
GPR18 Is predominantly expressed in the spleen, thymus and 
peripheral lymphocytes (Gantz et al., 1997; Kohno et al., 2006). 
Recent work conducted In the Bradshaw laboratory has shown that 
N-arachidonoyl glycine, AEA, THe and Abn-CBD are able to activate 
MAPK through this receptor (McHugh et al., 2012). Also, not only are 
AEA, THC and Abn-CBO agonists at this receptor but their responses 
can be inhibited using PTX, AM251 and CBO, a profile that would fit 
that of the putative CBe receptor (McHugh et al., 2012). However, as 
yet there are no studies to show the presence of GPR18 In any vascular 
bed. 
Other Receptor Sites (TRP channels) 
Transient receptor potential channels are a superfamily of six, 
six-trans-membrane cation channels; the canonical (TRPC), vanilloid 
(TRPV), melastatln (TRPM), ankyrin (TRPA), mucolipln (TRPML) and 
polycystln (TRPP) families. However, little is known about endogenous 
activators of these channels (Wu et al., 2010). A range of 
cannabinoids, Including phytocannabinolds and endocannabinoids, have 
been shown to bind to TRPV1, TRPV2, TRPM8 and TRPA8 (Pertwee et 
al., 2010). 
TRPV1 channels are activated by a range of stimuli including 
heat (>43°C), low pH and vanillold compounds such as capsaicin 
(found In hot chilli peppers) and capslnate (found in bell peppers) (Wu 
et al., 2010). Activation of TRPV1 by capsaicin Involves binding to 
22 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
TMH 2-3 (Jordt and Julius 2002). AEA has been shown to bind to this 
receptor in the same manner as capsaicin (Zygmunt et al., 1999; De 
Petrocellis et al., 2001). However, there is evidence to suggest that 
AEA binding to the TRPVl receptor requires facilitated transport across 
the cell membrane (De Petrocellis et al., 2001). Endocannabinoids, 
including AEA and NADA, and other endogenous lipids including some 
AA metabolites have affinity for the TRPVl receptor (De Petrocellis and 
DI Marzo 2005). The phytocannabinoids THC, cannabinol (CBN), CBD 
(Bisogno et al., 2001; Zygmunt et al., 2002), cannabigerol (CBG), 
cannabigerovarin (CBGV), Ll9-tetrahydrocannabivarin (THCV) (De 
Petrocellis et al., 2011) and synthetic AEA analogues (Di Marzo et al., 
2001) have also been shown to activate the TRPVl receptor. However, 
WIN55,212-2 is reported to have varying effects at TRPVl (Evans et 
al., 2007). 
Phosphorylation caused by PKC, PKA (Premkumar and Ahern 
2000; Bhave et al., 2002; Mohapatra and Nau 2005) and 
calmodulin-dependent kinase II (Jung et al., 2004) Increases the 
sensitivity of TRPVl. The receptor is desensitised by Ca2+ -dependent 
protein phosphatase 2B (Jung et al., 2004; Mohapatra and Nau 2005) 
and inhibited by phosphatidyl-inositol-bis phosphate (PIP2) (Chuang et 
al., 2001). Furthermore, activation of CB l receptors and subsequent 
CB l Intracellular signalling affects TRPVl sensitivity (De Petrocellis et 
al., 2001; Hermann et al., 2003). Activation of TRPVl channels 
increases intracellular calcium (Wu et al., 2010) and has been linked to 
the release of transmitters such as substance P (Vass et al., 2004), 
acetylcholine (ACh) (Geber et al., 2006) and calcitonin gene-related 
peptide (CGRP) (Zygmunt et al., 1999). 
TRPV2 channels are Similar to TRPVl channels in that they are 
activated by noxious heat (>53°C) and permeable to calcium (Wu et 
al., 2010). At present, there is limited research conducted on the ability 
of cannabinoids to activate TRPV2. However, in TRPV2-transfected 
HEK293 cells, a range of phytocannabinoids and synthetic cannabinoids 
has been shown to mobilise calcium currents (Qin et al., 2008). Further 
experiments revealed that CBD and CBN also caused calcium influx in 
TRPV2-transfected HEK293 cells using patch clamp techniques and 
stimulated the release of CGRP release from rat dorsal root ganglia 
neurons (Qin et al., 2008). 
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TRPM8 channels are permeable to calcium and function 
predominantly as cold sensors and In arterial smooth muscles TRPM8 
channels regulate vascular tone (Wu et al., 2010). A range of 
phytocannabinoids, cannabinoid botanical drug substances and 
endocannabinoids including CBO, CBG, THC, AEA and NAOA antagonise 
TRPM8-mediated calcium influx in TRPM8-overexpressing HEK293 cells 
(De Petrocellis et al., 2007; De Petrocellis et al., 2008; De Petrocellis et 
al., 2011). Further research into the effects of cannabinoids at this 
receptor Is limited. However, it has recently been shown that the 
botanical drug CBO reduces the size of prostate cancer xenograft 
tumours In mice, and that CBO causes apoptosis of prostate cancer 
cells lines partly through antagonism of TRPMB receptors, and 
subsequent activation of pro-apoptotic pathways (De Petrocellis et al., 
2013). 
TRPAl receptors serve primarily as chemosensors and are able 
to amplify calcium signalling through activation of other channels (Wu 
et al., 2010). Activators of TRPAl channels include cinnamaldehyde 
(found in cinnamon), isothiocyanates (found in mustard oil and wasabi) 
and acrolein (found In cigarette smoke) (Wu et al., 2010). The 
phytocannabinoid THC was shown to stimulate calcium currents In 
TRPA1-overexpressing HEK293 cells (Jordt et al., 2004). Further work 
showed that WINSS,212-2 was able to stimulate calcium currents and 
desensitise TRPAl channels in TRPA1-overexpressing Chinese hamster 
ovary cells (Akoplan et al., 2008). This work was further supported by 
the finding that WINSS,212-2 was unable to cause desensitisation in 
TRPAl neurons that were knocked down by siRNA (Akopian et al., 
2008). Recent work has shown that antinociceptive effects of CBO In 
mouse-tail were Inhibited In part by TRPAl antagonism (Maione et al., 
2011). Similarly, intrathecal injection of the phytocannabinoid 
Ll9-tetrahydrocannabiorcol causes antinoclception In wild type mice that 
Is lost In TPA1-/- mice (Andersson et al., 2011). 
PPAR Receptors 
Peroxisome prollferator-actlvated receptors (PPAR) receptors have 
been well reviewed in Bishop-Bailey (2000). In brief they are nuclear 
receptors that consist of three main Isoforms: a, y and 15. PPARa Is 
highly expressed In heart, liver, kidney and skeletal muscle. PPARy has 
high levels of expression In heart, spleen, kidney, Intestine, adrenal 
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tissue and skeletal muscle. P P A R ~ ~ is well expressed in the lung, kidney 
and brain. PPARs form heterodimers with the retinoid X receptor, 
leading to gene regulation and transcription at PPAR response elements 
(reviewed in Bishop-Bailey 2000). Cannabinoid binding to PPAR 
receptors has been associated with conformational changes of nuclear 
receptors, aiding in transcriptional activation (reviewed by O'Sullivan 
2007). A range of cannabinoids have been shown to activate PPAR 
receptors including AEA, 2-AG, OEA, PEA, THC, CBD, WIN55,212-2 and 
cannabinoid metabolites (reviewed in O'Sullivan 2007; Pertwee et al., 
2010). 
OEA mediates activation of gene transcription by PPARa 
receptors leading to lipolysis through increased expression of fatty acid 
binding protein and fatty acid translocase (Guzman et al., 2004). Since 
that study, other cannabinoids have been shown to activate PPARa 
receptors including THC, OEA, virodhamine, AEA, WIN55,212-2 and 
noladin ether in HeLa cells transfected with mPPARa-PPAR response 
element (reviewed in Sun et al., 2006). OEA, through inhibition of 
NF-kB, reduces Infarct size in a mouse cerebral artery occlusion 
ischaemia reperfusion model in mice expressing PPARa but is 
ineffective in PPARa-l - mice (Sun et al., 2007). It has also been shown 
that, partly through PPARa, PEA reduces the inflammatory effects 
associated with l3-amyloid (AI3) plaque formation on rat astrocytes 
(Scuderi et al., 2011). However, in a manner unrelated to changes In 
inflammatory markers PPARa antagonism inhibits the time-dependent 
vasorelaxant effects of AEA and PEA in bovine ophthalmic arteries 
(Romano and Lograno 2012). Further experiments revealed that the 
vasorelaxant effects of AEA and PEA were inhibited by NOS and BKca 
channel inhibitors, suggesting that, through PPARa activation, AEA and 
PEA increased NO and BKca channel activation (Romano and Lograno 
2012). 
In the rat aorta, THC causes time-dependent vasorelaxation that 
is associated with increased superoxide dismutase and inhibited by 
antagonism of the PPARy receptor (O'Sullivan et al., 2005). THC was 
also shown to bind to PPARy receptors in PPARy overexpressing 
HEK293 cells, and that THC stimulated adipocyte differentiation in 
3T3Ll fibroblast cells in a manner comparable to that of the PPARy 
agonist rosiglitazone (O'Sullivan et al., 2005). Similarly, work by 
Bouaboula et al. (2005) reported that AEA was also able to bind and 
25 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
activate PPARy in a range of cells that had been transfected with this 
receptor. This study went on to show that AEA was also able to 
stimulate adipocyte differentiation in 3T3Ll fibroblast cells associated 
with increased expression of aP2, C-EBPa, Acrp30 and lipoprotein lipase 
(Bouaboula et al., 2005). The endocannabinoids 2-AG and 2-AG ether 
also activate PPARy. In human Jurkat T cell lines transfected with 
PPARy, 2-AG and 2-AG ether inhibit Interleukin-2 secretion (Rockwell et 
al., 2006). Recently, it has been shown that the endocannabinoid 
oleamide was able to displace fluorescent ligands from PPARo, PPAR13 
and PPARy receptors (Dionlsl et al., 2012). In this assay, oleamide was 
only able to fully displace the fluorescent ligand from PPARy receptors, 
however this was at a lower potency than that of the known PPARy 
ligand rosiglitazone (Dionisl et al., 2012). In an in vivo study, 
WINss,212-2 reversed A13-induced TNF-o, activated caspase 3 and 
nuclear NF-kB expression In the rat hippocampus through CB1, CB2 and 
PPARy receptors (Fakhfourl et al., 2012). 
Much less evidence exists concerning the binding of 
cannabinoids to P P A R 1 3 / ~ ~ receptors. Fu et al. (2003) reported that OEA 
binds to HeLa cells that are transfected with P P A R 1 3 / ~ ~ receptors. 
However, the authors reported that the appetite suppression effects of 
OEA were unlikely to depend on OEA activation of P P A R 1 3 / ~ ~ (Fu et al., 
2003). Further studies have shown that ajulemic acid, 2-AG 
metabolites and PEA are all without P P A R 1 3 / ~ ~ affinity (Kozak et al., 
2002; Liu et al., 2003; LoVerme et al., 2006) 
1.2. Cannabinoids in the Vasculature 
1.2.1. Modulation of Vascular Tone 
Arterial tone is modulated through several pathways within smooth 
muscle and endothelial cells. Sympathetic sensory mechanisms control 
arterial tone via perivascular nerves. Perivascular nerves extend into 
arteries forming neuroeffector junctions on vascular smooth muscle 
cells and are capable of mediating both contraction and dilation 
(Kreulen 2003). Smooth muscle cells react to neurohormonal stimuli, 
interact with the endothelium, repair arterial damage and maintain 
vascular tone (Lacolley et al., 2012). Endothelial cells produce several 
vasoactive mediators that interact with smooth muscle cells causing 
vasoconstriction or vasodilatation (Vanhoutte et al., 2009). The main 
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mediators in vascular tone regulation appear to be NO and potassium 
channel hyperpolarisation. However, these mediators are often 
stimulated by physical forces, circulating hormones, platelet-derived 
products, autacoids and metabolites of arachidonic acid (AA) 
(Vanhoutte et al., 2009). Cannabinoids have also been shown to 
mediate vascular tone through a range of mechanisms of action, these 
mechanisms of action are broadly dependent on several factors 
Including the species, the vascular bed, the differences between the 
cannabinoid ligands and the method of investigation used. The 
pathways Involved include activation of cannabinoid receptors, 
activation of TRPV1 receptors, modulation of Ion channels, release of 
endothelium-derived relaxing factors, products of metabolism, 
activation of novel receptors and activation of PPAR receptors. There 
are excellent reviews available detailing the effects of cannabinoids in 
the vasculature (Hillard 2000; Kunos et al., 2000; Randall et al., 2002; 
Randall et al., 2004). The following sections will take Into account 
studies cited in these reviews plus more recent studies. 
1.2.2. In Vivo Anesthetised Animal Studies 
The first evidence of the vasodilator effects of cannabinoids was shown 
by measurement of cerebral artery diameter using a cranial window 
technique in live anesthetised rabbits after topical application of THC 
and AEA (Ellis et al., 1995). The effects of AEA and THC were 
insensitive to nitric oxide synthase (NOS) Inhibition using 
N (GLnitro-L-arginine methyl ester (L-NAME) and removal of oxygen 
free radicals using superoxide dismutase. However, responses to both 
agonists were inhibited using indomethacin, implicating the role of 
COX-derived metabolites. In the dural arteries of anaesthetised 
Sprague-Dawley rats, AEA-induced vasodilation has also been shown to 
be sensitive to TRPV1 and CRGP receptor antagonism (Akerman et al., 
2004). However, it must be noted that a role for COX metabolism was 
not investigated in this work (Akerman et al., 2004). 
Several cannabinoid agonists including THC, HU-210, CP5S,940, 
WINSS,212-2, JWH-01S, AEA and methanandamide cause prolonged 
hypotension In anaesthetised Sprague-Dawley rats, an effect that is 
sensitive to the CBl antagonist rimonabant (Lake et al., 1997; Wagner 
et al., 2001). However, Lake et al., (1997) reported that the inhibition 
of AEA by CBl antagonism was only at selected time points, unlike the 
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effects of CBl antagonism on the other cannabinoids used in the study. 
Similarly, in anaesthetised spontaneously hypertensive rats (SHR) and 
Wistar Kyoto rats, AEA, HU-210 and the FAAH inhibitor URBS97 caused 
reductions in mean arterial pressure, sensitive to rimonabant or AM2S1 
(Batkai et al., 2004). Further support for the role of the CBl receptor in 
the control of systemic blood pressure has been shown in anaesthetised 
SHR and cirrhotic rats (Batkai et al., 2004; Moezi et al., 2006; Batkai et 
al., 2007). In these models, it was also shown that a CBl antagonist 
given alone revealed a hypertensive effect (Batkai et al., 2004; Moezi 
et al., 2006; Batkai et al., 2007). It has also been shown that 
antagonism of the CBl receptor potentiates tachycardia and 
vasoconstriction associated with myocardial infarction (Rudz et al., 
2012). Suggesting that, under the ischaemic conditions associated with 
myocardial Infarction, endocannabinoids through CBl activation have 
both a bradycardic and hypotensive effect. 
CB2 agonists also have hypotensive and vasodilator effects. In 
anaesthetised Sabra rats, HU-308 caused a decrease in blood pressure 
that was attenuated using the CS2 antagonist SR144S28 (1 mg/kg-l ) 
and not rimonabant (3 mg/kg-l ) (Hanus et al., 1999). JWH-133 and 
JWH-01S also caused dilation of knee synovial blood vessels measured 
using laser Doppler imaging In Wistar rats, the effect of JWH-133 was 
attenuated using AM360 (10 nM) and TRPVl antagonism (McDougall et 
al., 2008). 
In vivo anaesthetised studies clearly show that cannabinoids are 
able to cause hypotension in animals. This appears to be primarily 
through the CSl receptor, but also with some involvement from both 
CB2 and TRPV1 receptors. Furthermore, the roles of the CS l receptor 
and cannabinold Induced hypotension appear to be more pronounced in 
disease models. 
1.2.3. In Vivo Conscious Animal Studies 
The in vivo effects of cannabinoids In conscious rats differ significantly 
from their actions In anaesthetised animals. The cannabinoid agonlsts 
AEA, WINSS,212-2 and THC have all been shown to cause pressor 
effects accompanied by renal and mesenteric vasoconstriction and 
hindquarters vasodilation (Gardiner et al., 2001; Gardiner et al., 2002; 
Gardiner et al., 2002; O'Sullivan et al., 2007; Wheal et al., 2007; Ho 
and Gardiner 2009). The responses to WINSS,212 and THC were 
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antagonised using the CBl antagonist AM251 (Gardiner et a/., 2002). 
The pressor response to WIN55,212-2 was also attenuated by 
antagonising the vasopressin Vl receptor, angiotensin-II ATl receptor 
and ganglionic blockade (Gardiner et a/., 2001). However, the 
hindquarters vasodilation to WIN55,212-2 was inhibited by Ih receptor 
antagonism (Gardiner et a/., 2002). In a further study, the 
hindquarters vasodilation caused by THC was decreased in rats that 
had been chronically treated by a NOS inhibitor, suggesting that the 
vasodilation to THC may, in part, be mediated by NO release 
(O'Sullivan et a/., 2007). 
AEA (> 1.25 mg kg-l) caused a brief systemic pressor effect 
associated with vasoconstriction of renal and mesenteric vascular beds 
and vasoconstrictor and then vasodilator effects in the hindquarters 
(Gardiner et a/., 2002). Other works report similarly that AEA 
(3 mg kg-l) caused a brief constrictor effect in all vascular beds 
followed by a vasodilation in both the renal and mesenteric vascular 
beds (Ho and Gardiner 2009). In both studies, the effects of AEA were 
insensitive to AM251 (3 mg kg- l ). Gardiner et at. (2002a) report that 
the hindquarters vasodilation in response to high concentrations of AEA 
was inhibited using a f32 antagonist and that the same antagonist 
prolonged the renal and mesenteric vasoconstriction. Interestingly, 
FAAH inhibition prolonged the hindquarters vasodilation of high 
concentrations of AEA, but inhibited hindquarters vasodilation caused 
by low doses of AEA (Ho and Gardiner 2009). 
The effects of cannabinoids in conscious animals differ from 
those seen in unconscious animals. The above studies have revealed 
that cannabinoids cause a longer-lasting pressor responses and 
shorter-lasting decreases in mean arterial pressure than in 
anaesthetised animals. It has been suggested that in conscious 
freely-moving animals the cannabinoid response is dependent on the 
pre-existing level of sympathetic tone, which might be linked to the CB l 
receptors. The above studies reveal methodological differences 
between assessments of the actions of cannabinoids in the vasculature 
and could point to a potential role of anaesthesia. 
1.2.4. Cannabinoid Receptor Knockout Models 
Blood pressure and heart rate were similar in both CB l +/+ and CB l -!-
mice (Jarai et a/., 1999; Ledent et a/., 1999). This might suggest that 
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these receptors are not involved in blood pressure regulation under 
normal conditions. In both conscious and anaesthetised CB1-1- mice, or 
Isolated arteries from CB1-!- mice, WINSS,212-2, AEA and HU-210 were 
unable to cause the hypotensive effect that is seen In CB l +1+ mice 
(Jarai et al., 1999; Ledent et al., 1999; Szekeres et al., 2012). This 
suggests that the CB l receptor is intrinsic to cannabinoid-induced 
systemic hypotension. However, in an in vitro model, topical application 
of AEA, methanandamide and Abn-CBD caused vasorelaxation in the 
mesenteric vasculature of CB1-1- mice (Jarai et al., 1999). This 
vasorelaxation was sensitive to a relatively high concentration of 
Rimonabant (1 IJM), endothelium denudation, charybdotoxin (ChTX) 
and apamin. Furthermore, it was Insensitive to L-NAME and 
indomethacin (Jaral et al., 1999). These findings point towards the role 
of a putative cannabinold receptor located on the endothelium (CBe) 
that Is sensitive to rimonabant and potentially capable of ion channel 
modulation. Later work from the same group has shown that 
2-AG-lnduced hypotension of anaesthetised CB l +1+ and CB1-I- mice 
(Jaral et al., 2000). This vasodilation was insensitive to rimonabant 
(3 mg kg-1) but was Inhibited by Indomethacin (Jarai et al., 2000), 
suggesting that the systemic hypotensive effects caused by 2-AG are 
mediated via COX derived metabolites. 
Using CB2 knockout mice (CB2-1-) there is strong evidence to 
suggest that the CB2 receptor is not involved in systemic hypotension 
(Jaral et al., 1999). Recent reports have also shown CB2-1- mice share 
similar cardiovascular and haemodynamic traits as their wild type 
counterparts (Defer et al., 2009). However, CB2-1- mice have been 
associated with decreased protection from cardiovascular and vascular 
Injury (reviewed In Buckley 2008; Pacher and Hask6 2008). Indeed, 
studies have shown, using CB2-!- mice, that the effects of 
atherosclerosis are potentiated In the absence of the CB2 receptor. 
Atherosclerotic plaque sizes are reported to remain the same size as 
wild type, however CB2-1- mice are associated with Increased 
macrophage and smooth muscle cell Infiltration and loss of plaque 
stability (Netherland et al., 2010) and Increased macrophage Infiltration 
with Increased aortic superoxide production (Hoyer et al., 2011). 
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1.2.5. Summary of In Vivo Findings 
The in vivo anaesthetised animal studies have shown 
cannabinoid-induced hypotension is mediated predominantly via the 
CS1 receptor. However, in conscious animals, cannabinoids cause a 
pressor effect linked to CS1-mediated sympathoexcitation that may 
have previously been masked in anaesthetised animals. 
1.2.6. Cannabinoid Vascular Actions In Vitro 
Cannabinoid induced vasorelaxation has been shown In a variety of in 
vitro models via several key mechanisms, which are discussed in the 
following sections. 
CB 1 Receptor 
CS1 receptor mRNA has been detected In rat vasculature endothelial 
cells (Deutsch et al., 1997). Human vascular expression of CS1 mRNA 
has also been shown (Sugiura et al., 1998; Llu et al., 2000). A role for 
CS1-mediated vasorelaxation has been implicated in several studies 
using the CS1 antagonist rimonabant. However, at high doses 
rimonabant causes effects that are not selective to the CS1 receptor 
(for review see Pertwee 2005). Therefore in the following section, 
rimonabant and AM251 will only be considered to be antagonising CS1 
receptors at concentrations of S 1 !-1M. 
AEA, methanandamide, noladin ether, HU-210 and CP55,940 all 
have high affinities at the CS1 receptor and all cause vasorelaxation 
that is inhibited by CS1 antagonism. The vasorelaxant effects of AEA 
were reduced in rat resistance arteries in the presence of AM251 
(O'Sullivan et al., 2004). Similarly, the effects of noladin ether were 
completely abolished in the presence of AM251 or rimonabant in rabbit 
pulmonary arteries (Su and Vo 2007). Furthermore, in rat mesenteric 
resistance arteries, the potency and maximum vasorelaxation to 
CP55,940 and HU-210 were reduced by rimonabant (White and Hiley 
1998). 
To further establish the mechanisms behind CS1-mediated 
vasorelaxation, White et al. (1998) have shown that CP55,940 causes 
relaxation in rat mesenteric resistance arterial segments contracted 
using high potassium solution. This effect Is sensitive to rimonabant, 
suggesting that, through a CS1-mediated pathway, CP55,940 inhibits 
voltage-operated calcium channels. In vascular smooth muscle, AEA 
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and WIN 55212-2 are able to cause a decrease in peak Ca2+ current in 
cat cerebral smooth muscle arteries in a rimonabant- and pertussis 
toxin- (PTX, inhibitor of Gi/o proteins) sensitive manner (Gebremedhin 
et al., 1999). Also, vasorelaxation to AEA in rat coronary arteries was 
Inhibited by rimonabant and calcium dependent potassium channel 
blockade (Randall and Kendall 1997). In rat aorta, 
methanandamide-induced vasorelaxation is inhibited by CB l and CB2 
antagonism (Lopez-Miranda et al., 2010). This work also shows 
concurrent roles for cytochrome p450 and guanylate cyclase suggesting 
roles for metabolism and production of nitric oxide in 
methanandamide-induced vasorelaxation (Lopez-Miranda et al., 2010). 
Su et al. (2007) have shown that the vasorelaxation caused by 
noladin ether in rabbit pulmonary arterial strips is through the CB l 
receptor and associated with MEK/ERK 1/2 activation. This was 
confirmed using western blotting studies showing that CB l antagonism 
reduced MEK/ERK 1/2 phosphorylation associated with noladin ether. 
Interestingly, a recent study has shown that antagonism of the 
CB l using 02050, a neutral CB l antagonist as well as AM251 and 
rimonabant, augments the vasoconstrictor effects of angiotensin II 
(Szekeres et al., 2012). In the same work it is also reported that 
inhibition of 2-AG synthesis also augments angiotensin II responses, 
suggesting that 2-AG through CB l activation may counteract 
vasoconstriction (Szekeres et al., 2012). 
CBl Receptor 
CB2 receptor mRNA has been shown in the superior mesenteric arteries 
of rats (Moezl et al., 2006). Immunohistochemical analysiS of human 
cerebral endothelial cells has confirmed that 45% cells were positive for 
the CB2 receptor (Schley et al., 2009). In rat mesenteric resistance 
arteries, the CB2 receptor agonist JWH-015 causes vasorelaxation (Ho 
and Hiley 2003). However, the effects of JWH-015 were not inhibited 
by CB2 antagonism using SR144528, shedding doubt on the role for 
CB2• In the rat aorta, the vasorelaxant effect of the potent CBl and CB2 
agonlsts CP55,940 and WIN55,212-2 were partially inhibited by CB2 
antagonism using SR144528 (O'Sullivan et al., 2005; Dannert et al., 
2007). In rat coronary arteries, it has been shown that AEA and 
HU-210 Induced vasorelaxation that was antagonised using AM630 
(Malr et al., 2010). This work also showed that the effects of AEA were 
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not inhibited by removal of the endothelium, but were inhibited by the 
non-selective COX inhibitor indomethacin and the sphingosine kinase 
inhibitor SKi (Mair et al., 2010). The intracellular signalling coupled to 
the CB2 receptor regarding vasorelaxation has not been fully explored 
however the previous study suggests that CB2 stimulation may lead to 
ERKl/2 phosphorylation, production of arachidonic acid (leading to the 
production of vasorelaxant prostaglandins) and production of 
sphingosine-1-phosphate (leading to activation of endothelial SlP3 
receptors). 
TRPVl Receptor 
Zygmunt et al. (1999) first showed that the vasorelaxant effects of 
AEA, but not 2-AG, PEA, HU-210, WIN55,212-2 and CP55,940, could be 
antagonised by the TRPV1 antagonist capsazepine In rat mesenteric 
arteries. AEA caused vasorelaxation through TRPV1 stimulation of 
sensory nerves to release CRGP, which was further confirmed by 
Inhibition of vasorelaxation through CRGP antagonism using CGRPS-37 
(Zygmunt et al., 1999). However, AEA-induced vasorelaxation though 
the TRPV1 receptor has also been reported to be linked to stimulation 
of nitric oxide production in the rat mesenteric vascular bed (Poblete et 
al., 2005). Similarly, vasorelaxation to methanandamlde in rabbit 
aortic endothelium denuded rings was also completely inhibited by 
capsazepine and CGRPS-37 (Mukhopadhyay et al., 2002). Vasorelaxation 
caused by the endocannabinoid NADA in the rat superior mesenteric 
artery is inhibited by desensitisation of the TRPVl receptor using 
capsaicin and antagonism using capsazepine (O'Sullivan et al., 2004). 
However, In rat coronary arteries and rat pulmonary arteries 
AEA-induced vasorelaxation was not affected by Incubation with 
capsaiCin and capsazepine (White et al., 2001; Baranowska-Kuczko et 
al., 2012). Phytocannabinoids or their analogues have also been shown 
to cause TRPV1-mediated vasorelaxation. In rat hepatic arteries, THC 
and cannabinol-induced vasorelaxation are Inhibited by TRPV1 receptor 
desensitisation using capsaicin and antagonism of CGRP1 receptors 
using CGRPS-37 (Zygmunt et al., 2002). Interestingly, in mesenteric 
arteries from TRPV1 knockout mice, the vasorelaxation to AEA Is 
almost completely abolished, however the vasorelaxation to THC is only 
Slightly reduced (Zygmunt et al., 2002). This suggests that the TRPV1 
receptor is the main mechanism involved in AEA-induced 
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vasorelaxation, whereas TRPV1 only partially mediated the effects of 
THC. However, in rat mesenteric resistance arteries, the effects of THC 
are unaffected by capsaicin pre-treatment, capsazepine and ruthenium 
red (O'Sullivan et al., 2005). In the rat aorta, vasorelaxation to 
WINSS,212-2 was partially inhibited via TRPV1 desensitisation or 
antagonism (Dannert et al., 2007). 
Ion Channels 
In rat mesenteric arteries and rat coronary arteries, the vasorelaxant 
effects of AEA were inhibited using non-specific potassium channel 
inhibitors and BKca channel inhibitors (Plane et al., 1997; White et al., 
2001). A novel endogenous ligand chemically similar to AEA, 
N-arachidonoyl L-serine (ARA-S) has also been shown to directly 
activate BKca channels in rat mesenteric arteries which was confirmed 
by patch clamping in HEK cells (Godlewski et al., 2009). In rat 
mesenteric resistance arteries, JWH-01S, WINSS,212-2 and 
WINSS,212-3 produced vasorelaxation of methoxamine-constricted 
arterial segments that was insensitive to CB1 and CB2 antagonism (Ho 
and Hiley 2003). However, when calcium chloride was used as the 
contractile agent vasorelaxation to JWH-01S, WIN5S,212-2 and 
WINSS,212-3 was reduced, as was vasorelaxation to verapamil 
(L-type calcium channel blocker) (Ho and Hiley 2003), suggesting a 
direct inhibition of calcium influx. OEA Inhibits Increased perfusion 
pressure caused by caffeine-induced intracellular calcium release In the 
rat perfused mesenteric arterial bed in situ (Wheal et al., 2010). This 
inhibition was not sensitive to CB l antagonism, suggesting the direct 
Inhibition of release of Intracellular calcium. 
The Endothelium, Nitric Oxide and EDHF 
The endothelium has a substantial role In the regulation of vascular 
tone (reviewed in Feletou and Vanhoutte 2009). Vasorelaxation caused 
by AEA Is Inhibited by endothelial removal In bovine ophthalmic arteries 
(Pratt et al., 1998), rat first and third order mesenteric arteries 
(O'Sullivan et al., 2004; Ho and Randall 2007; Wheal et al., 2012), 
rabbit aortiC rings (Mukhopadhyay et al., 2002) and rabbit superior 
mesenteric arteries (Chaytor et al., 1999). 2-AG-, oleamide-, OEA- and 
NADA-induced vasorelaxatlon in the rat mesenteric resistance artery Is 
also Inhibited by removal of the endothelium (O'Sullivan et al., 2004; 
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Ho and Randall 2007; Sudhahar et al., 2009; Wheal et al., 2012). 
Methanandamide-induced vasorelaxation is also inhibited in rabbit 
aortic ring endothelium-denuded arterial segments (Mukhopadhyay et 
al., 2002). 
NO is an endothelium-derived factor capable of causing vascular 
hyperpolarisation (reviewed in Feletou and Vanhoutte 2009). Nitric 
oxide inhibition inhibits vasorelaxation to AEA in the rat renal 
vasculature (Deutsch et al., 1997), AEA and WIN55,212-2 in the bovine 
ophthalmic arteries (Romano and Lograno 2006), OEA in the rat 
isolated mesenteric bed (Wheal et al., 2010), AEA (first order) and OEA 
(third order) in isolated mesenteric arteries (Wheal et al., 2012) and 
methanandamide in rabbit aortic rings (Mukhopadhyay et al., 2002). 
However, in the rat and rabbit mesenteric resistance and rat conduit 
arteries, nitric oxide inhibition does not inhibit AEA-, NADA-, THC-, 
cannabinol- and Abn-CBD-induced vasorelaxation (Chaytor et al., 
1999; Zygmunt et al., 2002; Offertaler et al., 2003; O'Sullivan et al., 
2004; O'Sullivan et al., 2004). 
Endothelium-derived hyperpolarlslng factor (EDHF), involves 
activation of small- (SKca) and intermediate- (IKca) conductance 
calcium activated potassium channels (Xia et al 1998; Khanna et al 
1999). This activation leads to increases in intracellular Ca2+ In the 
endothelium and K+ efflux. The efflux of K+ leads to myocyte 
hyperpolarisations through inwardly rectifying potassium channels and 
sodium potassium ATP-driven exchangers (reviewed in Edwards et al., 
2010). A role for EDHF vasorelaxation has been implicated In 
cannabinoid-induced vasorelaxation. EDHF-mediated relaxation has 
been Implicated in AEA-induced vasorelaxation of rat arteries (Randall 
et al., 1996; Randall et al., 1997; O'Sullivan et al., 2004). Recent work 
has also shown that EDHF-mediated vasorelaxation of AEA and OEA in 
rat mesenteric arteries may Involve liberation of H20 2 as both AEA and 
OEA relaxations are inhibited by catalase (Wheal et al., 2012). 
Metabolism 
Vasoactive metabolites of AEA and THC have been shown to cause 
vasodilation in cerebral arterioles sensitive to the COX inhibitor 
indomethacin (Ellis et al., 1995). In rat skeletal arteries, AEA-induced 
vasorelaxatlon is inhibited by abolishing AEA breakdown through FAAH, 
COX and cytochrome P450 (Czikora et al., 2012). However, In rat 
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renal, mesenteric resistance and conduit arterial segments, the effects 
of AEA are not inhibited by indomethacin (Deutsch et al., 1997; 
O'Sullivan et al., 2004). The role for metabolism may be dependent on 
the cannabinoid in question. 2-AG is reported to be an unstable 
endocannabinoid readily susceptible to metabolism (Rouzer et al., 
2002). Endothelium-dependent metabolism of 2-AG by FAAH, MAGL 
and COX are responsible for 2-AG-induced vasorelaxation of bovine 
coronary arteries (Gauthier et al., 2005) or metabolism through 
CYP450 in rat mesenteric arteries (Awumey et al., 2008). However, 
metabolism of 2-AG is not implicated in causing 2-AG-induced 
vasorelaxation of the rabbit mesenteric artery (Kagota et al., 2001) or 
rat mesenteric arteries (Ho and Randall 2007). Interestingly however, 
it has been shown that COX-1 inhibition potentiates the vasorelaxation 
seen to OEA and 2-AG, whereas inhibition of COX-2 potentiates 
vasorelaxation seen to AEA in perfused in situ rat mesenteric arteries 
and isolated mesenteric arteries (Ho and Randall 2007; Wheal et al., 
2010). 
Non-CB l , Non-CB2 Vascular Receptors 
Early indications of a novel vascular cannabinoid receptor came from 
the works of larai et al. (1999), which showed that in CB1-1-, CB2-1- and 
wild type mice, AEA, methanandamide and Abn-CBD were able to 
cause vasodilation of the mesenteric vasculature (laral et al., 1999). 
The vasodilation was Inhibited by removal of the endothelium and the 
presence of rimonabant suggesting that rimonabant has Inhibitory 
affects at the CBe receptor. Further work has shown Abn-CBD caused 
vasorelaxation of the rat mesenteric artery, this relaxation Is sensitive 
to endothelium denudation, 0-1918 (a proposed antagonist at the CBe 
receptor that has no affinity at CBl or CB2 receptors) and PTX 
(Offertaler et al., 2003). This finding, as with that of laral et al. 
(1999b), suggests that the relaxation seen to Abn-CBD is mediated by 
an endothelial Gilo protein-coupled receptor that is neither the CBl nor 
CB2 receptor. Experiments in the rabbit pulmonary artery have shown 
also that Abn-CBD causes relaxation that Is only partially inhibited by 
CBl antagonism, yet fully inhibited by 0-1918 (Su and Vo 2007). In 
rabbit aortiC rings, AEA and methanandamide also cause vasorelaxation 
through the novel PTX-sensitive endothelial receptor (Mukhopadhyay et 
al., 2002). Studies in rat aorta have shown that AEA causes 
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endothelium-dependent vasorelaxation that is sensitive to PTX but 
insensitive to rimonabant (1 IJM) (Herradon et al., 2007). Oleamide is 
also sensitive to PTX, 0-1918 and antagonism of calcium-activated 
potassium channels but not 1 IJM AM251 in rat mesenteric resistance 
arteries (Hoi and Hiley 2006). Abn-CBD modulates BKca channel 
currents in human umbilical endothelial cells in patch clamp studies. 
This modulation was insensitive to CBt/CB2 receptor antagonism, but 
was inhibited using PTX or 0-1918 (Begg et al., 2003). These findings 
offer further support for the presence and vasorelaxant role of the CBe 
receptor, and suggest it is GI/a protein coupled, capable of activating 
calcium-operated potassium channels and antagonised by both 0-1918 
and rimonabant. 
The vasorelaxant effects of NADA and AEA in the rat aorta have 
been shown to be unaffected by AM251 (1 IJM) but are partly sensitive 
to PTX (O'Sullivan et al., 2005). However, removal of the endothelium 
did not affect the response to AEA or the maximum response to NADA 
(O'Sullivan et al., 2005). In rat mesenteric arteries, the 
endothelium-independent vasorelaxant effects of THC are mediated 
through a GI/a protein, potentially coupled to K+ and Ca2+ channels 
(O'Sullivan et al., 2005). These findings potentially suggest a further 
Gila protein-coupled receptor located on the smooth muscle that also 
has the ability to modulate ion channels. This receptor differs from CBe 
receptor, as the CBe receptor is antagonised by rimonabant in 
mesenteric resistance arteries (Jara! et al., 1999). 
Evidence suggests GPR55 is not the endothelial cannabinoid 
receptor, as mesenteric arteries of wild type and GPR55 knockout mice 
show vasorelaxation in the presence of Abn-CBD and 0-1602 (an 
analogue of Abn-CBO), which is sensitive to 0-1918 (Johns et al., 
2007). Furthermore, the pharmacological profile of the proposed 
endothelial cannabinoid receptor. differs from the pharmacological 
profile of GPR55, as GPR55 is either Ga13 or Gq coupled and the CBe 
receptor is GI/a coupled (Offertaler et al., 2003; Waldeck-Weiermair et 
al., 2008; Henstridge et al., 2009). 
PPAR Receptors 
The first report to show that cannabinoids modulate vascular tone 
through interactions with the PPAR receptors came from the work of 
O'Sullivan et al. (2005). This study showed that THe (10 IJM) caused a 
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time-dependent (over a period of 120 minutes) vasorelaxation in 
pre-constricted rat aorta. The maximum vasorelaxant effect of THC was 
similar to that of the PPARy agonist rosiglitazone, with both effects 
being inhibited by the PPARy selective antagonist GW9662 (O'Sullivan 
et al., 2005). The effects of THC were also inhibited by the addition of 
cycloheximide, endothelium denudation, L-NAME, catalase and SOD 
inhibition (O'Sullivan et al., 2005). These findings suggested that THC 
induced vasorelaxation through activation of PPARy receptors and 
subsequent increases in NO bioavailability (O'Sullivan et al., 2005). 
Furthermore, after two hours incubation with THe, the superior 
mesenteric artery shows enhanced ACh responses that was blocked by 
PPARy antagonism (O'Sullivan et al., 2006). PPARy-mediated 
vasorelaxation in rats seems to be exclusive to the conduit arteries as 
PPARy-mediated vasorelaxation in the mesenteric resistance arteries of 
rats was not observed (O'Sullivan et al., 2005; O'Sullivan et al., 2006). 
CBD, NADA and AEA have also been shown to cause 
time-dependent relaxation that was inhibited by antagonism/inhibition 
of PPARy, SOD, NO and protein synthesis (O'Sullivan et al., 2009; 
O'Sullivan et al., 2009). However, the effects of both NADA and AEA 
were partially dependent on the endothelium (O'Sullivan et al., 2009). 
This could suggest that NADA and AEA could have activated the smooth 
muscle PPARy receptor. NADA was also found to be dependent on the 
CB1 receptor. The authors concluded that NADA may activate the 
PPARy receptor via a CB1-dependent mechanism, potentially through 
the ERKl/2 and MAPK (O'Sullivan et al., 2009) 
Recent research has shown in the bovine ophthalmic artery that 
AEA and PEA cause vasorelaxation through a PPARa-mediated pathway 
(Romano and Lograno 2012). The vasorelaxation observed was not 
dependent on the presence of the endothelium, PPARy antagonism or 
TRPV1 desensitisatlon (Romano and Lograno 2012). However, 
vasorelaxation was Inhibited by PPARa antagonism, nitric oxide 
synthase Inhibition and blocking of BKca channels (Romano and Lograno 
2012). 
1.2.7. Summary of In Vitro Findings 
In vitro studies have shown that cannabinoids produce vasorelaxation 
through a range of mechanisms including activation of CB l receptors, 
CB2 receptors, TRPV1 receptors, sensory nerves, novel cannabinoid 
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receptors, endothelium-derived relaxant products including EDHF, 
metabolism, modulation of ion channels and interaction with PPARa and 
PPARy nuclear receptors. These mechanisms of action are dependent 
on the cannabinoid ligand used and the vascular bed studied. 
1.2.8. Cannabinoids in Cardiovascular Disease 
Heart Disease 
There is a range of evidence to support a role for the CB2 receptor in 
cardio-protection. Early work showed that LPS pre-treatment reduced 
infarct size caused by Ischaemia/reperfusion injury in Isolated rat 
hearts (Lagneux and Lamontagne 2001). However, the protective 
effects of LPS were inhibited when hearts were perfused with a CB2 
antagonist or a NOS inhibitor (Lagneux and Lamontagne 2001). 
Similarly, in isolated rat hearts, heat stress prior to 
ischaemia/reperfusion injury caused a reduction In infarct size, in a 
manner that was dependent on the CB2 receptor and NO (Joyeux et al., 
2002). Further studies then explored potential roles for 
endocannabinoid signalling in cardio-protection by pre-treating hearts 
with endocannabinoids prior to ischaemia/reperfusion. In hearts that 
were infused with 2-AG and PEA for 15 minutes prior to 
ischemia/reperfusion a reduced infarct size was observed (Lepicier et 
al., 2003). The cardio-protective effects of 2-AG and PEA were inhibited 
by CB2 antagonism or PKC, MAP kinase or ERKl/2 Inhibition (Leplcier et 
al., 2003). The synthetic CB2 agonist JWH-133 when perfused 
5 minutes prior to reperfusion was also able to reduce Infarct size 
associated with coronary artery ligation, an effect that was also 
dependent on CB2 signalling through ERKl/2 pathways (Montecucco et 
al., 2009). Interestingly, Montecucco et al., (2009) reported that CB2 
receptor mRNA was reduced In hearts that had suffered Ischaemia 
compared to sham operated controls. In vivo, the phytocannabinoid 
CBD also shows cardio-protective qualities (Durst et al., 2007). CBD 
when given 1 hour before coronary artery ligation reduced infarct size 
and promoted Increased left ventricular ejection fraction that were 
associated with decreased inflammation (Durst et al., 2007). A further 
study also reported that CBD given prior to coronary artery occlusion 
produced reductions in Infarction and also inhibited arrhythmia 
associated with infarction (Walsh et al., 2010). CBD also inhibits 
cardiodysfunction and cardiomyocyte damage induced by a high 
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glucose environment (Rajesh et al., 2010). In streptozotocin-induced 
diabetic mice, diabetes was associated with impaired diastolic and 
systoliC left ventricular function that was restored by CBO 
pre-treatment (Rajesh et al., 2010). In this model, the effects of CBO 
were associated with decreased inflammatory mediators, decreased 
oxidative stress, decreased nitrative stress and attenuation of high 
glucose-induced apoptosis (Rajesh et al., 2010). It has recently been 
shown by the same group, using the same model of diabetes, that 
genetiC deletion of the CB l receptor reduces the oxidative/nitrative 
stress, inflammation and fibrosis associated with chronic 
cardiomyopathy caused by diabetic diabetes (Rajesh et al., 2012). 
In humans with heart disease, there Is a consensus that 
endocannabinoid levels are raised when compared to healthy controls 
(Sugamura et al., 2009; Weis et al., 2010). However, receptor 
expression differs and this is presumably dependent on the specific 
type of heart disease. In the Sugamura et al. (2009) study it was 
reported that, in patients with unstable angina coronary artery plaque, 
content of CB l receptors is increased when compared to patients with 
stable angina. In this study the level of the CB2 receptor was reported 
to be lower than that of CB l expression, however CB2 receptor 
expression is not compared to patients with stable angina. The Weis et 
al. (2010) study reported that CB l and CB2 receptor protein expression 
was equal in autopsy samples of left ventricular myocardium taken 
from individuals who had died with no known heart condition. However, 
in chroniC heart failure patients, CBl protein expression was reduced, 
whereas CB2 receptor protein expression was elevated and mRNA 
expression was elevated 11 fold (Wels et al., 2010). 
Hypertension 
In models of hypertension the effects of cannabinoids have been shown 
to have different effects depending on the model of hypertension used 
and the experimental conditions. 
In anaesthetized rats, injection of AEA causes a tri-phasic 
haemodynamic response Initially causing hypotension followed by a 
brief pressor effect and then by a prolonged hypotension (Lake et al., 
1997). However, in spontaneously hypertensive rats (SHR) AEA causes 
a greater hypotensive response (Lake et al., 1997). A later study 
reported that in anaesthetised Wistar Kyoto (WKY) rats Injection with 
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AM2S1 had no effect on blood pressure, yet when injected into three 
different types of hypertensive model (SHR, Dahl salt-sensitive and 
angiotensin II-induced hypertensive Sprague-Dawley rats) it 
significantly increased blood pressure (Batkai et al., 2004). A further 
finding of interest was that injection with URBS97 decreased blood 
pressure in hypertensive rat models, an effect that could be inhibited 
using AM2S1 (Batkai et al., 2004). Immunochemical analysis of the 
hypertensive rats used In this study revealed increased CB l receptor 
expression, increased FAAH expression, decreased AEA levels and 
unaltered 2-AG levels (Batkai et al., 2004). 
In conscious freely-moving rats, CB l antagonism has a similar 
hypertensive effect in SHR rats that Is not seen in WKY controls (Wheal 
et al., 2007). In this same model it was shown that infusion with AEA 
caused a rise followed by a fall in blood pressure which was not 
associated with vasorelaxation of the mesenteric or hindquarters beds 
(Wheal et al., 2007). WINSS,212-2 was also used in this study, and the 
findings were the same as those for AEA albeit slightly more 
pronounced (Wheal et al., 2007). The responses to both AEA and 
WINSS,212-2 were not mediated by the CB l receptor and the overall 
responses were considered to be detrimental to cardiac function (Wheal 
et al., 2007). However, in models of acute hypertension using 
Sprague-Dawley rats made hypertensive using angiotensin II, both AEA 
and WINSS,212-2 were able to cause hypotension which was 
accompanied by vasodilation In the hindquarters, renal and mesenteric 
vascular beds (Ho and Gardiner 2009). In this study it was also shown 
that co-administration of URBS97 with AEA enhanced the hypotensive 
effects of AEA, and that the responses to WINSS,212-2 but not AEA 
were inhibited using AM251 (Ho and Gardiner 2009). 
In Isolated arteries the vasorelaxant effects of AEA are less 
potent in the perfused whole mesenteric vascular beds of SHR rats than 
in WKY controls (Wheal and Randall 2009). Capsaicin pre-treatment 
reduced the effects of AEA In both vascular beds, however the potency 
of AEA still remained enhanced In WKY compared to SHR rats (Wheal 
and Randall 2009). Pre-treatment with L-NAME however significantly 
reduced the potency of AEA in WKY In so much that there was no 
difference between WKY and SHR In responses to AEA (Wheal and 
Randall 2009). The same study then went on to the look at the effects 
of AEA In aortic ring segments from SHR and WKY rats. This showed 
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that the maximal response of AEA was enhanced in SHR aortic rings in 
a manner that was endothelium but not NO-dependent (Wheal and 
Randall 2009). Earlier work looking at the effects of THC reported that, 
in rats made hypertensive using L-NAME, THC-induced vasorelaxation 
was significantly enhanced in the mesenteric resistance arteries 
(O'Sullivan et al., 2007). In both L-NAME-treated and control arteries 
the effects of THC were reduced, with a greater reduction observed in 
the arteries from L-NAME-treated rats (O'Sullivan et al., 2007). 
However, in L-NAME-treated arteries vasorelaxation was also 
dependent on COX, a finding not observed In control arteries 
(O'Sullivan et al., 2007). Recent research has also shown a 
COX-dependent enhancement of vasorelaxation induced by oleamide in 
aortic rings of SHR rats compared to WKY rats (Hopps et al., 2012). 
Taken together these studies show that in unconscious animal 
studies and isolated tissue studies the vasorelaxant effects of 
cannabinoids are enhanced In models of hypertension. The enhanced 
effects seen are more commonly associated with the CB l receptor 
modulation of sympathetic tone in in vivo studies while in isolated 
tissues pathways vary depending on the cannablnoid ligand. However, 
In conscious-freely moving animals the effects of cannabinoids In 
chronically hypertensive animals have been considered detrimental to 
cardiac function as the hypotenSion observed is not associated with 
vascular bed vasodilation. In acutely hypertenSive freely-moving rats 
however, cannabinoids have been associated with enhanced 
hypotension and vasorelaxation of vascular beds suggesting a positive 
role in the cardiovascular system. 
1.3. The Effects of Cannablnoids in the Human Vasculature 
1.3.1. The Exogenous Effects of Cannabinoids In Vivo 
In vivo research on the hypotensive effects of cannabinolds revealed 
hypotension In some participants but not others. Intrapulmonary 
administration of pure THC using a vaporizer did not affect blood 
pressure (Zuurman et al., 2008). Also, smoking marijuana cigarettes 
caused inconsistent effects on blood pressure, however symptomatic 
hypotenSion was reported in 22% of partiCipants (Gorelick et al., 
2006). Interestingly, when participants were given rimonabant alone 
there were no alterations In blood pressure, and in the marijuana 
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cigarette group symptomatic hypotension was no longer reported 
(Gorelick et al., 2006). A further study on the effects of marijuana 
cigarettes has shown that heart rate was increased to > 140 bpm in 
50% of partiCipants and 25% of partiCipants experienced hypotension 
which lasted around 45 minutes (Hunault et al., 2008). In human 
forearm microcirculation however, interarterial injection of AEA had no 
effect on vascular tone, whilst topical application caused vasodilation in 
a TRPV1 mediated manner (Movahed et al., 2005). 
1.3.2. Research in vitro 
The first published in vitro report in human arteries showed that AEA 
and methanandamide (at concentrations up to 30 IJM) were without 
vasorelaxant effects in myometrial arteries taken from healthy patients 
without reports of hypertensive pregnancies (Kenny et al., 2002). In 
isolated human pulmonary arteries, virodhamine, Abn-CBO and 
anandamide have been shown to cause vasorelaxation (Kozlowska et 
al., 2007; Kozlowska et al., 2008). These relaxations were 
endothelium-dependent and insensitive to CBl antagonism. Antagonism 
of the CBe receptor, using 0-1918 (10 jJM) or CBO (3 jJM), reduced the 
potency of both Abn-CBO and virodhamine. Furthermore, virodhamine 
potency was also reduced in the presence of the potassium channel 
blockers charybdotoxin and apamin (Kozlowska et al., 2007; Kozlowska 
et al., 2008). The effects of pertussis toxin completely abolished the 
effects of Abn-CBD (Kozlowska et al., 2007). 
1.4. Summary 
This review has highlighted the endocannabinoid system and discussed 
receptor target sites for both endocannabinoids and phytocannabinoids. 
This review has also shown that· many cannabinoid ligands cause 
vasorelaxation in the vasculature of animals through well-established 
pathways. It is apparent from this review that the effects of 
cannablnoids are often dependent on the cannabinoid ligand, the 
species studied and the vascular bed used. To date, it has been shown 
that endocannabinoids and cannabinoid receptors are expressed within 
the human vasculature yet only four studies have been carried out to 
establish the pharmacological effects of cannabinoids in human 
arteries. These works have already revealed some discrepancies 
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between human and animal work. Therefore there is a need for further 
human work to be carried out to understand the effects of different 
cannabinoid ligands in differing vascular beds. 
In rat and bovine arteries only, cannabinoids have been shown 
to induce time-dependent vasorelaxation that can be inhibited through 
antagonism of nuclear receptors. Furthermore, incubation with 
cannabinoids has been shown to enhance endothelium-dependent 
vasorelaxation through cannabinoid interactions with nuclear receptors, 
suggesting a possible therapeutic for disease states associated with a 
decline In endothelium-dependent vasorelaxation. However, 
time-dependent, nuclear receptor-mediated vasorelaxation has not 
been investigated In human arteries. Given the potential therapeutic 
scope for this cannabinoid-induced effect there is a definite need to 
conduct work to see if this effect carries over in humans. 
Finally the effects of cannabinoids are altered in models of 
disease, with cannabinoid-induced vasorelaxation/hypotension being 
enhanced In some states. Similarly, current human work has shown 
that in disease states endocannabinoid levels are often raised, yet the 
effects of cannabinoids in isolated arteries from humans with vascular 
disease are unknown. 
1.5. Alms 
The first aim of the present study was to screen a range of cannabinoid 
compounds for their ability to induce vasorelaxation in human 
mesenteric arteries. The second aim of this study was to probe the 
mechanisms of action of the most efficacious endocannabinoid and 
phytocannabinoid. The third aim of this study was then to investigate a 
potential role for PPARy-mediated time-dependent vasorelaxation of 
cannabinoids In human mesenteric arteries. Finally all cannabinoid 
responses were assessed in relation to the medical condition from the 
patient that they were taken. 
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2. MATERIALS AND METHODS 
2.1. Chemicals, Buffers and Drug solutions 
2.1.1. General Chemicals 
Table 2.1 shows the salt composition of buffers used in this study. 
Table 2.2 shows the chemicals that were used in this study. 
Purchasing, stock concentration, storage and bath concentration are all 
given in the relevant columns. 
Table 2.1. Composition of buffers used. 
Composition of buffers used in this study, buffers were made as 
required and all dilutions were made in triple distilled water 
Buffer Salt Purchased C!::Qflcentrl:ltlQrI 
mM/t 
PSS Sodium chloride (Na CI I) S Igma 1 19 
Potassium chloride (KCI) Sigma 4.7 
Calcium chloride dihydrate Sigma 2.5 
lCaCb.2H2O) 
Magnesium sulphate Sigma 1.17 
(MQS04.7H2O) 
Sodium bicarbonate Sigma 25 
(NaHC03) 
Potassium dihydrogen Sigma 1.18 
phosphate (KH2P04) 
Ethylenediaminetetraacetic Sigma 0.027 
acid (CloH16N20S) 
Glucose (C6H1206) Sigma 5.5 
KPSS As with PSS with the 
following exceptions 
Exclusion of NaCI Sigma 
Inclusion of KCI Sigma 123.7 
CaH free As with PSS with the 
PSS exclusion of CaCb.2H 2O 
Cal+ free As with KPSS with the 
KPSS exclusion of CaClz.2H2O 
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Table 2.2. Chemicals and dilutions. 
Chemicals used in this study with stock concentrations and storage. 
Further dilutions from stock were made In triple distilled water. M.A.R 
denotes made as required. 
Chemica! Purt:;hased 5 t o t : ~ ~ S t o n l : ~ g e e Bath 
t:;Qru:entratlon concentration 
2-AG Ascent 10 mM in EtOH -20°C 0.1-100 (.JM 
Acetylcholine Sigma 10 mM H2O M.A.R 10 (.JM 
AH6809 Sigma 10 mM in EtOH -20°C 1 & 10 (.JM 
AM251 Tocris 10 mM in DMSO -20°C 100 nM 
AM630 Tocris 10 mM in DMSO -20°C 100 nM 
Anandamide Tocris 10 mM in EtOH -20°C 0.1-100 (.JM 
Bradykinin Sigma 10 mM H2O -20°C 10 (.JM 
Cannabidiol GW Pharma 10 mM in EtOH -20°C 0.1-100 (.JM 
Capsaicin Tocris 10 mM in EtOH M.A.R 10 (.JM 
CAYI0441 Cayman 10 mM in DMSO -20°C 100 nM 
CP55,940 Tocris 10 mM in EtOH -20°C 0.1-100 (.JM 
Endothelin-1 Sigma 0.01 mM in H2O -20°C 1-10 nM 
Flurbiprofen Tocris 10 (.JM in PSS M.A.R 10 (.JM 
GW9662 Sigma 10 mM in EtOH -20°C 1 (.JM 
HU308 Tocris 10 mM in EtOH -20°C 0.1-100 (.JM 
Indomethacin Sigma 10 (.JM in PSS M.A.R 10 !-1M 
JZL 184 Sigma 10 mM in DMSO -20°C 1 (.JM 
L161982 Tocris 10 mM in DMSO -20°C 1 (.JM 
L-NAME Sigma 10 (.JM in PSS M.A.R 300 !-1M 
LY320135 Tocris 10 mM in DMSO -20°C 1 (.JM 
Methoxamine Sigma 10 mM In H2O -20°C 1-50 (.JM 
NimesuJide Tocris 10 (.JM in PSS M.A.R 10 (.JM 
Noradrenaline Sigma 0.1 mM in H2O -20°C 0.1-1 (.JM 
0-1918 Tocris 10 mM in DMSO -20°C 10 (.JM 
THC Tocris 10 mM in EtOH -20°C 0.1-100 (.JM 
U46619 Tocris 0.1 mM in H2O -20°C 50-300 nM 
URB597 Sigma 10 mM in DMSO -20°C 1 (.JM 
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2.2. Ethics and Tissue Acquisition 
2.2.1. Ethical Considerations 
This study received ethical approval from the Derbyshire Research 
Ethics Committee (REC) and Derby Hospitals Foundation Trust 
Research and Development. It was carried out in accordance with the 
ethical principles outlined in the declaration of Helsinki 1996. Other 
ethical influences on this project have been the International 
Conference on Harmonisation-Guideline for Good Clinical Practice 
(sections 4 and 5), the Department of Health Governance Framework 
for health and social care 2nd edition 2005 (sections 2 and 3), the 
Human Tissue Act 2004 chapter 30 and the Data Protection Act 1998. 
2.2.2. Patient Inclusion and Consent 
Patients undergoing colorectal resections were identified from the 
elective theatre list. Patients were included In this study if they were 
above sixteen years of age and undergoing colorectal re-section for 
invasive carcinoma, colorectal polyps, Crohn's disease or diverticular 
disease. Patients were excluded from this study if they were 
undergoing emergency surgery, unable to give informed consent, had a 
mental Incapacity to give informed consent or patients who did not 
understand written or verbal information in English. Appropriate 
patients were given a Patient Information Sheet in the outpatient clinic 
several days/weeks before surgery. On the morning of the surgery the 
study was discussed with the patient and any questions were 
answered, written informed consent was then obtained. A Unique 
Patient ID was allocated to a" patients on the consent form. This 
ensured that the patient remained anonymous. A" patient Information 
including consent forms and computer files containing patient medical 
notes were kept in locked cabinets or password protected. Access to 
such files was limited to staff working on t ~ s t u d y . .
2.2.3. Patient Information 
After the patients had given informed consent the patient's 
pre-operative assessment form was viewed. This provided information 
containing the patient's medical history and a list of current medication, 
of particular interest was any conditions/medications with a known 
impact on vascular function. The information taken was used to fill out 
the patient information sheet, and used for post-hoc analysis. Patient 
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Information sheets were made anonymous and stored as stated in 
section 2.2.2. 
2.2.4. Tissue Acquisition and Transportation 
A 2-3 cm square piece of mesenteric tissue was dissected from the 
colon by a histopathologist and placed in physiological salt solution 
(PSS, see table 1 for composition), within 1 hour of removal from the 
patient. Tissue was placed on Ice and transported back to the 
laboratory. Tissue was dissected Into arterial segments and stored at 
4°C in fresh PSS solution until analysis. The time between tissue 
storage and analysis was always within 24 hours. However on average, 
tissue was used within 10 hours and the maximal time between tissue 
collection and analysis was 22 hours. 
2.3. Dissecting and Mounting 
2.3.1. Dissection Procedure 
Mesenteric arteries were dissected from tissue samples under a 
microscope using fine forceps and scissors (World Precision 
Instruments, Hertfordshire, England). Arteries were identified from 
veins due to their thicker muscular walls and an acute angle at the site 
of branching (Figure 2.1A). The luminal diameter of the artery was 
estimated according to the chosen experiment « 1 mm, for wire 
myography; > 1 mm, for fixed hook myography). Appropriate arteries 
were identified, carefully dissected from mesenteric tissue and cleaned 
of all remaining connective and adipose tissue. Arteries were cut into 
2 mm segments and placed in fresh PSS solution at 4°C and stored 
until use. However, on average the arteries were used immediately and 
therefore were not stored. The maximum length of storage was 15 
hours. 
2.3.2. Myography General 
Myographs were cleaned daily and calibrated on a bi-monthly basis as 
per the manufacturer's guidelines. Myography was carried out on a 
DMT myograph (DMT 620 myograph system, Aarhus, Denmark), using 
either wire or fixed hook myograph fixings. Recordings were made 
using lab chartS (ADInstruments, Oxford, England). Myograph 
chambers were filled with 5 mL fluid, kept at 37°C and gassed with 5% 
CO2 in 02. 
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2.3.3. Wire Myography Mounting Procedure 
A 40 J.Im tungsten wire was secured under a mounting screw with the 
unsecured end clamped in position by the myograph jaws. A 2 mm 
arterial segment was carefully positioned at the end of the wire, the 
artery was pulled over the wire and into the gap between the 
myograph jaws. The remaining free end of the wire was secured. A 
second piece of wire was passed through the artery and secured to the 
screws on the opposite myograph jaw. The mount was assessed to 
ensure wires were tight, parallel and that the artery sat in the middle of 
the jaws free of tension or obstruction. 
2.3.4. Fixed Hook Myography Mounting Procedure 
Fixed hooks were assessed to ensure they were parallel with each 
other. A 2 mm long arterial segment was placed in the myograph 
chamber. The segment was lightly manipulated and mounted over both 
fixed hooks. Once on the hooks the artery rested under no tension. 
2.3.5. Normalisation 
Arteries were normalised, setting each artery at an Internal diameter 
that produced 90% of the tension which would occur at 13.3 kPa (Lab 
chart five normalisation software, ADInstruments), this process 
Involved; arterial tension being Increased In a stepwise manner using 
the micrometer screw to open the myograph jaws/fixed hooks. On 
turning the micrometer arterial tension would sharply increase, and 
gradually relax to a plateau above baseline over a period of 2 minutes 
(Figure 2.18). This was repeated a minimum of four times until the 
target force was achieved (Figure 2.18). The force and micrometer 
readings from this process were used to determine arterial wall tension 
(mN/mm) and internal circumference (J.Im). These values were used to 
form an exponential curve, which was fitted to an Isobar curve 
corresponding to 13.3 kPa. The tension and internal circumference that 
occur at 13.3 kPa (IC1oo) is determined by the pOint at which the 
exponential curve Intersects the isobar curve, which is determined 
using the Laplace equation (Mulvany and Halpern 1977). The artery 
was set to a baseline tension that produced 90% of IClOo which enables 
rat mesenteric arteries to generate optimal active tenSion (Mulvany and 
Halpern 1977). In human arteries this Is also more effective than other 
methods available for generating optimal contractile responses from 
tissues (Wareing et al., 2002). Computational and mathematical 
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modelling have suggested that the human mesenteric circulation is 
typically exposed to between 10.2 kPa and 14.6 kPa of pressure 
(Mabotuwana et a/./ 2007). 
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Difference between arteries and veins can be seen (A). Increase and 
decrease in arterial force during normalisation (B). Force generated in 
(B) is then fitted to an isobar curve using the Laplace equation to 
determine arterial circumference at 90% 100 mmHg. 
2.4. Preliminary Studies 
2.4.1. Testing Contractile Agents on Human Mesenteric Arteries 
In vitro human mesenteric arteries were contract by depolarisation 
using 124 mM high potassium physiological saline solution (Tottrup and 
Kraglund 2004), or in the presence of the receptor agonists; 
noradrenaline (non-selective a/j3-adrenoceptor agonist (Romero et al., 
1997; Vaughan et al., 2005), U46619 (TP receptor agonist (Tottrup 
and Krag/und 2004; Hall et al., 2006)), endothe/in-1 (ETA and ETs 
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receptor agonist (Ferrero et al., 2008» and methoxamine 
(selective aI-agonist (Vaughan et al., 2005». Preliminary experiments 
were conducted to establish suitable agents and concentrations for 
contraction. In these experiments arteries were mounted and 
normalised as above. Once arteries were equilibrated and had stable 
tone, contractile agents were added in various concentrations (with the 
exception of KPSS, that was always at 124 mM), to achieve a stable 
contraction greater than 5 mN net contraction. These experiments 
revealed that noradrenaline and methoxamine were both unable to give 
stable or reliable contractions (Figure 2.2A & B). U46619 and 
endothelin-1 given alone produced reliable contractions that were 
similar to KPSS responses. However, higher doses of contractile agent 
were needed and arterial stability was often compromised (Figure 
2.2C). Given together, at lower concentrations, U46619 and 
endothelin-1 produced stable contractions that were comparable to 
KPSS responses (Figure 2.3A and B). Therefore in further experiments 
combinations of U46619 and endothelin-1 were used. 
2.4.2. Testing Vasorelaxant Agents on Human Mesenteric Arteries 
In vitro, in human mesenteric arteries, endothelium-dependent 
vasorelaxation is observed in the presence of acetylcholine (ACh) 
(Hutri-Kahonen et al., 1999) and bradykinin (BK) (Ferrero et al., 
2008). Preliminary experiments were therefore conducted to establish 
an appropriate agent and concentration to show the presence of a 
functioning endothelium. In these experiments arterial segments were 
contracted using combinations of U46619 and endothelin-l. Once a 
stable contraction above 5 mN was achieved, a single dose (10 IJM) of 
ACh or BK was added to the myograph chamber. ACh caused 
vasorelaxation (37 ± 6% [mean ± standard error of mean (s.e.m)) 
n=7) (Figure 2.3B), which is lower than has previously been reported 
(Hutri-Kahonen et al., 1999). However BK caused vasorelaxation (74 ± 
6%, n=7) (Figure 2.3A) similar to that previously reported (Ferrero et 
al., 2008). Therefore, vasorelaxation to bradykinin that was ~ 7 0 % % was 
used to show the presence of a functioning endothelium. 
2.4.3. Standard Start Protocol 
A standard start protocol was then devised in order to control for 
variation in arterial function. The protocol was based on experiments 
carried out in 2.4.1 and 2.4.2 and was designed to test contractile 
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ability and endothelium-dependent vasorelaxation. Arterial contraction 
to KPSS is mediated via membrane depolarisation and calcium influx 
through voltage-operated calcium channels (Karaki et al., 1997). 
Arterial contraction to U46619 is mediated through TP receptor 
activation and subsequent release of calcium from intracellular stores 
(Hall et al., 2006). Therefore, testing artery contractions in such a way 
enabled both these pathways to be observed. BK-induced 
vasorelaxation is endothelium-dependent and associated with NO 
production and potassium channel activation (Chadha et al., 2011). 
Therefore, testing arteries in this way allowed for the assessment of 
the function of the endothelium. To carry out these assessments, 
arteries were dissected, mounted and normalised as section 2.3. Once 
arterial segments were normalised 124 mM KPSS was added to the 
myograph chamber, if a contraction of less than 5 mN was observed 
the artery was discarded. In arteries where the contractile response 
was greater than 5 nM the chamber was washed out a minimum of 
three times with PSS. Once baseline arterial tone had stabilised, 50 nM 
U46619 was added to the myograph chamber. If a contraction greater 
than 5 mN was not observed, the artery was discarded. However, in 
arteries where a stable contraction greater than 5 mN was observed a 
concentration of 10 IJM BK was added. Arteries were discarded if a 
vasorelaxation less than 70% was achieved. Arteries were then washed 
out a minimum of three times and arterial tone allowed to stabilise 
before conducting cannabinoid experiments. This protocol can be 
viewed as a schematic in Figure 2.4. 
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Figure 2.2 Preliminary studies trace data. 
Trace data showing the effects of the contractile agents, noradrenaline 
(A), methoxamine (8), endothelin - l (top pane C) and U46619 (lower 
pane C). 
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Figure 2.3 Endothelium-dependent vasore laxant agents. 
Screening endothelium-dependent vasorelaxation to BK (A) and ACh 
(B) in arteries contracted using U46619 and endothelin-l in 
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Figure 2.4 Standard start protocol 
Protocol derived from preliminary experiments and was subsequently 
carried out to validate arterial segments. 
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2.5. Concentration-Response Curves 
2.5.1. Contraction and Artery Stability 
Viable arteries were washed out a minimum of three times with fresh 
PSS and baseline allowed to stabilise over :::::20 minutes. Arteries were 
exposed to 50 nM U46619 and 1 nM endothlin-l to induce contraction. 
If an increase of 5 mN force was not achieved, further U46619 and 
endothlin-l was added until a maximum of 300 nM U46619 or 10 nM 
endothelin-l had been added. Contractions were allowed to stabilise 
over a period of :::::20 minutes Figure 2.5A. 
2.5.2. Addition of Cannabinoid 
Concentrations of cannabinoids were added in five minute intervals in a 
cumulative manner (O'Sullivan et al., 2004). Cannabinoids and vehicle 
were diluted as described in table 2.3. Once a stable contraction had 
been achieved, cannabinoid (100 nM-l00 !-1M) or ethanol (0.001-1%) 
was added 'to the chamber as described in table 2.3. Figure 2.5A shows 
a trace sample of a concentration-response curve. 
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Table 2.3 Concentration-response curve 
Volume and concentrations used in concentration-response curves in all 
cannabinoid experiments. Additions were made to the myograph 
chamber in 5-minute intervals. 
Compound Stock Volume Added to Cumulative Bath 
8 Concentration 
" ~ 0 0 0
Bath 8 8 Concentration 8 ~ ~ ~ ~ ~
¥!iN ii'N ~ ~ 8 0 
" 0 
B 0'\G'%iY0 Gyi& f#$0!iD \\ is'&: @ B* XiX", M \; \; 
Ethanol Vehicle 1% in H2O 5 IJL 0.001% 
1% in H2O 10 IJL 0.003% 
1% in H2O 35 IJL 0.01% 
10% in H2O 10 IJL 0.03% 
10% in H2O 35 IJL 0.1% 
10% in H2O 100 IJL 0.3% 
100% in H2O 35 IJL 1% 
Cannabinoid 100 IJM in H2O 5 IJL 100 nM 
100 IJM in H2O 10 IJL 300 nM 
100 IJM in H2O 35 IJL 1 IJM 
1 mM in H2O 10 IJL 3 IJM 
1 mM in H2O 35 IJL 10 IJM 
1 mM in H2O 100 IJL 30 IJM 
10 mM in EtOH 35 IJL 100 IJM 
2.5.3. Measurements 
Measurements of artery responses were taken in the final minute after 
cannabinoid addition!vehicle addition (Figure 2.5A). Responses were 
determined as shown in equation 1. 
% reduction in pre - imposed tone = (Contractile tone - drug response) + 
(Contractile tone - baseline tone)xlOO 
Equation 1. Equation used to calculate the %reduction in pre-imposed 
tone 
2.5.4. Time-dependence Experiments 
To establish potential time-dependent vasorelaxation induced by 
cannabinoids, the largest arteries available in mesenteric tissue 
samples (> 1 mm) were dissected. Arteries were mounted onto fixed 
hooks and subjected to the same standard start protocol as previously 
described. Viable arteries were contracted using a combination of 
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U46619 and endothelin-1 and allowed to stabilise. Once vessel stability 
had been maintained for ~ 2 0 0 minutes, a single concentration of 
cannabinoid or vehicle control was added. Measurements were taken 
directly before addition of cannabinoid or vehicle and at 15 minute 
intervals thereafter (O'Sullivan et at., 2005) (Figure 2.58) 
o 
1 : 50 :00 2 :00:00 2 : 1 0 :00 
20 
Figure 2.5. Cannabinoid responses. 
Traces of typical concentration response curve (A), or time-dependent 
response curve (8). Cannabinoids were added, either in 5-minute 
intervals (A) or as one concentration (8), once a stable contraction had 
been maintained for 20 minutes. Responses were taken in the last 
minute of each 5-minute period for acute vasorelaxation studies (A), or 
in the last minute of each 15-minute period in time dependence studies 
(8). 
2.6. Tissue Overnight Storage 
2.6.1. Storage Procedure 
For feasibility reasons some tissues were stored overnight (4°C) and 
used the following day. All arterial segments stored overnight were 
used within 24 hours of collection from theatre. 
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2.6.2. Assessment of Contractile Responses in Arterial Segments Used 
Fresh and After Storage 
To assess the effects of overnight storage, the second KPSS and the 
50 nM U46619 responses were compared between fresh arteries and 
arteries that had been stored overnight. The average second 
contraction to KPSS was not Significantly different between arteries 
used fresh or arteries stored overnight (fresh artery segments 23 ± 1 
mN, n=291; arterial segments stored overnight 21 ± 1 mN, n=197; 
see Figure 2.6A). The second KPSS response was taken as the arteries 
maximum contractile response, therefore the response to 50 nM 
U46619 was expressed as a percentage of the second KPSS. Responses 
to 50 nM U46619 were also unaltered by overnight storage of arterial 
segments (fresh artery segments 85 ± 2% 2nd KPSS [mean ± s.e.m], 
n=291; artery stored overnight 88 ± 2% 2nd KPSS, n=197; see Figure 
2.6B). 
2.6.3. Assessment of Bradykinin in Arteries Used Fresh and After 
Storage 
To assess whether overnight storage affects endothelium-dependent 
vasorelaxation, 10 ~ M M bradykinin responses were compared between 
both sets of arteries. Bradykinin responses were not Significantly 
altered by overnight storage of arteries (fresh artery segments 88 ± 
1 % relaxation, n=258; artery segments stored overnight 85 ± 1% 
relaxation, n=181; see Figure 2.6C) 
2.6.4. Assessment of Cannabinoid Responses in Arteries Used Fresh 
and After Storage 
To assess whether overnight storage affects concentration-response 
curves to cannabinoids comparisons were made between both sets of 
arteries (n=6). There was no difference between cannabinoid 
vasorelaxant responses in arteries used fresh compared to those stored 
overnight (Figure 2.7 A, B, C, D & E). Given that contractile and 
vasorelaxant responses (cannabinoid and bradykinin) were unaltered, 
subsequent studies were carried out either fresh (66% of patient 
samples) or after overnight storage (34% of patient samples). 
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A 
D Fresh (n=291) 
- Overnight (n=197) 
B 
D Fresh (n=291) 
• Overnight (n=197) 
C 
D Fresh (n=258) 
_ Ovemight (n=181) 
Figure 2.6 Effects of overnight storage (non-cannabinoid responses) 
Comparisons of vascular responses to 124 mM KPSS (A), 50 nM 
U46619 (B) and 10 ~ M M bradykinin (C) in arteries used fresh or after 
overnight storage. Bars represent mean with error bars representing 
s.e.m. Comparisons were made using Mann Whitney test with P<0.05 
taken as significant. 
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Figure 2.7 Effects of overnight storage (cannabinoid responses) 
Comparisons between vasorelaxation responses to CPSS,940 (A), CBO 
(B), THC (C), 2-AG (D) and AEA (E) in arteries used fresh or after 
overnight storage. Data pOints represent means with error bars 
representing s.e.m. Comparisons made between arteries used fresh 
and after overnight storage using 2-way analysis of variance of 
concentration response curve with P<O.OS taken as significant. 
60 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
2.7. Pharmacological Investigations 
2.7.1. Receptor Antagonism 
Cannabinoids act through a range of receptors in the vasculature 
(reviewed Randall et a/., 2004). To probe the potential receptor 
involvement underpinning the vasorelaxant responses to cannabinoids 
a range of antagonists was used. 
AM251 
AM251 is an analogue of rimonabant, synthesised with chlorine 
substituted for iodine by the Makriyannis group in 1996 (Lan et a/., 
1996; Gatley et a/., 1997). AM251 binds to the CB1 receptor with a K; 
value of 7.49 nM and to the CB2 receptor with a K; 2,290 nM (Lan et 
a/., 1999). At high concentrations, it has been suggested that AM251 
may act as an inverse agonist or as an allosteric modulator at the CB1 
receptor site (Pertwee 2005). AM251 has also been shown to be an 
agonist of the novel G protein-coupled receptor GPR55 (Ryberg et a/., 
2007). AM251 (100 nM) inhibits cannabinoid-induced vasorelaxation in 
a range of vascular preparations (O'Sullivan et a/., 2004). AM251 
(100 nM (O'Sullivan et a/., 2004) was added to the myograph chamber 
10 minutes before arteries were contracted. Incubation with AM251 
had no effect on arteries baseline or contractile tone (see tables 2.4, 
2.5, 2.6). 
LY320135 
LY320135 is a benzofuran that is structurally distinct from the pyrazole 
structures of rimonabant and AM251 and was synthesised by Eli Lilly. 
LY320135 has affinity for CB1 of 224 nM and > 10,000 nM for the CB2 
receptor (Felder et al., 1998). However, at concentrations of >2 IJM 
LY320135 has been shown to antagonise; muscarinic, 5HT2, H1, 
adrenoceptors (OJ02) and dopamine (DJD2) receptors (Felder et a/., 
1998). LY320135 (1 IJM) has been shown to reverse the effects of 
CP55,940 in the rat mesenteric bed (Duncan et a/., 2004). LY320135 
(1 IJM, Duncan et a/., 2004) was added to arteries 30 minutes before 
contraction and did not affect baseline or contractile tone (see table 
2.5). 
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AM630 
AM630, an aminoalkylindole synthesised by the Makriyannis group in 
1995 (Pertwee et al., 1995), displays affinity for the CB2 receptor at 
31.2 nM and affinity for the CB1 receptor at 5,152 nM (Ross et al., 
1999). AM630 in the micromolar range has been shown to behave as a 
weak/partial agonist at the CB1 receptor (Ross et al., 1999). However, 
it has also been reported that AM630 may act as a CB1 inverse agonist 
(Landsman et al., 1998; Vasquez et al., 2003). AM630 has been shown 
to antagonise the vasorelaxant effects of cannabinoids (McDougall et 
al., 2008). In this study a concentration of 100 nM was used and, as 
per (O'Sullivan 2009), this was added to the myograph chamber 10 
minutes before contraction. Incubation with AM630 had no effect on 
vessel baseline or contractile tone (see tables 2.4, 2.5 and 2.6). 
0-1918 
0-1918 is an analogue of cannabidiol that was synthesised by the 
Kunos group and is unable to displace [3H] CP55,940 from CB1 or CB2 
receptors at concentrations up to and including 30,000 nM (Offertaler 
et al., 2003). 0-1918, an antagonist of the proposed novel endothelial 
cannabinoid receptor, inhibits cannabinoid-induced vasorelaxation in a 
range of vascular preparations (Offertaler et al., 2003; Hoi and Hiley 
2006) including human (Kozlowska et al., 2007; Kozlowska et al., 
2008). 0-1918 (10 j.JM, (Kozlowska et al., 2007» was added ten 
minutes before contraction. Incubation with 0-1918 had no effect on 
vessel baseline or contractile tone (see tables 2.5 and 2.6). 
Capsaicin 
Capsaicin is the chemical component responsible for heat and pain 
associated with chilli peppers. Capsaicin binds to TRPV1 channels with 
high affinity and can cause desensitisation and closure of the channel 
(Szallasi and Blumberg 1999). Capsaicin interacts with several targets 
other than TRPVl channels including, blockade of K+ channels, enzyme 
inhibition and alterations in membrane permeability (Szallasi and 
Blumberg 1999). In the guinea-pig basilar artery, rat hepatiC and rat 
mesenteric artery pre-treatment with capsaicin (10 j.JM) inhibits the 
vasorelaxant response of AEA (Zygmunt et al., 1999). Capsaicin 
(10 j.JM, (Zygmunt et al., 1999)) was added to the myograph chamber 
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and allowed to incubate for 1 hour. Arteries were washed out three 
times and contracted. Incubation with capsaicin significantly decreased 
baseline tone when compared to time control but had no effect on 
contractile tone (see tables 2.4 and 2.6). 
Cay10441 
Cay10441 is a 2-(phenylamino) imidazoline that demonstrates high 
affinity binding to human IP receptors with a K; of around 1.5 nM (Clark 
et al., 2004). Cay10441 does not bind to prostanoid EPjFP and TP 
receptors and does not have actions at a range of 30 other receptor 
and ion channel sites (Clark et al., 2004). However, Cayl0441 has 
been shown to bind to the a2A receptor (K; 3 !-1M) and the imidazoline 12 
receptor (K; 1.5 nM). In rat mesenteric arteries Cayl0441 (100 nM) 
antagonises IP receptor-induced vasorelaxation to novokinin (Yamada 
et al., 2008). Cayl0441 (100 nM, (Yamada et al., 2008)) was added to 
arteries 10 minutes before contraction. Incubation with Cay10441 had 
no effect on artery baseline or contractile tone (see table 2.4). 
L-161982 
L-161982 is a potent antagonist of the prostanoid EP4 receptor 
(Machwate et al., 2001). L-161982 also displays affinity at prostanoid 
EP1, EP2 , EP3, FP, IP, DP and TP receptors with K; values of 19.2, 19.2, 
1.9, 5.6, 6.8, 5.1 and 0.7 !-1M respectively (Machwate et al., 2001). 
L-161,982, through antagonism of EP4 receptors, has been shown to 
inhibit lipo-polysaccharide- (LPS) induced relaxation of mouse trachea 
(Balzary and Cocks 2006). L-161982 (1 !-1M (Balzary and Cocks 2006)) 
was added to the bath 10 minutes before contraction. Incubation with 
L-161982 had no effect on artery baseline or contractile tone (see table 
2.4). 
AH6809 
AH6809 antagonises prostanoid EP1, EP2, EP3, DP and TP receptors with 
Ki values of 1.2, 1.2, 1.6, 1.4 and 4.3 !-1 M respectively (Abramovitz et 
al., 2000). In rat mesenteric arteries, AH6809 (10 !-1M) inhibits 
vasorelaxation to 14,15-epoxyeicosatrienoic acid (14,15 EET) through 
antagonism of the EP2 receptors (Yang et al., 2010). AH6809 (10 !-1M 
(Yang et al., 2010)) was initially added to arteries 30 minutes before 
contraction. At this concentration AH6809 had no effect on artery 
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baseline tone but did Inhibit contractions (see table 2.4). Therefore a 
lower concentration of 1 !-1M was used. This concentration had no effect 
on artery baseline tone or contractile responses (see table 2.4). 
GW9662 
In (AOxh-TK-Luc promoter-transfected RAW264.7 macrophage cells, 
GW9662 antagonised BRL49653 activation of peroxisome proliferator 
activated receptor gamma (PPARy) (Huang et al., 1999). GW9662 
binds to PPARy, PPARa and PPARZS with respective IC50 values of 3.3, 
32 and 2000 nM (Leesnitzer et al., 2002), and at concentrations of 
1 !-1M has been shown to inhibit the time-dependent vasorelaxant 
effects of cannabidiol in rat aortae (O'Sullivan et al., 2009). GW9662 
(1 !-1M, (O'Sullivan et al., 2009» was added to arteries 10 minutes 
before contraction. Incubation with GW9662 had no effect on baseline 
tone or contractile response (see table 2.5 and 2.6). 
2.7.2. Enzyme Inhibition 
Endogenous cannabinoids can be degraded by a variety of different 
enzymes Including fatty acid amide hydrolase (FAAH), 
monoacylglycerol lipase (MAGL) and cyclooxygenase-2 (COX-l/-2) 
(Muccloli 2010). In some experiments, a range of inhibitors of these 
enzymes was used. 
URB597 
The carbamic acid ester URB597 was synthesised by the Piomelli group 
in 2003 (Kathurla et al., 2003). URB597 has an IC50 for fatty acid 
amide hydrolase of 5.6 nM and has no effect on the expression of 
monoacylglycerol lipase in rat brain homogenates or the binding of 
WIN55,212-2 to CBl and CB2 receptors in rat cerebellum membranes or 
transfected CHO cells respectively (Kathuria et al., 2003). In later 
studies, it has been shown that URB597 also has no action at a range 
of other receptors, transporters and enzymes including COX-l/-2 
(Piomelli et al., 2006). However, URB 597 (24.5 !-1M) activates TRPAl 
channels in transfected HEK cells (Niforatos et al., 2007). Furthermore, 
in activity based protein profiling studies using mouse and human liver 
proteomes URB597, at a concentration range between 0.5-100 !-1M, 
showed inhibition of a range of serine hydrolase peptides (Ahn et al., 
2007). In the rat mesenteric artery URB597 enhanced the vasorelaxant 
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responses to anandamide (Ho and Randall 2007). URB597 (1 ~ M , , (Ho 
and Randall 2007» was added to arteries 30 minutes before 
contraction. Incubation with URB597 had no effect on vessel baseline 
or contractile tone (see table 2.4 and 2.6). 
JZL184 
JZL184 is a carbamate synthesised as an irreversible inhibitor of 
monoacylglycerol lipase with an ICso of 8 nM for inhibition of 2-AG 
hydrolysis (Long et al., 2009). JZL184 also inhibited ABHD6 and FAAH 
but at a higher concentration (10 IJM) (Long et al., 2009). JZL184 
(1 IJM, (Long et al., 2009» was added to arteries 30 minutes before 
contraction. Incubation with JZL184 had no effect on vessel baseline or 
contractile tone (see table 2.4). 
Indomethacin 
Indomethacin is a non-steroidal anti-inflammatory drug, which in 
human blood inhibits both cyclooxygenase isoforms (COX-l and 
COX-2) with ICso values of 230 and 630 nM respectively (Palomer et 
al., 2002). Indomethacin, at 40 and 100 ~ M , , has activities at PPARy 
and PPARa respectively (Lehman 1996). At 100 IJM, indomethacin 
inhibits CP55,940 binding to CB l receptors, and can inhibit anandamide 
hydrolysis by fatty acid amide hydrolase (Holt et al., 2007). 10 ~ M M
indomethacin caused inhibition of vasorelaxation to virodhamine in the 
human pulmonary artery (Kozlowska et al., 2008). Indomethacin 
(10 ~ M , , (Kozlowska et al., 2008» was added to the arteries 30 minutes 
before contraction. Incubation with indomethacin had no effect on 
vessel baseline or contractile tone (see tables 2.4, 2.5 and 2.6). 
Flurbiprofen 
Flurbiprofen is a non-steroidal anti-inflammatory agent, which 
preferentially Inhibits COX-lover COX-2 (ICso 100 nM COX-l compared 
ICso 400 nM COX-2) (Gierse 1995). Flurbiprofen, at a concentration of 
3 ~ M M inhibited capsaicin-induced calcitonin gene-related peptide 
release, an effect that can be inhibited by AM251 (Seidel et al., 2003), 
and in a pH dependant manner flurbiprofen inhibits FAAH metabolism 
of AEA (Fowler et al., 2003). Flurbiprofen (10 ~ M ) ) potentiates the 
effects of 2-AG in the rat mesenteric artery (Ho and Randall 2007). 
Flurbiprofen (10 ~ M , , (Ho and Randall 2007» was added to arteries 30 
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minutes before contraction. Incubation with flurbiprofen had no effect 
on vessel baseline or contractile tone (see table 2.4). 
Nimesulide 
Nimesulide is a selective COX-2 inhibitor, which binds to COX-2 with an 
ICso of 10 nM. Nimesulide binds to COX-l at concentrations greater 
than 10 ~ M M (Cullen et al., 1998). Unlike flurbiprofen, nimesulide was 
shown not to affect FAAH metabolism of AEA (Fowler et al., 2003) 
Nimesulide (10 IJM) potentiates the effects of anandamide In the rat 
mesenteric artery (Ho and Randall 2007). Nimesulide (10 IJM, (Ho and 
Randall 2007» was added to arteries 30 minutes before contraction. 
Incubation with nimesulide had no effect on baseline or contractile tone 
(see table 2.4). 
2.7.3. Endothelium Dependence 
Cannabinold-Induced vasorelaxation has been shown to have an 
endothelium-dependent component. This component includes 
stimulation of nitric oxide release (Deutsch et al., 1997), through 
activation of an as yet unidentified endothelium-derived hyperpolarising 
factor (Randall et al., 1996) and activation of an as yet uncharacterised 
endothelial receptor (Offertaler et al., 2003). In some experiments, 
techniques were used to test the possibility that cannabinoids 
responses were endothelium-dependent (O'Sullivan et al., 2004). 
L-NAME 
L-NAME is an inactive NOS Inhibitor that requires hydrolysiS to an 
active form to Inhibit NOS (Griffith and Kilbourn 1996). L-NAME Inhibits 
Inducible-, neuronal- and endothelial-NOS with an ICso values of 4.5, 
6.1 and 5.8 IJM respectively (Boer et al., 2000). L-NAME, alone 
(Deutsch et al., 1997), or In combination with indomethacin and 
potaSSium channel blockers (O'Sullivan et al., 2004), has been shown 
to Inhibit endocannablnold-Induced vasorelaxation in a variety of rat 
vascular beds. L-NAME (300 IJM, (O'Sullivan et al., 2004» was added 
to arteries after standard start protocol and present throughout. 
Incubation with L-NAME had no effect on vessel baseline or contractile 
tone (see tables 2.4, 2.5 and 2.6). 
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Endothelial Denudation 
Vasorelaxation to a range of cannabinoids is reduced via removal of the 
endothelium (Mukhopadhyay et al., 2002; O'Sullivan et al., 2004; 
Kozlowska et al., 2007; Kozlowska et al., 2008). In some experiments 
the endothelium was removed via gentle abrasion with a human 
forearm hair. The removal of the endothelium was confirmed by < 10% 
vasorelaxation to 10 IJM bradykinin. Endothelium denudation had no 
effect on contractile tone (see tables 2.4, 2.5 and 2.6) 
2.7.4. Ion Channel Modulation 
In many studies cannabinoids have been shown to modulate ion 
channel activity either by inhibition of Ca2+ channels (Caulfield and 
Brown 1992; Mackie and Hille 1992; Ross et al., 2008) or through 
opening of K+ channels (Hampson et al., 1995). Therefore, in some 
experiments a potential role for ion channel involvement was assessed. 
The techniques used are described below with details of the effect 
these techniques had on vessel tone. 
Experiments in the Absence of Ca2+ 
Calcium flux has a key role in controlling vascular tone; removing 
extracellular calcium limits the available calcium to that which can be 
released from intracellular stores. Several vasorelaxant agents 
including ACh cause release of Intracellular calcium and influx of 
extracellular calcium in their vasorelaxant mechanisms (Socha et al., 
2012). To establish a potential role of extrace"ular calcium, in some 
arteries, extracellular calcium was removed from the buffer after the 
standard start protocol. These arteries were incubated for a minimum 
period of ten minutes, contracted and cannabinoid 
concentration-response curves were carried out. Removal of Ca2+ from 
PSS had no effect on vessel baseline or contractile tone (see table 2.4). 
CaCI2 Contraction Experiments 
CaCI2 contractions in high potassium medium are mediated through 
voltage-operated calcium channels (VOCCs) (Xu et al., 2012). 
Cannabinoids inhibit a range of VOCCs (Caulfield and Brown 1992; 
Mackie and Hille 1992; Ross et al., 2008), and oppose CaCI2 
contractions in the rat aortae (O'Sullivan et al., 2009). In some arteries 
the role of Ca 2+entry was assessed by bathing arterial segments (10 
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minutes) in Ca2+ -free PSS, then for 10 minutes in Ca 2+ -free KPSS and 
then carrying out a concentration-response curve to CaCb (0.001-30 
mM) in the presence of cannabinoid or vehicle control. 
KPSS-contracted arterial segments 
KPSS causes depolarisation of arteries and causes contraction through 
VOCCs (Karaki et al., 1997). Synthetic cannabinoids have previously 
been shown to relax KPSS-pre-contracted rat mesenteric arteries, 
through receptor-mediated VOCC inhibition (White and Hiley 1998). 
KPSS contractions also limit potaSSium efflux (Quignard et al., 1999). 
To explore these possibilities, some arteries were contracted with KPSS 
solution and cannabinoid concentration-responses curves carried out. 
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Table 2.4 Effects of a range of inhibitors/antagonists on artery baseline 
tone and contractile responses, 2-AG studies. 
The effects of the inhibitors used in 2-AG experiments on baseline tone 
and contractile responses. II alteration in baseline tone determined by 
the baseline tone after addition of inhibitor/antagonist minus baseline 
tone before addition of inhibitor/antagonist. Contractile tone to U46619 
(10-300 nM) in combination with endothelin-1 (1-10 nM) is expressed 
as percentage of response to 124 mM KPSS. Values given ± s.e.m with 
n equal to the number of patients. Comparisons made using 1-way 
ANOVA with Dunnett's post-hoc test to compare all responses to time 
control. ** P<O.Ol 
Artery; treatment 6asellne tonl!l mN Contrl!lctlll!l t"'l 
fi1 a l t l ! l t ~ ~ t l o n J J 'rOI'le C ~ / ~ ~
KPSS) 
Time control -0.05±O.03 80±4 44 
AH6809 (1 JJM) -0.35±0.66 60±7 6 
AH6809 (10 !-1M) 0.9±0.9 34±20** 5 
AM251 0.11±0.04 91±13 7 
AM630 0.28±0.18 85±13 5 
Calcium free PSS 0.31±0.09 73±7 7 
Capsaicin -1.13±0.S2** 89±13 6 
CAY10441 0.23±0.36 79±6 9 
Endothelium-denuded 81±6 8 
Flurbiprofen -0.31±0.27 83±7 6 
Indomethacin -0.29±0.2S 98±3 8 
JZL 184 -0.14±0.11 82±4 8 
L161982 -0.3S±0.3S 84±14 6 
L-NAME -0.07±0.03 97±10 6 
Nimesulide 0.18±0.15 93.7±8 10 
URB597 -0.20±0.19 76±10 7 
69 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
Table 2.5 Effects of a range of inhibitors/antagonists on artery baseline 
tone and contractile responses, CBO studies 
The effects of the inhibitors/antagonists used in CBO experiments on 
baseline tone and contractile responses. fl alteration in baseline tone 
determined by the baseline tone after addition of inhibitor/antagonist 
minus baseline tone before addition of inhibitor/antagonisL Contractile 
tone to U46619 (10-300 nM) in combination with endothelin-1 
(1-10 nM) is expressed as percentage of response to 124 mM KPSS. 
Values given ± s.e.m with n equal to the number of patients. 
Comparisons made using l-way ANOVA with Dunnett's post-hoc test to 
compare all responses to time control. 
Table 2.6 Effects of a range of inhibitors/antagonists on artery baseline 
tone and contractile responses, AEA studies. 
The effects of the inhibitors/antagonists used in AEA experiments on 
baseline tone and contractile responses. fl alteration in baseline tone 
determined by the baseline tone after addition of inhibitor/antagonist 
minus baseline tone before addition of inhibitor/antagonist. Contractile 
tone to U46619 (10-300 nM) in combination with endothelin-l 
(1-10 nM) is expressed as percentage of response to 124 mM KPSS. 
Values given ± s.e.m with n equal to the number of patients. 
Comparisons made using l-way ANOVA with Dunnett's post-hoc test to 
compare all responses to time control. ** P<O.Ol 
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2.8. Statistical Analysis 
Unless otherwise stated, data are displayed as means with error bars 
representing s.e.m and n equalling the number of different patients. In 
contractile studies data pOints are derived from either the absolute 
response (mN) or the 11 value. In all relaxation studies, the percentage 
reduction in pre-imposed tone was used (see equation 1). In contractile 
and relaxant studies, sigmoidal concentration-response curves were 
fitted to these data using three-parameter logistic equation (bottom, 
top and ECso) and a standard Hill slope of 1 in Prism (Version 5; 
GraphPad Software, La Jolla, California, USA). A standard Hill slope of 1 
was chosen based on curve fit and given the low number of data 
pOints. 
2.8.1. Statistical Analysis Used in Artery Storage 
Second KPSS, U46619 and bradykinin responses were assessed for 
normal distribution using the Kolmogorov-Smirnov test. This revealed 
that these data were not normally distributed and therefore a Mann 
Whitney U test was used to compare arteries used fresh or those that 
had been stored overnight. To compare the potential effects of 
overnight storage on cannabinoid responses, data were tested for 
normal distribution using the Kolmogorov-Smirnov test. Data were 
normally distributed and therefore a two-way analysis of variance 
(2-way ANOVA) with a Sonferroni post-hoc test was used to compare 
whole data sets. P<O.OS was taken as significant. 
2.8.2. Statistical Analysis Used in Cannabinoid Experiments 
Vehicle control and cannabinoid test artery data sets were assessed for 
normal distribution using a Kolmogorov-Smirnov test. All data sets 
were found to have a normal distribution. Therefore, whole data sets 
were compared using 2-way ANOVA with Sonferroni post-hoc test. 
P<O.OS was taken as significant. In some experiments pECso and Rmax 
were compared using i-way ANOVA with Sonferroni post-hoc test. 
2.8.3. Statistical Analysis Used in Analysis of Patient Notes 
Cannabinoid concentration-response curves were compared between 
patients with various cardiovascular diseases/cardiovascular disease 
risk factors and those without. Artery data sets were assessed for 
normal distribution using a Kolmogorov-Smirnov test. All data sets 
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were found to have a normal distribution. Therefore, whole data sets 
were subsequently compared using 2-way ANOVA with Bonferroni 
post-hoc test. P<O.OS was taken as significant. 
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3. VASORELAXANT EFFECTS OF CANNABINOIDS IN HUMAN 
MESENTERIC ARTERIES 
3.1. Introduction 
The first evidence of the vasodilator effects of cannabinoids were 
shown using THC and AEA in rabbit cerebral arteries (Ellis et al., 1995). 
This study found that both THe and AEA caused ~ 2 5 % % vasodilation at 
concentrations between 0.1 and 1 mM (Ellis et al., 1995). The effects of 
AEA but not THC were attributed to increases in the production of 
prostaglandin E2 (PGE2) and PGh and could be inhibited using 
indomethacin (Ellis et al., 1995). Since then much work has been 
carried out to support the vasorelaxant effects of cannabinoids in 
various vascular preparations, however efficacy, potency and 
mechanisms of action often differ depending on the cannabinoid, the 
species used or the vascular bed studied (reviewed in Randall et al., 
2004). 
In vitro studies using rat third order mesenteric arteries showed 
that AEA causes maximal vasorelaxation that is partly 
endothelium-dependent and sensitive to CBl antagonism (White and 
Hiley 1997), with similar findings reported by O'Sullivan et al (2004). 
However, AEA efficacy is reduced in larger mesenteric arteries from the 
rat, which may be explained by the loss of an endothelial dependent 
component in these arteries (O'Sullivan et al., 2004). The effects of 
AEA in larger mesenteric arteries or in the mesenteric bed, despite 
being endothelium-independent, are inhibited by rimonabant (Randall 
et al., 1996; O'Sullivan et al., 2004), desensitisation of the TRPV1 
receptor (O'Sullivan et al., 2004) or inhibition of potassium efflux 
(Randall et al., 1996), implicating that the main vasorelaxant pathways 
in these preparations are activation of potassium channels and CBl 
and TRPV1 receptors. These studies found no role for the production of 
nitric oxide in AEA-induced vasorelaxation. In contrast, in small rat 
renal arteries, AEA caused vasorelaxation through CB1- and nitric 
oxide-dependent pathways (Deutsch et al., 1997). This study also 
showed that rat renal endothelial cells produce nitric oxide when 
stimulated with AEA via CBl activation. 
The first work to study the effects of AEA in human arteries used 
the myometrial vascular bed and found that AEA did not cause 
vasorelaxation (Kenny et al., 2002). In the human forearm 
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microcirculation, Intra-arterial administration of AEA had no significant 
effect on blood flow, however dermal application of AEA (30 mM) 
increased forearm blood flow in a TRPV1 receptor-dependent manner 
(Movahed et al., 2005). The only other study to look at the effects of 
AEA In human arteries is that of Kozlowska et al. (2007). This study 
showed that AEA caused maximal vasorelaxation of larger (2-4 mm 
outer diameter) human pulmonary arteries. The mechanisms of AEA 
action in the human pulmonary artery were not probed by Kozlowska et 
al. (2007). 
2-AG causes maximal vasorelaxation of bovine coronary 
arteries, which is dependent on metabolism through MAGL, FAAH, COX 
and cytochrome P450 pathways (Gauthier et al., 2005). In rat third 
order mesenteric arteries, 2-AG causes near maximal vasorelaxation, 
which can be enhanced to maximal vasorelaxation by incubating 
arteries with the COX-1 Inhibitor flurbiprofen (Ho and Randall 2007). In 
rabbit mesenteric arteries, 2-AG caused near maximal vasorelaxation 
which is unaffected by inhibition of COX and nitric oxide, blockade of 
potassium channels or endothelial denudation, but is inhibited by high 
concentrations of CB l antagonist (Kagota et al., 2001). By contrast, In 
rat isolated aortiC rings 2-AG causes COX-mediated contractions 
(Stanke-Labesque et al., 2004). There have been no reports of the 
effects of 2-AG in human arteries. However one study has reported that 
2-AG causes release of nitric oxide In human artery endothelial cells 
(Stefano et al., 2000). 
THC causes half-maximal vasorelaxation of third order 
mesenteric arteries that is dependent on G protein-coupled receptors 
and Ion channel modulation (O'Sullivan et al., 2005). In the rat 
mesenteric vascular bed, the vasorelaxant effects of THC are reduced 
in arterial branches closer to the superior mesenteric artery, with THC 
causing contraction In the superior mesenteric artery (O'Sullivan et al., 
2005). In the rat aorta however, THC causes slight vasorelaxation with 
similar efficacy and potency to that of AEA (O'Sullivan et al., 2005). In 
the rat aorta the effects of THC are inhibited by PTX, TRPV1 
desensltlsatlon and removal of the endothelium, whilst the effects of 
AEA are Inhibited by PTX only (O'Sullivan et al., 2005). 
The potential vasorelaxation/vasoconstriction effects of CBD 
have not been fully reported In any vascular preparation. In arterial 
segments from the rat mesenteric vascular bed, CBO caused a 
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concentration-dependent near-maximal vasorelaxation (Offertaler et 
al., 2003), but the underlying mechanisms were not probed. In several 
studies, including those involving human arteries, CBD has been 
proposed as an antagonist of a proposed novel endothelial cannabinoid 
receptor (Offertaler et al., 2003; Kozlowska et al., 2007). 
Synthetic cannabinoid ligands have been reported to cause 
vasorelaxation. CP55,940 caused maximal vasorelaxation of rat third 
order mesenteric arteries, which was sensitive to CB l antagonism 
(White and Hiley 1998; O'Sullivan et al., 2004). Vasorelaxation to 
CP55,940 was found to be endothelium-independent and had both 
receptor-mediated and direct action on ion channels (White and Hiley 
1998). In rat aortae, CP55,940 caused maximal vasorelaxation 
sensitive to CB2 antagonism (O'Sullivan et al., 2005). Synthetic CB2 
specific ligands have also been reported to cause both hypotension and 
vasorelaxation. In vivo, HU-308 caused hypotension of rats that was 
inhibited by CB2 receptor antagonism (Hanus et al., 1999). JWH-015 
caused maximal vasorelaxation of rat mesenteric arteries, which was 
mainly through inhibition of Ca2+ entry and was not inhibited by CB2 
antagonism (Ho and Hiley 2003). Topical application of JWH-015 or 
JWH-133 also caused slight or half-maximal vasorelaxation in rat knee 
synovial blood vessels (McDougall et al., 2008). In this study CB2 
antagonism inhibited the effects of JWH-133 but not JWH-015 
(McDougall et al., 2008). 
In summary, a wealth of research has shown that 
endocannabinolds, phytocannabinoids and synthetic cannabinoid 
ligands are capable of causing vasorelaxation in a range of vascular 
beds. However, few studies to date have investigated the effects of 
cannabinoids in human. 
3.2. Aims 
The aim of this study was to screen a range of cannabinoids in their 
ability to cause vasorelaxation of human mesenteric arteries. Screening 
experiments revealed 2-AG to be the most efficacious endocannabinoid 
tested. Therefore, a subsequent aim of this study was to characterise 
the underlying mechanisms of 2-AG-induced vasorelaxation. 
75 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
3.3. Methods 
3.3.1. Patient Consent and Arterial Preparation 
In screening studies informed consent was taken from 2S patients for 
the use of mesenteric arteries, only 20 patients granted the use of their 
personal details and medical notes in this study. In further studies to 
characterise the effects of 2-AG, Informed consent was taken from 
patients (n=44) for the use of mesenteric arteries, only 41 patients 
granted the use of their personal details and medical notes in this 
study. Patients were receiving colorectal re-sections for cancer (n=S1) 
and inflammatory bowel disorders (n=10). As described in section 2.3 
tissues were dissected, removing small mesenteric arteries that were 
either used fresh (n=36) or after overnight storage (n=33) as 
described in section 2.6 
3.3.2. Myography Experiments 
Arteries were mounted on a Mulvany-Halpern myograph subject to the 
normalisation and standard start procedures as described in sections 
2.3 and 2.4. Cannabinoid concentration-response curves were carried 
out in viable arterial segments and compared to vehicle controls from 
an adjacent arterial segment from the same patient. To characterise 
the mechanisms of action of 2-AG, a range of pharmacological 
techniques were used as described in section 2.7. Comparisons were 
made between test and control arteries taken from the same patient. 
3.3.3. Post-hoc Analysis 
Post-hoc analysis was performed on control 2-AG responses from 
patients that had granted access to personal details and medical notes 
(n=41). 2-AG responses were analysed depending on the patient's 
medical history and medications. Particular attention was paid to 
diseases and medications that have either a direct vascular impact or 
are vascular disease risk factors. 
3.3.4. Statistical Analysis 
Mean percentage relaxation Is displayed with error bars representing 
the s.e.m, and n equalling the number of patients. Sigmoidal 
concentration-responses curves with a standard Hill slope of 1 were 
fitted to those data using GraphPad Prism software. In vasorelaxation 
studies and analysis of patient disease state, BMI and medication 
comparisons were made between test and control vessel segments 
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from the same patient using 2-way ANOVA comparing the effects of 
treatment and log concentration. In CaCI2 contraction studies 
comparisons were made using i-way ANOVA. Significance was 
determined with P<O.OS. 
3.4. Results 
3.4.1. Cannabinoid Screening 
The characteristics of patients used in screening studies are given in 
Table 3.1. With the exception of the CB2 agonist HU-308, all 
cannabinoids tested caused concentration-dependent vasorelaxation of 
human mesenteric arteries (see Table 3.2 and Figure 3.1). The 
maximal (Rmax) response to CPSS,940 was significantly greater than all 
other cannabinoids tested (Figure 3.2A). 2-AG was the most efficacious 
endocannabinoid tested and CBD was the most efficacious 
phytocannabinoid tested (Figure 3.2B). All cannabinolds caused 
vasorelaxation with equal potency with the exception of CBD, which 
had statistically lower potency than both THC and AEA (Figure 3.2A). 
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Table 3.1 Patient characteristics screening studies 
Charlcterlstlc Range Mean :1:: $,e,m 
Ethnicity 20 UK white 
Male 18 
Female 2 
Age 48-85 72±2 
Weight (kg) 50-113 84 ± 4 
BM! (kg/mol) 20-39 28±1 
Artery size (I-Im) 375-1257 698±65 
Bradykinin response 
(% reduction in pre-imposed tone) 72-110 85±2 
Smoking habits 
Non smokers 17 
o - 10 CPD 2 
10 - 20 CPD 1 
> 20 CPD 0 
Drinking habits 
< 10 units p/w 10 
10 - 20 units p/w 6 
> 20 units p/w 4 
Operation 
Right hemicolectomy 8 
Left hemicolectomy 4 
Sigmoid colectomy 1 
Anterior resection 4 
Abdominoperineal resection 2 
Total colectomy 1 
Reason for surgery 
Cancer 19 
Inflammato_ry bowel disorder 1 
Dukes staging 
Dukes A 8 
Dukes B 6 
Dukes C 5 
Dukes D 0 
Systolic blood pressure (mm/Hg) 117-172 147±3 
Diastolic blood pressure (mm/Hg) 65±101 81±2 
Type-2 diabetic 10 
Heart disease 10 
Heart failure 0 
Hypercholesterolaemia 13 
Hypertensive 13 
0-1 adrenoceptor antagonist (total) 1 
Alfuzosln 0 
Terazosin 1 
ACE inhibitors (total) 6 
Llsinopril 2 
Ramipril 4 
AT1 receptor antagonists (total) 2 
Losartan 1 
Valsartan 1 
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CharacteristiC: Range Mean * s.E!.m 
Seta blockers (total) 5 
Metoprolol 2 
Atenolol 2 
Sisoprolol 1 
Calcium channel blocker (total) 6 
Amlodipine 3 
Nifedipine 2 
Lodipine 1 
DiQoxin 1 
Diuretics (total) 2 
Furosemide 2 
GTN 5 
Hypoglycaemic medication (total) 12 
Gliclazide 5 
Metformin 7 
NSAID medication (total) 14 
Aspirin 9 
Ibuprofen 1 
Paracetamol 4 
Co Codamol 0 
Statin (total) 11 
Atorvastatin 2 
Simvastatin 9 
Pravastatin 0 
Thiazolidinedione (total) 2 
Pioglitazone 2 
Table 3.2 Effects of cannabinoids in human mesenteric arteries. 
Comparisons made between concentration response curve and vehicle 
control curve using 2-way ANOVA. *** P<O.OOl. 
AEA 28%2.3 *** 
2-AG 41.8%2.6 5.5%0.1 12 *** 
THe 26.6%2.4 6±0.2 12 *** 
CSD 38.6%3.6 5.2%0.2 12 *** 
CP55,940 56.6%3.1 5.4±0.1 12 *** 
HU308 Did not cause vasorelaxation 5 
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Figure 3.1. Screening concentration-response curves 
Concentration-response curves showing the effects of cannabinoids in 
human mesenteric arteries. Points represent means with error bars 
representing the s.e.m. Comparisons between curves were made using 
2-way ANOVA. *** P<O.OO1. 
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Figure 3.2 Cannabinoid efficacy and potency 
Compari sons of ca nnabinoid pECso (A) and Rmax (B) values in human 
mesenteric arteries. Comparisons made using 1-way ANOVA with 
Bonferron i post-hoc test. P<O. OS *, P<O.Ol ** and P< O.OOl *** . 
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3.4.2. Characterisation 
2-Arachidonoylglycerol 
of the Vasorelaxant Effects of 
44 patients (table 3.3) were used in further 2-AG vasorelaxation 
studies, in these patients 2-AG caused vasorelaxation with an Rmax of 
67 ± 3% and a pECso of 5.5 ± 0.1 (Figure 3.3A). 2-AG caused a 
modest reduction In baseline tone (Figure 3.3B). 
Antagonism of the CB l (AM251, 100 nM) or CB2 (AM630, 100 
nM) receptors (Figure 3.4A and B), desensitisation of the TRPVl 
receptor using capsaicin (10 jJM) (Figure 3.4C) had no effect on 
2-AG-induced vasorelaxation. Removal of the endothelium or 
incubation of endothelium-intact arterial segments with L-NAME (300 
jJM) had no effect on vasorelaxation to 2-AG (Figure 3.5A and B). 
Incubation with the MAGL inhibitor JZL184 (1 jJM) or the FAAH inhibitor 
URB597 (1 jJM) had no effect on 2-AG-induced vasorelaxatlon (Figure 
3.SC and D). 
Incubation with the non-selective COX inhibitor Indomethacin 
(10 jJM) significantly reduced vasorelaxation to 2-AG (Figure 3.6A). The 
COX-l favourable Inhibitor flurbiprofen (10 jJM) but not the COX-2 
Inhibitor nimesulide (10 jJM) Inhibited 2-AG-induced vasorelaxation 
(Figure 3.6B & C). Antagonism of the prostanoid IP (Cayl0441, 100 
nM) and EP4 (L-161,982, 1 jJM) receptors significantly reduced the 
vasorelaxant responses to 2-AG (Figure 3.60 & E). However, the 
prostanoid EP1, EP2, EP3, DP and TP receptor antagonist 
(AH6809, 1 jJM) potentiated the response to 2-AG (Figure 3.6F). 
In arteries contracted with U46619 in Ca2+ -free PSS, 
2-AG-lnduced vasorelaxation was significantly inhibited compared to 
PSS containing Ca2+ (Figure 3.7A). In arteries contracted with KPSS 
solution to Inhibit potassium efflux and allow voltage gated calcium 
Influx, 2-AG-induced vasorelaxation was Inhibited (Figure 3.7B). In 
arteries bathed In high potassium Ca 2+ -free solution and incubated with 
2-AG, the maximum contraction to CaCI2 was inhibited in arterial 
segments incubated with 100 jJM, but not 10 jJM 2-AG (Figure 3.7C). 
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Table 3.3 Patient characteristics, diagnosis and medications 2-AG study 
Characteristic Range Mean = s.e.m 
Ethnicity 44 UK white 
Male 30 
Female 11 
Age 27 - 82 68 ± 2 
Weight (kg) 50 - 117 82 ± 3 
BMI (kg/m") 20 - 39 28 ± 1 
Vessel size (I-Im) 302 - 1309 668 ± 40 
Bradykinin response 
(% reduction in pre-imposed tone) 71 - 110 89 ± 2 
Smoking habits 
Non smokers 30 
0- 10 CPD 2 
10 - 20 CPD 8 
> 20 CPD 1 
Drinking habits 
< 10 units p/w 21 
10 - 20 units p/w 5 
> 20 units p/w 5 
Operation 
Right hemicolectomy 14 
Left hemicolectomy 7 
Sigmoid colectomy 2 
Anterior resection 11 
Abdominoperineal resection 1 
Total colectomy 6 
Reason for surgery 
Cancer 32 
Inflammatory bowel disorder 9 
Dukes staging 
Dukes A 11 
Dukes B 11 
Dukes C 10 
Dukes D 0 
Systolic blood pressure (mm/Hg) 110 - 188 150 ± 3 
Diastolic blood pressure (mm/Hg) 65 ± 110 86 ± 1 
Type-2 diabetic 10 
Heart disease 9 
Heart failure 0 
Hypercholesterolaem ia 16 
Hypertensive 16 
0-1 adrenoceptor antagonist (total) 1 
Alfuzosin 1 
Terazosin 0 
83 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
C h a r a c t e r i s t i c ~ ~ % ' G ~ t R \ \ ~ & f f ~ \ ' 4 ' & Z ~ B t i $ , , ' 0 0 \ i f ~ \ \ %' 0 % i i \ ~ ~ \ + ; ; ; 2 0 y i 0 t ~ " " Range ~ \ i \ z \ : ~ 4 * W " " ; ; W ~ Y Y * , ~ ' i i J J \ £ ~ ~ Mean ± s.e.m ~ ~
ACE inhibitors (total) 6 
Lisinopril 4 
Ramipril 2 
AT1 receptor antagonists (total) 2 
Losartan 1 
Irbesartan 1 
Beta blockers (total) 8 
Metoprolol 2 
Atenolol 5 
Bisoprolol 1 
Calcium channel blocker (total) 4 
Amlodipine 2 
Nifedipine 0 
Lodipine 2 
Digoxin 1 
Diuretics (total) 2 
Furosemide 2 
GTN 5 
Hypoglycaemic medication (total) 6 
Gliclazide 2 
Metformin 4 
Nsaid medication (total) 14 
Aspirin 10 
Ibuprofen 1 
Paracetamol 2 
Co Codamol 1 
Statin (total) 16 
Atorvastatin 4 
Simvastatin 12 
Pravastatin 0 
Thiazolidinedione (total) 1 
Pioglitazone 1 
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Figure 3.3 2-AG responses 
2-AG-induced vasorelaxation in all patient samples with representative 
trace (A and C). Effects of 2-AG on baseline compared to vehicle 
control and representative trace (8 and D). Comparisons made using 
2-way ANOVA. * P<O.05. 
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Figure 3.4 Potential receptor Involvement In 2-AG responses 
2-AG-Induced vasorelaxation In arteries Incubated with the CB l 
antagonist AM251 (A), In arteries incubated with the CB2 antagonist 
AM630 (B) or In arteries where the TRPVl receptor had been 
desensltlsed after l-hour incubation with the TRPVl agonist capsaicin 
(C). Comparisons made using 2-way ANOVA 
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Figure 3.5 Potential involvement of the endothelium In 2-AG responses 
2-AG induced vasorelaxation in arteries after endothelium denudation 
(A), In arteries Incubated with the nitric oxide synthase inhibitor 
L-NAME (B), in arteries incubated with the MAGL inhibitor JZL184 (C) 
or in arteries incubated with the FAAH inhibitor URB597 (D). 
Comparisons made using 2-way ANOVA. 
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Figure 3.6 Potential COX Involvement in 2-AG responses 
-4 
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-4 
2-AG induced vasorelaxation In arteries incubated with the 
non-selective COX inhibitor indomethacin (A), the COX-l favourable 
inhibitor flurblprofen (6) and the COX-2 Inhibitor nimesulide (C). 
2-AG-lnduced vasorelaxation In the presence of the prostanoid IP 
receptor antagonist Cayl0441 (D), the prostanoid EP4 receptor 
antagonist L-161982 (E) and the prostanoid EP1, EP2, EP3, OP and TP 
antagonist AH6809. Comparisons made using 2-way ANOVA. 
** P<O.Ol and *** P<O.OOl. 
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Figure 3.7 Potential Ion channel involvement in 2-AG responses 
2-AG-induced vasorelaxation in arteries incubated with Ca2+ -free PSS 
(A) or in arteries contracted with KPSS (6). CaCI2 contractions in 
arterial segments Incubated with 2-AG (C). Comparisons of 
vasorelaxation made using 2-way ANOVA. Comparisons of CaCI2 made 
comparing Rmax values using l-way ANOVA, * P<O.OS, ** P<O.Ol and 
*** P<O.OOl. 
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3.4.3. Post-hoc Analysis of Patient Medical Records 
Oue to the variability of control responses to 2-AG among patients 
(response range at 100 IJM 2-AG, 0-103% relaxation), post-hoc 
analysis of patient responses were compared between a variety of 
variables such as diagnosis, current medication and cardiovascular risk 
factors. 
2-AG responses were not correlated with age but were reduced 
in males compared to females (Figure 3.8A & D). There was no 
correlation between the maximal responses to 2-AG and the patient's 
vasorelaxant response to bradykinin (Figure 3.8B). 2-AG responses 
were not different in patients with cancer and those without 
(Figure 3.8C). 2-AG responses were significantly reduced in patients 
diagnosed with heart disease (previous myocardial infarction and/or 
ischaemic heart disease), hypercholesterolaemia and type-2 diabetes 
(Figure 3.9A, B & C), but not those with hypertenSion, a 
BMI >25 kg/m 2 or smokers (Figure 60, E, & F). 2-AG responses were 
reduced in those taking NSAIOs, statins and hypoglycaemic medication 
(Figure 3.10A, B & C) but not those taking beta-blockers or ACE 
inhibitors (Figure 3.100 & E). 
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Figure 3.8 Patient characteristics and 2-AG responses. 
Responses to 100 I-IM 2-AG correlated with patient age (A) and 
2-AG-induced vasorelaxation compared between male and female 
patients (6). 100 I-IM 2-AG responses correlated with 10 I-IM bradykinin 
response (C). 2-AG responses in patients with cancer vs. those without 
(D). Comparisons made using 2-way ANOVA and correlations made 
using Spearman correlation coefficient, ** P<O.Ol. 
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Figure 3.9 Cardiovascular disease/disease risk factors and 2-AG 
responses 
2-AG concentration-response curves In patients with heart disease (A), 
hypercholesterolaemia (B), type-2 diabetes (C), hypertension (D), 
elevated BMI (E) and in patients who smoke (F). Comparisons were 
made between patients with a given characteristic and those without 
using 2-way ANOVA. ** P<O.Ol and *** P<O.OOl. 
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Figure 3.10 Patient medication and 2-AG responses 
-4 
-4 
2-AG concentration-response curves in patients taking NSAIDs (A), 
statins (6), hypoglycaemic (C), beta-blocking (D) and ACE Inhibiting 
medication (E). Comparisons were made between patients taking a 
given medication and those that were not using 2-way ANOVA. 
*** P<O.OOl. 
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3.5. Discussion 
The aim of this study was to screen the effects of a range of 
cannabinoids In human mesenteric arteries. This study reports that all 
cannabinoids tested, with the exception of the CB2 agonist, cause 
vasorelaxation of human mesenteric arteries. Given that 2-AG was the 
most efficacious endocannabinoid tested, the mechanisms of action this 
ligand were probed. These experiments revealed that 2-AG-induced 
vasorelaxation was dependent on COX metabolism, prostanoid receptor 
activation, extracellular calcium and ion channel modulation. Post-hoc 
analysis of patient notes revealed that 2-AG responses were blunted in 
a range of cardiovascular diseases or cardiovascular disease risk 
factors. 
This study has shown that AEA, 2-AG, THC, CBO and CP55,940 
but not HU308 cause concentration-dependent vasorelaxation of 
human mesenteric arteries. The initial screening experiments revealed 
vasorelaxation to all cannabinoids was reduced in efficacy compared to 
mesenteric arteries from animal models. In rat mesenteric arteries, 
AEA caused maximal vasorelaxation with a pECso in the low micromolar 
range (White and Hiley 1997; O'Sullivan et al., 2004), yet in human 
mesenteric arteries AEA causes only a small degree of vasorelaxation 
with similar low micromolar potency. In rat mesenteric arteries, 2-AG is 
reported to have a pECso in the low micromolar range and cause near 
maximal vasorelaxation (Ho and Randall 2007), yet in human 
mesenteric arteries 2-AG causes a half maximal vasorelaxation with 
similar low micromolar potency. In rat mesenteric arteries, THC Is 
reported to have a pECso in the low micromolar range and cause 
half-maximal vasorelaxatlon (O'Sullivan et al., 2005), yet in human 
mesenteric arteries THC causes only slight vasorelaxation with similar 
low micromolar potency. In the rat mesenteric arteries, CP55,940 Is 
reported to have a pECso In the low micromolar range and cause 
maximal vasorelaxation (White and Hiley 1998; O'Sullivan et al., 
2004), yet In human mesenteric arteries CP55,940 causes half-maximal 
vasorelaxation with similar low micromolar potency. In rat mesenteric 
arteries CBO causes maximal vasorelaxation, however potency was not 
reported (Offertaler et al., 2003). Given, that CSO potency was not 
reported in the previous study, comparisons couldn't be made, however 
comparisons of efficacy show that vasorelaxation seen in human 
mesenteric arteries Is less than seen by Offertaler et al., (2003). 
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Comparisons between efficacy and potency of HU308 cannot be made, 
as these values have not previously been determined. Reduced 
cannabinoid potency in human pulmonary artery has previously been 
reported (Kozlowska et al., 2007; Kozlowska et al., 2008). Inter-
species variability in cannabinoid potency and efficacy has previously 
been reported, for example in rat coronary arteries AEA causes 
approximately half maximal vasorelaxation (White et al., 2001) 
whereas AEA does not have a vasorelaxant effect on porcine coronary 
arteries (Fleming et al., 1999). Therefore, reduced responses might be 
ascribed to the differences in species. However, the patients who took 
part in this study had a high average age. Ageing is associated with 
decreased vascular smooth muscle and endothelial function (reviewed 
by Byung Pal and Hae Young 2001; Taddei et al., 2006), and has been 
used to explain the reduced efficacy seen between acetylcholine 
relaxation in humans and rats (Hutri-Kahonen et al., 1999). The mean 
age of participants in this study was 72 and the mean age of 
participants In both works of Kozlowska et al. (2007; 2008) were 
approximately 60 years old. Therefore, the reduced efficacy observed 
could be attributed to the participant's age. However, 2-AG responses 
were not negatively correlated with patient age, which suggests 2-AG 
efficacy Is not dependent on age. 
In animal arteries, AEA causes vasorelaxation of near maximal 
magnitudes and often displays greater efficacy than 2-AG. However, in 
the present study 2-AG caused statistically greater vasorelaxation than 
that of AEA. The disparity between the findings of this study and those 
in the rat mesenteric vasculature (O'Sullivan et al., 2004) or human 
pulmonary artery (Kozlowska et al., 2007) may be attributed to species 
differences. However, in this study arteries were taken from a patient 
population that presented with at least one medical condition, therefore 
this factor could have masked/reduced AEA-induced vasorelaxation. For 
example, Ho et al. (2007) observed that AEA-induced vasorelaxation 
could be potentiated if COX-2 and FAAH enzymes were inhibited, which 
may be true in humans, especially In conditions where COX and FAAH 
may be altered. 
The Rmax of CP55,940 was significantly greater than all other 
cannabinoids tested, whilst HU308 was ineffective as a vasorelaxant. 
Given that CP55,940 Is highly potent at both CB l and CB2 receptors 
(Showalter et al., 1996) and HU308 Is a potent CB2 agonist that Is 
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devoid of CB l activity (Hanus et al., 1999), this could suggest that the 
CB l receptor, but not the CB2 receptor may contribute to vascular tone 
in the human mesenteric arteries. 
Given that Initial screening experiments revealed 2-AG to be the 
more efficacious endocannabinoid tested, further work was carried out 
to establish the underlying mechanisms of action. In a larger patient 
sample 2-AG Induced vasorelaxation of human mesenteric arteries with 
Rmax and pECso values of 67 ± 3% and 5.5 ± 0.1, n=44. This is a 
similar potency and efficacy to that observed in rat mesenteric arteries 
(Ho and Randall 2007), but lower than that observed in rabbit 
mesenteric arteries (Kagota et al., 2001). It should be noted that the 
vasorelaxation reported In this study is above reported physiological 
and pathophysiological levels of 2-AG (Quercioli et al., 2011). However, 
2-AG is an unstable compound (Rouzer et al., 2002) that is produced 
on demand to function in a paracrine fashion (Maccarrone 2008), 
therefore, it is likely that plasma concentrations of 2-AG may not 
actually reflect cellular 2-AG concentrations. 
This study has shown that 2-AG-induced vasorelaxation was not 
dependent on activation of CB1, CB2 or TRPV1 receptors which has been 
shown to partially underpin the vasoactive effects of other cannabinoid 
ligands in the mesenteric arteries of rats (O'Sullivan et al., 2005). 2-AG 
activation of the CBl receptor causes vasorelaxation of rat cerebral 
arteries (Hillard et al., 2007) and rabbit mesenteric arteries (Kagota et 
al., 2001; Hillard et al., 2007). Also, despite the findings that, under 
some conditions, 2-AG binding affinity for the CB2 receptor is enhanced 
(Ben-Shabat et al., 1998), and that 2-AG has been shown to stimulate 
Ca2+ Influx through the TRPV1 receptors in human brain endothelial 
cells (Golech et al., 2004), the potential role of these two receptors in 
2-AG-induced vasorelaxation was previously untested. In the present 
study, 2-AG-induced vasorelaxatlon of human mesenteric arteries was 
not found to be mediated by these receptors, although all are present 
In human vascular smooth muscle cells (Sugiura et al., 1998; Rajesh et 
al., 2008; Wang et al., 2008) and endothelial cells (Fantozzi et al., 
2003; Rajesh et al., 2007). 
In rat mesenteric arteries, vasorelaxation to 2-AG has been 
shown to be endothelium-dependent (Ho and Randall 2007). However, 
this study reports that 2-AG-induced vasorelaxation is not inhibited by 
removal of the endothelium or inhibition of nitric oxide. Furthermore, 
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the maximal vasorelaxant response to 2-AG was not correlated with the 
endothelium-dependent response to bradykinin in the same patient. A 
lack of a role for the endothelium or nitric oxide production in the 
vascular response to 2-AG in human mesenteric arteries is in 
agreement with previous findings in rabbit mesenteric arteries (Kagota 
et al., 2001), but not in rat mesenteric arteries (Ho and Randall 2007) 
or bovine coronary arteries (Gauthier et al., 2005), possibly 
highlighting species differences in 2-AG vascular responses. 
2-AG is reported to be an unstable compound (Rouzer et al., 
2002), which can be hydrolysed by MAGL and FAAH (Muccioli 2010). 
Hydrolysis of 2-AG, potentially through both these pathways has 
previously been shown to cause vasorelaxation of bovine coronary 
arteries (Gauthier et al., 2005). However, this study reports that 
2-AG-induced vasorelaxation is not mediated by 2-AG hydrolYSiS 
through MAGL and FAAH. COX-1 and -2 are expressed in human 
endothelium and smooth muscle cells (Zidar et al., 2009), and 2-AG 
serves as a substrate for COX metabolism (Kozak et al., 2000; Rouzer 
and Marnett 2005). Furthermore, COX metabolism has been Implicated 
in vasorelaxation to 2-AG in the bovine coronary artery (Gauthier et al., 
2005), but not rat or rabbit mesenteric arteries (Kagota et al., 2001; 
Ho and Randall 2007). This study examined any potential role for COX 
metabolism and found that 2-AG-induced vasorelaxation of the human 
mesenteric artery Is Inhibited by the non-selective COX inhibitor 
indomethacin. To further explore the specific COX isoform, the COX 
inhibitor flurblprofen, which displays greater affinity for COX-l, and the 
selective COX-2 inhibitor nimesulide, were used (Warner et al., 1999). 
Flurbiprofen, but not nimesulide, caused inhibition of 2-AG-lnduced 
vasorelaxation, suggesting that 2-AG-induced vasorelaxation 
preferentially occurs through COX-1:-dependent pathways in this model. 
In contrast, in the rat mesenteric artery 2-AG-induced vasorelaxation is 
limited by COX-l metabolism (Ho and Randall 2007). Therefore, 
2-AG-lnduced vasorelaxation that Is COX-l dependent Is a novel finding 
that may be unique to humans. This finding also shows disparity 
between 2-AG pathways In rat and human mesenteric arteries and 
therefore suggests the need for further human work. 
COX metabolism of 2-AG produces a range of novel prostanoid 
glycerol esters (Nirodi et al., 2004). Prostanoid glycerol esters, In 
human and rat plasma, are reported to undergo hydrolysis to 
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prostanoids (Kozak et al., 2001). However, the rate of hydrolysis 
depends on the assay conditions. For example in rat and human 
plasma the half-life of prostanoid glycerol esters is reported to be 
16 seconds and 16 minutes respectively (Kozak et al., 2001). However, 
in cerebral spinal fluid and In the presence of RAW264.7 macrophages 
prostaglandin glycerol esters are reported to be stable (Kozak et al., 
2001; Nirodi et al., 2004). Therefore, given the potential for prostanoid 
production, further experiments investigated potential roles for the OP1, 
EP2, EP4 and IP prostanoid receptors, which are all reported to cause 
vasorelaxation (Coleman et al., 1994; Norel 2007). This study found 
that 2-AG-lnduced vasorelaxation is dependent on activation of the 
prostanoid EP4 and IP receptors. In the rat aorta, the endocannabinoid 
AEA has been shown to cause vasorelaxation through multiple 
pathways including activation of prostanoid EP4 receptors (Herrad6n et 
al., 2007). Since prostaglandin glycerol esters are unable to activate 
prostanoid receptors (Nirodi et al., 2004), it is likely that COX 
metabolism of 2-AG results in PGE2 and PGh formation via 
prostaglandin glycerol ester production and subsequent hydrolysis to 
prostanoids. The finding that AH6809 potentiated 2-AG Induced 
vasorelaxatlon could be explained due to AH6809 having low 
micromolar affinity for contractile prostanoid receptors (Abramovitz et 
al., 2000). Metabolism of 2-AG through COX-l may result in formation 
of both contractile and relaxant prostanoids. It Is therefore likely that 
AH6809 has antagonised any potential activity of contractile 
prostanoids. 
Cannabinoids cause vasorelaxation partly through ion channel 
modulation (Randall et al., 1997), which was Investigated in the 
present study. When arteries were contracted using high potassium 
PSS, 2-AG-induced vasorelaxation was inhibited, suggesting that 
2-AG-induced vasorelaxation Is not primarily through Inhibition of 
VOCCs and may be dependent on K+ channel activation. This is a 
finding common with a number of cannabinoid ligands in a range of 
vascular preparations (Randall et al., 1997; White et al., 2001), 
Including human arteries (Kozlowska et al., 2007). To determine a 
potential role for calcium channels, some arterial segments were 
contracted using U46619 in calcium-free PSS. Under these conditions, 
partial Inhibition of 2-AG-induced vasorelaxation was observed, 
suggesting that 2-AG-lnduced vasorelaxation Is in part 
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calcium-dependent. Cannabinoids also cause vasorelaxation via 
inhibition of Ca2+ entry through voltage-operated calcium channels 
(White and Hiley 1998). In the present study, 2-AG, at the highest 
concentrations, inhibited the maximum contraction to calcium chloride, 
suggesting that 2-AG can inhibit calcium entry, and may explain the 
slight vasorelaxation observed in KPSS contracted arteries. Taken 
together, these findings show that 2-AG modulates some ion channels 
to favour vasorelaxation, which may be either coupled to prostanoid 
receptor activation or a direct action. 
Given that the patient population in this study is elderly and has 
a range of medical problems, post-hoc analysis of the control 2-AG 
responses in each patient were carried out to establish if these 
variables influenced the effects of 2-AG. No correlation between 2-AG 
responses and patient age was observed, however 2-AG responses 
were blunted in males compared to females. In rat mesenteric arteries 
non-endothelium-dependent vasorelaxation is reduced in males 
compared to females (Keung et al., 2005). This reduction is attributed 
to over activation of contractile prostaglandin receptors and is reversed 
by 17-beta estradiol (Keung et al., 2005). 
In patients with chronic heart failure, plasma 2-AG levels are 
reported in the mid-nanomolar range when compared to low nanomolar 
concentrations in healthy controls (Weis et al., 2010), similarly 2-AG 
levels are measured at high nanomolar concentrations in patients with 
acute myocardial infarction compared to mid-nanomolar concentrations 
in healthy patients (Wang et al., 2011). Local tissue levels of 2-AG are 
Increased in the aorta and visceral adipose tissue in atherosclerotic 
mice (Montecucco et al., 2009). To try and understand the potential 
significance of altered levels of 2-AG on the vasorelaxant response to 
2-AG, post-hoc analysis was performed in patients with or without 
cardiovascular disease or risk factors. This study found that patients 
diagnosed with heart disease, diabetes and hyperlipidaemia had 
blunted responses to 2-AG when compared to patients without the 
diseases. It is known in all these disease states that prostaglandin 
pathways are often dysfunctional and often associated with increased 
production of COX-derived contractile prostaglandins (Goodwill et al., 
2008; Goodwill et al., 2008), increased actions at thromboxane 
TP receptors from contractile and non-contractile prostaglandins (Xiang 
et al., 2006), increased COX-induced oxidative stress (Goodwill et al., 
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2008) and genetic alterations of prostacyclin synthase (Nakayama 
2010). Therefore, under these conditions it is possible that the 
COX-derived metabolites of 2-AG also activate contractile prostaglandin 
receptors, blunting the vasorelaxation response, in common with other 
vasorelaxant mediators (reviewed in Vanhoutte et al., 2009) 
Interestingly, this study found that patients taking NSAID, statin, and 
hypoglycaemic medications had significantly blunted 2-AG responses. 
This suggests that the vasorelaxant effect of 2-AG, and any other 
positive vascular consequence of 2-AG, may be compromised in 
patients taking these medications. However, it is difficult to determine 
as to whether the blunted 2-AG responses are a consequence of the 
medication or the disease state the medication Is treating. 
In conclusion, this study has shown that cannabinoids cause 
vasorelaxation of human mesenteric arteries often with decreased 
efficacy compared to animal models. The most efficacious compound 
tested was the highly potent CB l and CB2 agonist CP55,940. This 
finding potentially implicates roles for these receptors in inducing 
vasorelaxation in the human mesenteric artery. However, given the 
fact that the CB2 receptor agonist HU308 did not cause vasorelaxation, 
this receptor can be potentially ruled out. The most efficacious 
phytocannabinoid tested was the reported CBe antagonist CBD. Finally 
this study has shown that the most efficacious endocannabinoid tested 
was 2-AG, which caused significantly greater vasorelaxation than AEA 
suggesting, differences between human and animal arteries. 
2-AG-induced vasorelaxatlon was not mediated by CB1, CB2, 
TRPV1, the endothelium or metabolism by FAAH or MAGL. Rather, 
vasorelaxation to 2-AG In humans Is dependent on COX-l metabolism 
and subsequent activation of EP4 and IP prostanoid receptors. 
Vasorelaxation to exogenously applied 2-AG is reduced In patients with 
heart disease, type-2 diabetes and patients with 
hypercholesterolaemla. Furthermore, 2-AG responses are also reduced 
In patients taking NSAIDs, statins and hypoglycaemic medications. The 
data from this study suggests that the vasorelaxant effects of 
cannablnolds are different (maximal responses and underlying 
mechanisms) to those observed In animal studies. 
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4. CHARACTERISATION OF CBD-INDUCED VASORELAXATION IN 
HUMAN MESENTERIC ARTERIES 
4.1. Introduction 
In chapter three, CBD was shown to cause vasorelaxation of human 
mesenteric arteries with a significantly greater Rmax than that of THC. 
Few studies have examined the vasorelaxant effects of CBD in animal 
vasculature. larai and colleagues (1999) found that perfusing 10 (JM 
CBD into phenylephrine-constricted rat mesenteric vascular beds had 
no effect on vascular tone. However, in arterial segments taken from 
rat mesenteric vascular beds, CBD caused a concentration-dependent 
near-maximal vasorelaxation (Offertaler et al., 2003). Unfortunately, 
the mechanisms of action were not probed in this study. In the rat 
aorta, CBD (at concentrations above 100 nM) caused time-dependent 
vasorelaxation. This time-dependent vasorelaxation was inhibited using 
the PPARy antagonist GW9662 or the SOD inhibitor 
diethyldithiocarbamate (DETCA) (O'Sullivan et al., 2009). 
CBD has been proposed as an antagonist for the putative CBe 
receptor (larai et al., 1999). In this study Abn-CBD, an analogue of 
CBD, which does not bind to the CBl receptor, caused hypotension in 
both CBl+I+/CB2+1+ and CBl-l-/CB2-1- mice. These effects were inhibited 
by high concentrations of rimonabant, endothelium denudation and 
CBD (larai et al., 1999). In humans it has been shown that Abn-CBD 
caused vasorelaxation of pulmonary arteries which was also inhibited 
by endothelial denudation, using CBD and the CBD analogue 0-1918 
(Kozlowska et al., 2007). Interestingly, Kozlowska et al. (2007) 
observed a slight vasorelaxation effect when CBD was added to 
un-constricted arteries. However, this effect was not further explored. 
More recently, it has also been shown by the same group that CBD 
inhibited AEA-induced vasorelaxation of rat pulmonary arteries, which 
was again ascribed to antagonism of the CBe receptor (Baranowska-
Kuczko et al., 2012). 
To date, the effects of CBD on vascular tone in vivo have not 
been fully studied, and the limited work that has been conducted has 
shown conflicting findings. A recent study has shown that in 
pentobarbitone-anaesthetised rats, CBD causes a Significant but 
transient 16 mmHg fall in mean arterial blood pressure without 
affecting heart rate (Walsh et al., 2010). However, In other studies 
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using rats, it is reported that intraperitoneal injection of CBO has no 
effect on baseline heart rate or blood pressure (Resstel et al., 2006; 
Resstel et al., 2009). A recent review also concluded that chronic CBO 
treatment In humans fails to have any effect on blood pressure or heart 
rate (Bergamaschi et al., 2011). 
CBO has been shown to have a variety of beneficial effects In 
cardiovascular disease. Recent work has shown that CBO reduces 
endothelial and cardiac dysfunction In cardiomyopathy associated with 
diabetes through Immune modulation and decreased oxidative stress 
(Rajesh et al., 2007; Rajesh et al., 2010). CBO reduces Infarct size in a 
mouse model of stroke when delivered both pre- and post-ischaemic 
Injury through activation of 5HTh receptors (Mishima et al., 2005; 
Hayakawa et al., 2007; Hayakawa et al., 2007; Hayakawa et al., 
2008). CBO also reduces vascular inflammation associated with 
endotoxic shock (Ruiz-Valdepenas et al., 2011), has a protective role In 
diabetic retinopathy (EI-Remessy et al., 2006) and reduces infarct size 
after coronary artery ligation as well as having an anti-arrhythmic 
effect (Walsh et al., 2010). 
There Is a wealth of work to support the beneficial effects of 
CBO in the cardiovascular system, however, the direct effects of CSO 
on vascular tone are in doubt, with studies showing CSO causes, 
inhibits, or has no effect on vasorelaxation. Current work In humans 
has shown that CSO does not affect blood pressure when given 
chronically (Bergamaschl et al., 2011), and in in vitro CBO antagonises 
vasorelaxation caused by other cannabinoids (Kozlowska et al., 2007). 
4.2. Aims 
The first aim of this study was to follow on from findings in Chapter 
three and probe the mechanisms of actions of CBO. The second aim of 
this study was to investigate whether CBO caused time-dependent 
vasorelaxatlon in human mesenteric arteries, and if so was this through 
PPARy mediated pathways. The third aim of this study was to analyse 
the arterial responses to CBO to see If, as with 2-AG, patient 
characteristics Influenced vascular responses to CBO. 
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4.3. Methods 
4.3.1. Patient Consent and Arterial Preparation 
Informed consent was taken from patients (n=37) for the use of 
mesenteric arteries, only 34 patients granted the use of their personal 
details and medical notes in this study. Patients were receiving 
colorectal re-sections for cancer (n=27) and inflammatory bowel 
disorders (n=7) and were approached as described in section 2.2. 
Tissues were dissected, removing small mesenteric arteries that were 
either used fresh (n=28) or after overnight storage (n=9) as described 
in section 2.3. 
4.3.2. Myography Experiments 
Arteries were mounted onto a Mulvany-Halpern myograph and subject 
to normalisation and the standard start procedure as described in 
section 2.3 and 2.4. CBO concentration-response curves were carried 
out in viable arteries and compared to vehicle controls from an 
adjacent arterial segment from the same patient. To characterise CBO 
mechanisms of action, a range of pharmacological techniques were 
used as described in section 2.7, with comparisons made between 
responses in test and control arteries taken from the same patient. 
Some arteries were incubated with antagonists and 
concentration-response curves were carried out to ethanol (EtOH) 
vehicle control. This was to assess the effects of these antagonists on 
the vasorelaxant effect of the vehicle control seen in Figure 3.1. 
In some arteries, potential time-dependent effects of CBO were 
investigated. In these experiments, larger arteries (>1 mm diameter) 
were used, as it has previously been shown that THe causes 
time-dependent vasorelaxation In conduit but not resistance arteries 
(O'Sullivan et al., 2006). ,Therefore, the biggest arterial segments 
available were taken from tissue samples and assessed for potential 
time-dependant effects. Artery segments were mounted on to fixed 
hooks and a single concentration of 10 ~ M M CBO (in the presence or 
absence of 1 ~ M M GW 9662 O'Sullivan et al., 2009) or 0.1 % EtOH was 
added to the myograph chamber. Readings were taken every 
15 minutes to assess potential time-dependent vasorelaxation. 
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4.3.3. Post-hoc Analysis 
Post-hoc analysis was performed on all control CBD responses from 
patients who gave consent for access to medical notes (n=34). Arterial 
CBD responses were analysed depending on the patient's medical 
history and medications. Particular attention was paid to diseases and 
medications that have either a direct vascular impact or are vascular 
disease risk factors. 
4.3.4. Statistical Analysis 
Mean percentage relaxation is displayed with error bars representing 
the s.e.m, and n equalling the number of patients. Sigmoidal 
concentration-responses curves with a standard Hi" slope of 1 were 
fitted to those data using GraphPad Prism. Statistical comparisons 
between test and control concentration-response curves and 
time-dependent experiments were made using 2-way ANOVA. 
Comparisons of pECso and Rmax were made using 1-way ANOVA with 
Bonferroni's post-hoc test. 
4.4. Results 
4.4.1. Acute CBD-Induced Vasorelaxation 
The medical characteristics of patients used in this study are given in 
table 4.1. CBD caused vasorelaxation with an Rmax of 45 ± 2% and a 
pECso of 5.5 ± 0.1 (Figure 4.1A & C). CBD had no effect on baseline 
tone (Figure 4.1B & D). 
Antagonism of the CB l receptor using AM251 (100 nM) or 
LY320135 (1 JJM) significantly inhibited CBD-induced vasorelaxation 
(Figure 4.2A & B). Antagonism of the CB2 receptor using AM630 
(100 nM) or antagonism of the proposed endothelial cannabinold 
receptor using 0-1918 (1 !-1M) had no effect on CBD-induced 
vasorelaxatlon (Figure 4.2C & D). Desensitization of the TRPV1 
receptors using capsaicin (10 !-1M) caused Inhibition of CBD-induced 
vasorelaxation (Figure 4.2E). CBD-induced vasorelaxation was also 
significantly reduced in arteries contracted using a high potassium 
physiological saline solution (Figure 4.2F) 
Removal of the endothelium and Incubation of arteries with 
L-NAME (300 !-1M) significantly altered CBD-induced vasorelaxation 
(Figure 4.3A & B). Incubation of the arteries with indomethacin (10 !-1M) 
had no effect on the CBD-Induced vasorelaxatlon (Figure 4.3C). 
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In experiments to determine the location of the CB l receptor, 
using different arterial segments from the same patient, AM251 
(100 nM) or endothelial denudation alone, slightly but not significantly 
reduced the pECso of CBO (Figure 4.4A & B). However, pECso values 
were significantly reduced in arteries that had undergone both 
endothelial denudation and incubation with AM251 (100 nM) 
(Figure 4.4A & B). Rmax values were reduced in arteries incubated with 
AM251 and AM251 incubation plus endothelial denudation 
(Figure 4.4 A & C). However, Rmax values were unaltered in 
endothelium-denuded arteries (Figure 4.4 A & C). When comparisons 
were made between denuded arteries incubated with AM251 and 
denuded arteries alone or AM251 incubated arteries alone there was no 
difference in pECso or Rmax values. 
The vasorelaxation to EtOH vehicle-treated control arteries 
(Figure 3.10) was not inhibited by incubation with AM251, LY320135, 
capsaicin, L-NAME or in endothelium-denuded arterial segments 
(Figure 4.5 A-E). However, when EtOH was added to KPSS-contracted 
arteries, enhanced contraction was observed when compared to control 
(U46619 and endothelin-1 contracted) arteries (Figure 4.5 F). 
4.4.2. Time-dependent Effects of CBO 
In time-dependent vasorelaxation experiments, a single concentration 
of 10 I-SM CBO caused significant vasorelaxation compared to vehicle 
control (Figure 4.6A). An Initial vasorelaxation of 57 ± 4 % relaxation 
was observed at 15 minutes, this developed to 78 ± 7 % relaxation at 
120 minutes (Figure 4.6A). In the presence of the PPARy antagonist 
GW 9662, this vasorelaxation was not inhibited (Figure 4.6B). 
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Table 4.1 Patient characteristics, diagnosis and medications CBD study 
Cnaractel"lstic Range Mean ~ ~ s.e.m 
Ethnicity 34 UK white 
Male 24 
Female 10 
Age 36 - 82 65 ± 2.1 
Weight (kg) 52 - 126 76 ± 3 
BMI (kg/mol) 17.5 - 36.4 27.1 ± 0.7 
Vessel size (lJm) 346 - 1372 701 ± 42 
Bradykinin response 
(% reduction in pre-imposed tone) 70 - 109 85 ± 1.4 
Smoking habits 
Non smokers 28 
0- 10 CPD 3 
10 - 20 CPD 3 
Drinking habits 
< 10 units p/w 23 
10 - 20 units p/w 7 
> 20 units p/w 4 
Operation 
Right hemicolectomy 10 
Left hemicolectomy 7 
Sigmoid colectomy 5 
Anterior resection 10 
Abdominoperineal resection 1 
Total colectomy 1 
Reason for surgery 
Cancer 27 
Inflammatory bowel disorder 7 
Dukes staging 
Dukes A 10 
Dukes B 9 
Dukes C 8 
Dukes D 0 
Systolic blood pressure (mm/Hg) 110 - 188 143 ± 3 
Diastolic blood pressure (mm/Hg) 62 ± 101 82 ± 1 
Diabetic 10 
Heart disease 9 
Heart failure 0 
Hypercholesterolaemia 15 
HypertenSive 16 
0-1 adrenoceptor antagonist (total) 3 
Alfuzosln 1 
Terazosin 2 
ACE Inhibitors (total) 7 
Llslnopril 2 
Ramipril 5 
ATI receptor antagonists (total) 2 
Losartan 1 
Irbesartan 1 
Beta blockers (total) 6 
Metoprolol 2 
Atenolol 4 
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Characteristic R<mge Mean = s.E!.m 
Calcium channel blocker (total) 3 
Amlodipine 1 
Nifedipine 1 
Lodipine 1 
Digoxin 2 
Diuretics (total) 3 
Furosemide 3 
GTN 3 
Hypoglycaemic Medication (total) 6 
Gliclazide 3 
Metformin 3 
NSAID Medication 14 
Aspirin 8 
Ibuprofen 2 
Paracetamol 7 
Co Codamol 1 
Statin (total) 14 
Atorvastatin 4 
Simvastatin 9 
Pravastatin 1 
Thiazolidinedione (total) 1 
Pioglitazone 1 
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Figure 4.1 CBD responses 
CBD-induced vasorelaxation in all patient samples with representative 
trace (A and C). Effects of CBD on baseline compared to vehicle control 
and representative trace (B and D). Comparisons made using 2-way 
ANOVA. 
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Figure 4.2 Potential receptor and ion channel involvement in CBO 
responses 
CBO-induced vasorelaxation in arteries incubated with the CB1 
antagonist AM251 (A), the CB l antagonist LY320135 (B), CB2 
antagonist AM630 (C), the putative CBe receptor antagonist 0-1918 
(0), in arteries where the TRPV1 receptor had been desensitised after 
1-hour incubation with the TRPV1 agonist capsaicin (E) or in arteries 
contracted with high potassium physiological salt solution (F). 
Comparisons made using 2-way ANOVA, * P<0.05 and *** P<O.OOl. 
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Figure 4.3 Potential involvement of the endothelium and COX in CBO 
responses 
CBO-induced vasorelaxation after endothelium denudation (A), in 
arteries that have been incubated with the nitric oxide synthase 
inhibitor L-NAME (B) or In arteries Incubated with the non-selective 
COX Inhibitor Indomethacin (C). Comparisons made using 2-way 
ANOVA, *** P<O.OOl. 
110 
Q) 
c 
~ ~
-0 Q) 
Vl 
0 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
A 
0 
20 
Cl. 
E 
I 
~ ~
a.. 
"-0 
c 
0 
B 
:::J 
-0 
Q) 
a:: 
~ ~0 
CI 
o 
-' 
~ ~
Q) 
~ ~,.... 
Q) 
c 
~ ~
"0 
8! 
8. 
E 
I 
e! 
a.. 
"-0 
c: 
0 
B 
:::J 
a:l 
a:: 
~ ~0 
40 
60 
80 
100 
S 
8 
c 
--e- Control 
----
Endothelium Denuded 
--.- AM251 (100 nM) 
-tr- AM251 + Denuded 
-7 -6 -5 
CSD Log Concentration [M] 
pEC50 
,------ * ------, 
-4 
_ Control 
~ ~ Endothelium Denuded 
S AM251 (100 nM) 
!IIII1J AM251 + Denuded 
• Control 
m Endothelium Denuded 
~ ~ AM251 (100 nM) 
IIIIJ1] AM251 + Denuded 
Figure 4.4 Experiments to establish the potentia l relationship between 
the CB l receptor and the endothelium. 
CBD-induced vasorelaxation in control arteries (empty squares), 
endothelium-denuded arteries (filled squares), in arteries incubated 
with the CB I antagonist AM251 (filled triang les) or in arteries that are 
endothelium-denuded and incubated with AM251 (empty triang les)(A). 
Comparisons between pECso (B) and Rmax (C), values derived from (A) 
Comparisons made using 1-way ANOVA and Bonferroni post-hoc test. 
**P<O.05 and ** P<O.Ol. 
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Figure 4.5 Ethanol concentration-response curves. 
Ethanol concentration-response curves carried out in arteries under the 
following conditions; incubation with 100 nM AM251 (A), incubation 
with 1 ~ M M LY320135 (B), 1 hour incubation with capsaicin (C), after 
endothelium-denudation (D), in the presence of L-NAME or in arteries 
contracted using KPSS. Comparisons made using 2-way ANOVA. 
** P<O.Ol. 
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Figure 4.6 Potential time-dependent effects of CBO 
Time-dependent vasorelaxation to a single concentration of CBO 
(10 IJM) compared to ethanol vehicle control (A) and in the presence of 
the PPARy antagonist GW 9662 (B). Comparisons made using 2-way 
ANOVA. P<O.OOl ***. 
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4.4.3. Post-hoc Analysis of Patient Medical Notes 
Due to the variability of control responses to CSD among patients 
(response range at 100 IJM CSD, 2.2 - 75% reduction in pre-imposed 
tone), and that 2-AG responses are reduced depending on patient 
medical condition or medication, post-hoc analysis of patient 
vasorelaxant responses to CSD was carried out. The variables 
compared were diagnosis, current medication and cardiovascular risk 
factors. CSD responses were reduced in males compared to females 
and positively correlated with bradykinin response (Figure 4.7A & D). 
CSD responses did not correlate with age, nor were they reduced in 
patients with cancer and those without (Figure 4.7S & C). CSD 
responses were significantly reduced in patients diagnosed with 
hypercholesterolaemia, type-2 diabetes and hypertenSion (Figure 4.8S, 
C & D). Interestingly, analysis of patient notes showed a modest yet 
significant increase in CSD-induced vasorelaxation in patients that 
smoke compared to those that do not (Figure 4.8F). CSD-induced 
vasorelaxation was not reduced in patients with heart disease or a SMI 
>25 kg/m 2 (Figure 4.8 A & E). CSD responses were reduced in those 
taking NSAIDs, statins, hypoglycaemic medication and beta-blockers 
(Figure 4.9A - D), but not those taking ACE inhibitors (Figure 4.9E). 
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Figure 4.7 Patient characteristics and CBD responses 
CBD-induced vasorelaxation in females compared to males (A). CBD 
Rmax responses did not correlate with patient age (B). CBD-induced 
vasorelaxation in patients with cancer compared to patients without 
cancer (C). CBD Rmax responses correlated with bradykinin response 
from the same artery (D). Comparisons made using 2-way ANOVA and 
correlations made using Spearman correlation coefficient. * P<O.05. 
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Figure 4.8 Cardiovascular disease/disease risk factors and CBO 
responses 
CBO concentration-response curves in patients with heart disease (A), 
hypercholesterolaemia (B), type-2 diabetes (C), hypertension (D), 
elevated BMI (E) and In patients who smoke (F). Comparisons were 
made between patients with a given characteristic and those without 
using 2-way ANOVA, * P<O.OS, ** P<O.Ol and *** P<O.OOl. 
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Figure 4.9 Patient medication and CBO responses 
CBO concentration-response curves in patients taking NSAIOs (A), 
statins (B), hypoglycaemic (C), beta-blocking (D) and ACE inhibiting 
medication (E). Comparisons were made between patients taking a 
given medication and those that were not using 2-way ANOVA. 
* P<O.OS, and *** P<O.OOl. 
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4.5. Discussion 
The aims of this chapter were to characterise the vasorelaxant effects 
of CBO In human mesenteric arteries, to assess CBO for potential 
time-dependent PPARy-mediated vasorelaxation and to assess CBO 
control responses In light of the patient medical history. This study has 
shown that CBO-induced vasorelaxation is dependent on CB l and 
TRPVl receptor activation, the endothelium, NO and ion channel 
modulation. In human small resistance mesenteric arteries, CBO does 
not cause PPARy-mediated vasorelaxation. Post-hoc analysis of patient 
responses revealed slight, but significant reductions in responses to 
CBO in patients with hypercholesterolaemia, type-2 diabetes and 
hypertension. 
In human mesenteric arteries CBO caused half-maximal 
vasorelaxation of human mesenteric arteries with a pECso In the mid 
mlcromolar range. These findings are similar with those reported In the 
rat mesenteric artery, where CBO causes vasorelaxation with similar 
potency to that observed In this study, however, in the rat model CBO 
caused near maximal vasorelaxation (Offertaler et al., 2003). This 
might suggest that the efficacy of CBO is reduced in human 
vasculature, which is In contrast to other work which has shown that 
cannabinoid potency, but not efficacy, is reduced when comparing 
human and rat vascular responses to cannabinoids (Kozlowska et al., 
2007; Kozlowska et al., 2008). This finding could be explained by 
species differences which have previously been shown with other 
cannablnolds (Randall et al., 2004). However, an alternative 
explanation could lie in the patients from whom samples were taken, as 
less than half the patient population used in this study were without 
co-morbidities that post-hoc analysis showed reduced CBO responses. 
Hypertension, diabetes, increased cholesterol and smoking were 
observed to reduce CBO responses and are associated with increased 
reactive oxygen species, increased vasoconstrictor prostanoids, 
decreased vasorelaxant responses and subsequent endothelial and 
vascular smooth muscle dysfunction (Vanhoutte et al., 2009). It is also 
possible that differences In the efficacy could be explained by the 
differences In contractile agent used. Offertaler and colleagues (2003) 
contracted arteries using phenylephrine, however In this study U46619 
and endothelin-l were used. In rat mesenteriC arteries and human 
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coronary myocytes, U46619 has been shown to inhibit BKca channels 
and SKCa channels (Crane and Garland 2004; LI et al., 2010). 
Potassium channel activation was found to be a potential contributor to 
CBO-Induced vasorelaxation In human mesenteric arteries. Therefore, 
BKca and SKca channel inhibition caused by U46619 could explain the 
reduced efficacy seen in this work. 
In animal models, activation of CB1, CB2 and TRPV1 receptor 
sites has been implicated in cannabinoid-induced vasorelaxatlon 
(Zygmunt et al., 1999; O'Sullivan et al., 2004; O'Sullivan et al., 2005). 
Since human vascular smooth muscle and endothelial cells express 
these receptors (Sugiura et al., 1998; Liu et al., 2000; Fantozzi et al., 
2003; Rajesh et al., 2007; Rajesh et al., 2008; Wang et al., 2008), and 
CBO has been shown to bind to these receptors at low micromolar 
concentrations (Showalter et al., 1996; Bisogno et al., 2001), they 
were considered potential mechanisms that underpinned CBO-induced 
vasorelaxation. Antagonism of the CB l receptor using AM251 revealed 
inhibition of CBD-induced vasorelaxation. Since CBO has a complex 
pharmacology at the CB l receptor, whereby it has been shown to cause 
antagonism/inverse agonism at micromolar concentrations (reviewed 
Pertwee 2008) and AM251 is reported to have effects at targets other 
than CBl (reviewed Pertwee 2005) including activation of GPR55 
(Ryberg et al., 2007), the role of CBl was confirmed using another 
antagonist at this receptor, LY320135 which Is a CB l antagonist that Is 
structurally distinct from AM251 and rimonabant (Felder et al., 1998). 
LY320135 also showed inhibition of CBD-induced vasorelaxation, albeit 
less inhibition than observed using AM251, confirming the role for CB l 
in CBO-induced vasorelaxation. However given that in various cell 
types, CBD is reported to be void of activation of cannabinoid receptors 
(Bisogno et al., 2001; Lauckner et al., 2005), an alternative 
explanation for the inhibitory effects of AM251 in CBO-induced 
vasorelaxation may lay in the pharmacology of this antagonist. AM251, 
in an Invertebrate model void of cannabinold receptors, has been 
shown to reverse capsaicin induced long term synaptic depression 
(Yuan and Burrell 2010), suggesting that AM251 may inhibit TRPV1 
responses. The plausibility of this explanation is increased considering 
that TRPV1 desensitisation also inhibited CBD-induced vasorelaxation. 
However, it is unknown if LY320135 has activity at TRPVl. Therefore a 
further explanation may be that CBO acts as an inverse agonist at CBl 
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(reviewed Pertwee 2008), and as CB l receptors are negatively coupled 
to cAMP resulting in inhibition of PKA, inverse agonism would increase 
PKA activity. Elevations of PKA are reported to increase the sensitivity 
of TRPVl receptors (01 Marzo et al., 2002). Therefore, as this study 
also shows that TRPVl desensitisation Inhibits CBO-induced 
vasorelaxation it Is possible that CBD does not directly cause 
vasorelaxation through the CB l receptor. Instead there is the possibility 
that CBO sensitises the TRPVl receptor through Inverse agonism of the 
CB l receptor. However, it has recently been shown that CBO decreases 
gut permeability In a CBrdependent manner that is not dependent on 
TRPVl (Alhamoruni et al.,· 2010). Alhamoruni et al. (2010) suggest 
direct activation of CB l by CBO In the gut, therefore the possibility of 
CBO directly activating CB l In the current study cannot be ruled out. 
Antagonism of the CBl receptor using AM630 did not inhibit 
CBO-induced vasorelaxation. Other studies have also shown that CBz 
receptor activation is not commonly found to underpin the vasorelaxant 
effects of cannabinoids (White et al., 2001; Hoi and Hiley 2006; 
O'Sullivan et al., 2009). This finding Is further supported in Chapter 
Three, as the selective CBl agonist HU308 did not cause vasorelaxation. 
Oesensltisation of TRPVl channels using the TRPVl agonist 
capsaicin also caused Inhibition of CBD-induced vasorelaxatlon. Work In 
the rat mesenteric artery has shown that vasorelaxation to two 
chemically closely-related cannabinoids, THe and cannabinol, Is 
Inhibited by capsaicin pre-treatment (Zygmunt et al., 2002). 
Plant-derived cannablnolds are good activators of the TRPV channel 
family (De Petrocellis et al., 2011), and CBD has been suggested to 
have a therapeutic use in cancer cell apoptosis (Yamada et al., 2010), 
reduction of cancer cell invasion (Ramer et al., 2010), 
anti-hyperalgaeslc responses to both chronic and acute inflammatory 
pain (Costa et al., 2004; Costa et al., 2007) through activation of TRPV 
channels. Furthermore, in cultured rat dorsal root ganglion, CBD, 
through TRPV2, causes release of calcitonin gene-related peptide 
(CGRP), a known vasomodulator associated with cannabinoid/TRPV 
channel induced vasorelaxation (Qin et al., 2008). Therefore, It would 
be of future interest to probe the potential Involvement of other TRPV 
receptors using the non-selective TRPV channel blocker ruthenium red 
and or selective channel blockers. 
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Taken together, the above findings show that CBD causes 
vasorelaxation that Is sensitive to CB l receptor antagonism and TRPV1 
receptor desensitisation. Given the reported pharmacology between the 
CB l receptor and CBD, the role for the CB l receptor, and potential 
regulation of the TRPV1 receptor, requires further investigation. Also, 
the above findings taken together with Chapter Three would further 
suggest that the CB2 receptor does not mediate vasorelaxation in 
human mesenteric arteries. 
The endothelium has been shown to mediate vasorelaxation of 
the CBD analogue Abn-CBD, and this vasorelaxation is often associated 
with activation of the putative CBe receptor that can be antagonised 
using 0-1918 (Begg et al., 2003; Offertaler et al., 2003; Kozlowska et 
al., 2007). The present study found that removal of the endothelium 
reduced responses to CBD in submaximal concentration ranges. 
However, in the presence of 0-1918, CBD-induced vasorelaxation is 
unaltered, suggesting that the endothelial component is not linked to 
activation of the as yet unidentified 'endothelial' receptor. NO is a 
well-known endothelium-dependent vasorelaxant and has been shown 
to mediate vasorelaxation to anandamide and WIN 55,212-2 in rat 
renal vasculature and rat aortae respectively (Deutsch et al., 1997; 
Dannert et al., 2007). Incubation with the nitric oxide synthase 
Inhibitor L-NAME reduced CBD-induced vasorelaxation at sub-maximal 
concentrations but not at maximal concentrations, In a similar manner 
to that observed in arteries that had been endothelium-denuded. 
This suggests that CBD acts on the endothelium and releases 
nitric oxide. Previous studies have shown AEA can increase NO through 
CB1- (Deutsch et al., 1997) and TRPV1- (Poblete et al., 2005) mediated 
pathways, therefore the NO component of CBD-induced vasorelaxation 
might in part be through receptor-mediated NO release. 
In rabbit arterioles the effects of both AEA and THC are inhibited 
by indomethacin (Ellis et al., 1995), suggesting the role of COX 
metabolism in vasorelaxation to both endogenous cannabinoids and 
phytocannabinoids. Therefore, the potential for endothelial or smooth 
muscle production of COX and subsequent metabolism of CBD into 
vasoactive compounds was investigated. Indomethacin had no effect on 
CBD-induced vasorelaxation, suggesting COX metabolism of caD was 
not involved In vasorelaxation. It has recently been shown however, 
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that CBD attenuates Inducible COX expression In human colon 
adenocarcinoma cells (Ruhaak et al., 2011). 
Cannablnoid-induced vasorelaxation has previously been shown 
to be inhibited in arteries pre-contracted with high potassium solution 
(White and Hiley 1998). The present study also reports that 
CBD-induced vasorelaxation Is inhibited In arteries contracted using 
high potassium solution. Contractions to high potassium solution are 
mediated through Influx of calcium through voltage-operated calcium 
channels (Karakl et al., 1997). Therefore, the inability of CBD to cause 
vasorelaxation might suggest that CBD is unable to inhibit calcium 
influx through these channels. However, Increases in extracellular 
potassium have been shown to Inhibit potassium channel-mediated 
hyperpolarisatlon (reviewed In Quignard et al., 1999), therefore, a 
predominant mechanism of CBD-induced vasorelaxation might be 
activation of potassium channels and subsequent hyperpolarisation. 
The CB I receptor Is expressed in both human endothelial cells 
and vascular smooth muscle cells in culture (Sugiura et al., 1998; Liu 
et al., 2000). Further experiments were carried out to establish if the 
endothelium sensitive and AM251 sensitive components were additive, 
and therefore potentially suggesting the location of the CB l receptor. 
To test this arterial segments from the same patient were either 
untreated (contrOl), endothelium denuded, incubated with AM251 or 
endothelium denuded and incubated with AM251. Comparisons of CBD 
pECso and Rmax values were then made between differing treatments. 
This revealed that there were no differences in pECso values between 
untreated arteries and arteries that were endothelium denuded alone 
or AM251 incubated alone. However, there was a significant difference 
between untreated arteries and endothelium denuded AM251 incubated 
arteries, suggesting an additive effect. When Rmax comparisons were 
made there were significant (P<O.Ol) reductions of 20% (AM251 
Incubated) and 18% (endothelium denuded AM251 incubated) in Rmax 
compared to untreated arteries. However, when AM251 incubated 
arteries and endothelium denuded AM251 incubated arteries were 
compared to endothelium denuded alone there was a 14% and 13% 
reduction in Rmax respectively. These differences were not significant, 
although they show a trend towards being significantly different to 
endothelium denuded arteries alone. Therefore these experiments were 
Inconclusive in showing whether the endothelium dependent and 
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AM251 sensitive components were additive, and further experiments 
are needed to draw a satisfactory conclusion. 
In rat aortae, CBO caused time-dependent vasorelaxation that 
can be inhibited by PPARy antagonism (O'Sullivan et al., 2009). 
Although this study reports that, over time, CBO-induced 
vasorelaxation gradually increased, this effect was not inhibited by 
PPARy antagonism. THC caused similar PPARy-mediated 
time-dependent vasorelaxation in the rat aorta (O'Sullivan et al., 
2005). However, in third order mesenteric arteries THC was unable to 
cause time-dependent vasorelaxation that is significantly different from 
vehicle control (O'Sullivan et al., 2006). The PPARy receptor is 
expressed in human aortic and coronary smooth muscle cells (Benson 
et al., 2000), human saphenous vein endothelial cells (Marx et al., 
1999) and in human inferior mesenteric arteries (Soumian et al., 
2005). Furthermore, it has been shown that incubation with a PPARy 
agonist (GW1929) can enhance endothelium-dependent vasorelaxation 
in human omental arteries from elderly patients or patients with 
cardiovascular disease risk factors (Angulo et al., 2012). Therefore, the 
lack of PPARy-mediated vasorelaxation seen to CBO may be due to 
vascular bed or arterial size differences. However, an interesting 
observation was the non-recoverable vasorelaxation observed to CBO. 
In rat G3 mesenteric arteries THC did not cause PPARy mediated 
vasorelaxation and the vasorelaxation to THC started to recover during 
the 2 hour period (O'Sullivan et al., 2006). The present study suggests 
that the non-recoverable response to CBO was mediated by either the 
CB l and TRPV1 receptors, as seen in acute vasorelaxation, or by an 
additional unknown mechanism. CB l and TRPV1 receptors are both 
prone to desensitization and internalisation (Sim et al., 1996; Zygmunt 
et al., 1999). Therefore, if these receptors mediated the effects of CBO 
over 2 hours It would suggest that 10 J.IM CBO over a 2 hour period did 
not desensitise these receptors in this system. 
Taken together these findings show that CBO-induces 
vasorelaxation of the human mesenteric artery dependent on CB l and 
TRPV1 receptor activation, the endothelium, NO and ion channel 
modulation. This study also shows there is a trend for increased 
Inhibition in CBO response when arteries are denuded of their 
endothelium and incubated with AM251 compared to endothelium 
denuded alone. Finally, mechanistic work has shown that ceo causes 
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vasorelaxation over a 2-hour period that is not mediated by the PPARy 
receptor. 
Given the variability of the responses seen to CBO and the 
influence of patient medical conditions and medications seen in chapter 
three, post-hoc analysis of patient medical notes was undertaken. 
This study found that CBO-induced vasorelaxation was 
enhanced in females compared to males. The enhanced vasorelaxation 
observed In female patient arteries compared to males may be due to 
protective effects of oestrogen on endothelial function (Novella et al., 
2012). However, it is worth noting that early research also showed that 
CB1 receptor expression was Increased in the leukocyte cells of females 
when compared to males (Onaivl et al., 1999). 
CBO responses were not dependent on patient age. Increasing 
age is associated with endothelial dysfunction (Vanhoutte et al., 2009), 
yet CBO responses did not correlate with age in this study which may 
suggest that mechanisms behind CBO-Induced vasorelaxation may be 
preserved in aging populations. 
CBO responses were not different between cancer patients and 
patients with inflammatory bowel disorders. Inflammatory bowel 
disorders are associated with increased COX-2 expression (Tabernero 
et al., 2003). However, the effects of CBO were unaltered by COX 
Inhibition, suggested COX levels have no bearing on CBO-induced 
vasorelaxation. 
Positive correlations were observed between CBO and 
bradykinin response. In humans mesenteric arteries, as in animals, 
bradykinin causes vasorelaxation that is dependent on the endothelium 
(Cherry et al., 1982). This finding adds further support to the role of 
the endothelium in CBO-Induced vasorelaxation. 
Similar to 2-AG, CBO responses are reduced In the vasculature 
of those with some cardiovascular diseases. CBO responses were 
reduced In those with Increased cholesterol, diabetes and hypertension. 
Key mechanisms underlying CBO-induced vasorelaxation were CB1 and 
the TRPV1 receptor activation. CB1 receptor expression Is Increased In 
vascular diseases such as atherosclerosis and acute myocardial 
infarction (Sugamura et al., 2009; Wang et al., 2011). However, In rats 
fed high cholesterol diets CB1 receptor expression Is reduced 
(Hayakawa et al., 2007). Also, In diabetes TRPV1 receptor coupling to 
nitric oxide and BKca potassium channels is disrupted (Guarini et al., 
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2012). Therefore, it is likely that the decreased responses of CBO In 
patients with cardiovascular disease are a result of complex changes 
occurring at a receptor or post-receptor level, whereby receptor 
expression potentially Increases to compensate for loss of function or Is 
down-regulated. However, it should be noted that the reductions 
observed ranged from 3% In patients with hypertension to 12% in type 
two diabetic patients. Whilst these values were significant they may 
have little in vivo significance on systemic blood pressure. Wheal et al. 
(2007) reported that in vivo administration of AEA to conscious rats 
caused a 40% decrease in mesenteric conductance that was in parallel 
to a 20% increase in mean arterial pressure. Wheal et al. (2007) in the 
same study, also reported that AEA caused both increases and 
decreases in vascular conductance depending on the vascular bed 
studied. Therefore, in isolated arteries, small reductions in 
vasorelaxation should be interpreted with caution, as such effects may 
not be mirrored in other vascular beds and may not translate to in vivo 
conditions. 
CBO responses are reduced in patients taking NSAID, statin, 
hypoglycaemic and beta blocking medication. In some patients it has 
been reported that NSAIO medication, through loss of PGI2, increases 
the risk of cardiovascular and vascular disease (Amer et al., 2010). 
However, statins and hypoglycaemic agents including simvastatin and 
metformin have been shown to Improve endothelial function through 
reduced thromboxane activities (McNeish et al., 2012; Puyo et al., 
2012). Therefore, with the potential exception of NSAIOs, it Is likely 
that the reduced vasorelaxation observed to CBO is a result of the 
underlying medical condition and not the medication. 
In conclusion, this study reports that CBO causes vasorelaxation of the 
human mesenteric artery. This vasorelaxation Is mediated through CB1, 
TRPV1, the endothelium, nitriC oxide and potassium hyperpolarisatlon. 
CBO also causes time-dependent vasorelaxation of human mesenteric 
arteries, but this was not due to PPARy activation. The vasorelaxant 
effects of CBO are reduced in patients with hypercholesterolaemia, 
type-2 diabetes and hypertension. Given that CBO partly causes 
vasorelaxation through CB l and TRPV1 receptors, and that these 
receptors are altered in diseases that affect the vasculature, further 
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work is needed to fully understand alterations in these receptors and 
how they interact with endocannabinoids. 
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5. CHARACTERISATION OF AEA-INDUCED VASORELAXATION IN 
HUMAN MESENTERIC ARTERIES 
5.1. Introduction 
AEA causes maximal vasorelaxation of third order rat mesenteric 
arteries with potency in the micromolar range (Randall et al., 1997; 
White and Hiley 1997; O'Sullivan et al., 2004). In rat third order 
mesenteric arteries, vasorelaxation to AEA is underpinned by several 
key pathways including CB l and CB2 receptor activation (Randall et al., 
1997; White and Hiley 1997; O'Sullivan et al., 2004), liberation of 
EDHF, activation of TRPV1 channels (O'Sullivan et al., 2004) and 
activation of the putative CBe receptor (Offertaler et al., 2003). Whilst 
there are some mechanistic similarities between different vascular 
beds/species, some differences have been observed. For example, 
inhibition of AEA-induced vasorelaxation by inhibiting nitric oxide 
synthase has only been observed in rat small renal arterioles (Deutsch 
et al., 1997), but not in rat mesenteric arteries (O'Sullivan et al., 
2004). Also, AEA induces 25-50% vasorelaxation of rabbit cerebral 
arterioles (Ellis et al., 1995), 50% vasorelaxation of bovine coronary 
arteries (Pratt et al., 1998), and 80% vasorelaxation of ovine coronary 
arteries (Grainger and Boachie-Ansah 2001) through COX-dependent 
pathways (Ellis et al., 1995; Pratt et al., 1998; Grainger and Boachie-
Ansah 2001). However, in rat mesenteric arteries, metabolism of AEA 
has been suggested to limit the vasorelaxant effects of AEA (Ho and 
Randall 2007). These authors showed that incubation of third order rat 
mesenteric arteries with COX or FAAH inhibitors was able to 
significantly increase the potency of AEA. The study concluded that in 
third order rat mesenteric arteries the endothelium might represent a 
metabolic barrier limiting AEA-induced vasorelaxation (Ho and Randall 
2007). 
Taken together these studies show that the efficacy and 
mechanisms of AEA-induced vasorelaxation differ depending on the 
species and vascular bed studied. 
In the rat aorta, AEA causes acute vasorelaxation that is a 
quarter of the amount seen In rat third order mesenteric arteries 
(O'Sullivan et al., 2005). However, prolonged exposure to AEA (5 (.1M) 
causes time-dependent vasorelaxation of around 50% over a 2-hour 
period (O'Sullivan et al., 2004; O'Sullivan et al., 2009). Vasorelaxation 
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is inhibited by PPARy antagonism (GW9662), inhibition of protein 
synthesis (cycloheximide), endothelial denudation, nitric oxide 
inhibition (L-NAME) and superoxide dismutase inhibition 
(diethyldithiocarbamate) (O'Sullivan et al., 2009). Metabolism of AEA 
through FAAH was not involved in the PPARy-mediated actions of AEA 
(O'Sullivan et al., 2009). 
In humans, plasma AEA concentrations are reported to be 
between 0.3-2.S nM (Zoerner et al., 2009). Circulating AEA 
concentrations are raised in a variety of disease states that directly 
affect the vasculature or in patients that have risk factors for 
cardiovascular disease. For example, AEA levels are increased by 35% 
in obese patients plasma (Engeli et al., 2005), increased by 65% in 
blood serum from patients with type-2 diabetes compared to healthy 
controls (Matias et al., 2006) or increased by 200% in tissue compared 
to obese non-type-2 diabetic patients (Annuzzi et al., 2010), correlate 
with coronary dysfunction (Quercioli et al., 2011) and increased by 
S5% In semi purified plasma samples from patients with portal 
hypertension associated with cirrhosis (Fernandez-Rodriguez et al., 
2004 ). Interestingly, the latter study reported that elevations in AEA 
concentrations were not associated with any haemodynamic changes 
(Fernandez-Rodriguez et al., 2004). The reasons behind the increase in 
AEA concentrations in these conditions are unknown. Animal studies 
might suggest that the increase in AEA serves as a protective measure 
against further vascular decline. In vivo work has shown that the 
systemic hypotensive effect of AEA is apparent in SHR but not 
normotensive rats (Lake et al., 1997; Wheal et al., 2007). In vitro work 
supports this showing that increased AEA and increased CB l levels are 
associated with decreased arterial contractions to high potassium and 
phenylephrine, with enhanced vasorelaxant responses to ACh and SNP 
in the mesenteric arteries of biliary cirrhotic rats (Yang et al., 2007). 
However, there may be species and vascular bed differences in this 
finding as Wheal et al. (2009) found that, in the mesenteric vascular 
bed, AEA caused less vasorelaxation in arteries of hypertensive rats 
compared to normotensive controls. However, in the aortae of the 
same rat model AEA was shown to have increased efficacy (Wheal and 
Randall 2009). 
In humans there has been limited work looking at the vascular 
effects of AEA. In human arteries, AEA is ineffective as a vasorelaxant 
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in myometrial arteries (Kenny et al., 2002). However, AEA causes 
increased blood flow in the forearm circulation when applied topically 
but not intra-arterially (Movahed et al., 2005). In this study Movahed 
et al. (2005) show that the vasorelaxation caused by AEA Is inhibited 
by co-application with the TRPV1 antagonist capsazepine. AEA also 
causes maximal vasorelaxation of human pulmonary arteries 
(Kozlowska et al., 2007). The mechanisms behind AEA-induced 
relaxation were not probed in the study of Kozlowska et al. (2007). 
5.2. Aims 
In Chapter Three it was suggested that the vasorelaxation produced by 
AEA in human mesenteric arteries was significantly less than that seen 
In animals. Therefore, the first aim was to assess the potential role of 
metabolism in limiting AEA-induced vasorelaxation (Ho and Randall 
2007). The second aim was to characterise the AEA-induced 
vasorelaxation. The third aim was to assess whether AEA causes 
time-dependent PPARy-mediated vasorelaxation of human mesenteric 
arteries (O'Sullivan et al., 2009). Finally, given the findings in chapters 
three and four, and in light of the often altered levels of AEA In 
cardiovascular disease or disease risk factors, the fourth aim was to 
look at AEA-induced vasorelaxation in respect of patient medical 
condition. 
5.3. Methods 
5.3.1. Patient consent and arterial preparation 
Informed consent was taken from patients (n=32) receiving colorectal 
re-sections for cancer (n=17) and inflammatory bowel disorders 
(n=l1) as described in section 2.2. Four patients consented to the use 
of their arteries in this research' but declined research access to 
hospital notes. Tissues were dissected, removing small mesenteric 
arteries that were either used fresh (n=24) or after overnight storage 
(n=8) as described In section 2.3 
5.3.2. Myography Experiments 
Arteries were mounted onto a Mulvany-Halpern myograph and 
subjected to normalisation and the standard start procedure as 
described In section 2.3 and 2.4. Cannabinoid concentration-response 
curves were carried out in viable arteries and compared to vehicle 
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controls from an adjacent arterial segment from the same patient. To 
reveal potential limiting factors in AEA-induced vasorelaxation or to 
characterise the mechanisms of action of AEA, a range of 
pharmacological techniques were used as described in section 2.7, with 
comparisons made between responses in test and control arteries 
taken from the same patient. 
In some arteries, potential time-dependent effects of AEA were 
investigated. In studies using rats, PPARy-mediated vasorelaxation was 
only observed in conduit arteries (O'Sullivan et al., 2006). Therefore, in 
these experiments, larger arteries (> 1 mm) were mounted onto fixed 
hooks and a single concentration of 10 I-IM AEA (5 I-IM concentration 
was shown to cause PPARy-mediated effects In rat aorta (O'Sullivan et 
al., 2009» (In the presence or absence of GW 9662 1 I-IM) or 0.1 % 
EtOH was added to the myograph chamber. Readings were taken every 
15 minutes to assess potential time-dependent vasorelaxation. 
5.3.3. Post-hoc Analysis 
Post-hoc analysis was performed on control AEA responses from 
patients who granted access to personal details and medical notes 
(n=28). Arterial AEA responses were analysed depending on the 
patient's medical history and medications. Particular attention was paid 
to diseases and medications that have either a direct vascular impact 
or are vascular disease risk factors. 
5.3.4. Statistical Analysis 
Mean percentage relaxation is displayed with error bars representing 
the s.e.m, and n equalling the number of patients. Sigmoidal 
concentration-responses curves with a standard Hill slope of 1 were 
fitted to those data using GraphPad Prism. Statistical comparisons 
between test and control concentration-response curves and 
time-dependent experiments were made using 2-way ANOVA. 
5.4. Results 
5.4.1. The Acute Actions of AEA 
The characteristics of patients used In this study are given In table 5.1. 
AEA caused vasorelaxation with an Rmax of 32 ± 2% and a pECso of 6.0 
± 0.2, n=32 (Figure S.lA & C). AEA caused a significant vasorelaxation 
of baseline tone (Figure S.lB & D). Incubation with Indomethacin or 
URB597 did not modify AEA concentration-response curves (Figure 
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S.2A & B). Antagonism of the CB1 receptor using AM2S1 (100 nM) 
significantly inhibited AEA-induced vasorelaxation (Figure S.3A). 
Antagonism of the CB2 receptor using AM630 (100 nM) or 
desensitization of TRPVl receptors using capsaicin (10 f.IM) had any 
effect on AEA-induced vasorelaxation (Figure S.3B & C). Antagonism of 
the putative CBe receptor using 0-1918 (1 f.IM) inhibited AEA-induced 
vasorelaxation (Figure S.4C). Removal of the endothelium and 
incubation of arteries with L-NAME significantly inhibited AEA-induced 
vasorelaxation (Figure S.4A & B). 
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Table 5.1 Patient characteristics, diagnosis and medications AEA study 
Ch!ractel'istlc: Range Mean :t s.e,m 
Ethnicity 28 UK white 
Male 22 
Female 6 
Age 32 - 82 66::1: 2.1 
WeiQht (kq) 49 - 122 80::1: 4 
BMI (kg/m2 ) 17.6 - 36.7 27.4 ::I: 1 
Vessel size (\.1m) 346 - 1372 763 ::I: 46 
Bradykinin response 70 - 102 84 ::I: 1.6 
(% reduction in pre-Imposed tone) 
Smoking habits 
Non smokers 22 
0- 10 CPD 3 
10 - 20 CPD 3 
Drinking habits 
< 10 units p/w 18 
10 - 20 units p/w 8 
> 20 units p/w 2 
Operation 
Right hemicolectomy 7 
Left hemicolectomy 2 
Sigmoid colectomy 7 
Anterior resection 7 
Abdominoperineal resection 1 
Total colectomy 4 
Reason for surgery 
Cancer 17 
Inflammatory bowel disorder 11 
Dukes staging 
Dukes A 9 
Dukes B 4 
Dukes C 3 
Dukes D 1 
Systolic blood pressure (mm/Hg) 110 - 172 142::1: 3 
Diastolic blood pressure (mm/Hg) 65 ::I: 101 83::1: 2 
Diabetic 8 
Heart disease 22 
Heart failure 0 
Hypercholesterolaemia 14 
Hypertensive 16 
0-1 adrenoceptor antagonist (total) 1 
Alfuzosin 0 
Terazosin 1 
ACE Inhibitors (total) 7 
Lisinopril 5 
Ramipril 2 
ATl receptor antagonists (total) 2 
Losartan 1 
Irbesartan 1 
Beta Blockers (total) 5 
Metoprolol 1 
Atenolol 3 
Propranolol 1 
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CharacteristiC: Range Mean. I.e.rn 
Calcium channel blocker (total) 2 
Amlodipine 1 
Nifedipine 1 
Lodipine 0 
Digoxin 1 
Diuretics (total) 2 
Furosemide 2 
GTN 3 
Hypoglycaemic medication (total) 5 
Gliclazide 5 
Metformin 4 
Nsaid medication (total) 13 
Aspirin 5 
Ibuprofen 1 
Paracetamol 4 
Co Codamol 3 
Statin (total) 15 
Atorvastatin 4 
Simvastatin 10 
Pravastatin 1 
Thiazolidinedione (total) 1 
Pioglitazone 1 
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Figure 5.1 AEA responses 
AEA-induced vasorelaxation in all patient samples with representative 
trace (A and C). Effects of AEA on baseline compared to vehicle control 
and representative trace (8 and D). Comparisons were made using 
2-way ANOVA. 
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Figure 5.2 Potential role for metabolism in limiting AEA responses 
AEA-induced vasorelaxation in arteries that have been incubated with 
the non-selective COX inhibitor indomethacin (A) or the FAAH inhibitor 
UR6597 (6). Comparisons were made using 2-way ANOVA. 
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Figure 5.3 Potential receptor involvement in AEA responses 
AEA-induced vasorelaxatlon in arteries Incubated with the CB1 
antagonist AM251 (A), the CB2 antagonist AM630 (B) and In arteries 
pre-treated with the TRPVl agonist capsaicin (C). Comparisons made 
using 2-way ANOVA, ***P<O.OOl. 
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Figure 5.4 Potential endothelium Involvement In AEA responses 
AEA-induced vasorelaxation after endothelial denudation (A), in arteries 
that have been incubated with the nitric oxide synthase inhibitor 
L-NAME (B) or in arteries incubated with an antagonist of the proposed 
putative endothelial cannabinoid receptor (C). Comparisons were made 
using 2-way ANOVA, ** P<O.Ol and *** P<O.OOl. 
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5.4.2. Time-dependent vasorelaxation to AEA 
In arteries (> 1 mm), a single concentration of 10 IJM AEA caused 
significant vasorelaxation compared to vehicle control (Figure 5.5A). An 
initial vasorelaxation of 23 ± 3 % relaxation was observed at 
15 minutes, this developed to 70 ± 10 % relaxation at 120 minutes 
(Figure 5.5A). In the presence of the PPARy antagonist GW9662, 
vasorelaxation was not inhibited at any time point compared to AEA 
alone (Figure 5.56). 
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Figure 5.5 Potential time-dependent effects of AEA 
Time-dependent vasorelaxation to a single concentration of AEA 
compared to ethanol vehicle control (A) and in the presence of GW9662 
(B). Comparisons were made using 2-way ANOVA, *** P<O.OOl. 
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5.4.3. Post-hoc analysis of patient medical notes 
Due to the variability of control responses to AEA among patients 
(vasorelaxant response range at 100 ~ m o l / L L AEA, -4.8 to 83.1% 
relaxation) post-hoc analysis of patient responses was carried out. AEA 
responses were not gender-related or correlated with bradykinin 
responses or age (Figure 5.6A, B & D). AEA responses were greater in 
patients with cancer compared to those with inflammatory bowel 
disease (Figure 5.6C). AEA responses were significantly reduced in 
patients diagnosed with heart disease and a BMI >25 kg/m 2 (Figure 
5.7A & E). AEA responses were not reduced in those with hypertension, 
diabetes and hypercholesterolaemia or in smokers (Figure 5.8B, C, D & 
F). AEA responses were reduced in those taking NSAIDs and 
beta-blockers (Figure 5.8A & D) but not those taking ACE inhibitors, 
statins or hypoglycaemic medications (Figure 5.8B, C & E). 
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Figure 5.6 Patient characteristics and AEA responses 
AEA-induced vasorelaxatlon in females compared to males (A). AEA 
Rmax responses correlated with patient age (B). AEA-induced 
vasorelaxation in patients with cancer compared to patients without 
cancer (C). AEA Rmax responses correlated with bradykinin response 
from the same artery (D). Comparisons made using 2-way ANOVA and 
correlations made using Spearman correlation coefficient. **P<O.Ol. 
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Figure 5.7 Cardiovascular disease/disease risk factors and AEA 
responses 
AEA concentration-response curves In patients with heart disease (A), 
hypercholesterolaemia (B), type 2 diabetes (C), hypertension (D), 
elevated BMI (E) and in patients who smoke (F). Comparisons were 
made between patients with a given characteristic and those without 
using 2-way ANOVA. * P<O.OS and **P<O.Ol. 
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Figure 5.8 Patient medication and AEA responses 
AEA concentration-response curves in patients tasking NSAIDs (A), 
statins (6), hypoglycaemic (C), beta-blocking (D) and ACE Inhibiting 
medication. Comparisons were made between patients taking a given 
medication and those that were not using 2-way ANOVA. * P<O.05 and 
**P<O.Ol. 
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5.5. Discussion 
Chapter three showed that although AEA caused vasorelaxation of 
human mesenteric arteries, the efficacy was reduced when compared 
to rat mesenteric arteries. A previous study in rat mesenteric arteries 
reported the vasorelaxant response to AEA could be enhanced by 
inhibition of AEA metabolism (Ho and Randall 2007). Therefore, the 
aim of this study was to explore the effects of AEA in human 
mesenteric arteries. AEA-induced vasorelaxation was not limited by 
FAAH or COX metabolism. However, AEA-induced vasorelaxation is 
dependent on CB1 and CBe receptor activation, the endothelium and 
NO. AEA produces vasorelaxation over time, however this is not 
mediated by the PPARy receptor. Post-hoc analYSis revealed that AEA 
responses were reduced in those with inflammatory bowel disease, 
ischaemic heart disease, elevated BMI and in patients taking NSAIDs 
and beta-blockers. 
In animal studies, AEA is a potent efficacious vasorelaxant 
whose effects often depend on the species or the arterial bed studied 
(Randall et al., 2004). In the present study AEA-induced vasorelaxation 
in the human mesenteric artery has reduced efficacy compared with rat 
third order mesenteric arteries (Randall et al., 1997j White and Hiley 
1997; O'Sullivan et al., 2004). In other human studies, AEA has been 
shown to be ineffective in human myometrial arteries (Kenny et al., 
2002). However, AEA causes an increase in blood flow in the human 
forearm when applied topically (Movahed et al., 2005) and in vitro, 
with lower potency than observed in this study, AEA causes maximal 
vasorelaxation of human pulmonary arteries (Kozlowska et al., 2007). 
Combined with the previous work, the present study might suggest 
that the Importance of AEA as a regulator of vascular tone depends on 
the vascular bed, and tha't its overall systemic effect may be minor. 
However, it should be noted that the patients that were used in this 
study were elderly and often had several medical conditions. In young 
healthy volunteers Movahed et al. (2005) observed that arterial 
infusion of AEA did not cause any alteration in systemic blood pressure 
or heart rate. This suggests that under otherwise healthy conditions the 
systemic cardiovascular effect of AEA may be limited. However, local 
increase in forearm microcirculation may not translate into systemic 
changes. 
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Other researchers have shown that the vasorelaxant effects of 
AEA could be enhanced by inhibition of its metabolism (Ho and Randall 
2007). Therefore, we investigated the possibility that the reduced 
vasorelaxation observed might be a result of AEA being metabolised 
before reaching potential vasorelaxant targets. Ho et al. (2007) showed 
that incubation with the irreversible FAAH inhibitor URBS97 or the 
COX-2 selective inhibitor nimesulide potentiated the potency of AEA, 
but not the maximal effect. In contrast, the present study found that 
Inhibiting AEA metabolism using URBS97 and the non-selective COX 
Inhibitor indomethacin had no effect AEA-induced vasorelaxation. This 
suggests that the decreased efficacy of AEA seen in human mesenteric 
arteries is not due to AEA metabolism. It also shows that the 
vasorelaxatlon seen to AEA in human mesenteric arteries is not due to 
AEA metabolites. 
In rat mesenteric arteries, the vasorelaxant response to AEA is 
sensitive to CBl, CBe antagonism and TRPV1 desensitisation (O'Sullivan 
et al., 2004). Therefore, experiments were carried out to characterise 
potential Involvement of these receptors in the vasorelaxant effects of 
AEA In human mesenteric arteries. In these experiments it was 
revealed that AEA-induced vasorelaxation was dependent on activation 
of the CBl and CBe receptors, but not CB2 or TRPV1 receptors. In CB l 
and CB2 transfected CHO cells, AEA binds to the CB l and CB2 receptors 
with K, values of 89 and 371 nM respectively (Showalter et al., 1996) 
and has previously been shown to cause vasorelaxation through these 
receptors (Randall et al., 1997; White and Hiley 1997; O'Sullivan et al., 
2004). CBl receptors are present in human vascular endothelium and 
smooth muscle cells (Sugiura et al., 1998; Liu et al., 2000) and in 
chapter 4 CB l receptors were shown to have vasorelaxant abilities. 
Therefore, considering AEA has a high affinity for the CB l receptor it is 
not suprislng AEA causes vasorelaxation In such a way. AEA-induced 
vasorelaxation was not Inhibited by antagonism of the CB2 receptor. 
This, taken with the results of chapter three that HU-308 did not cause 
vasorelaxatlon, suggests that in human mesenteric arteries CB2 
receptors are not Involved in vasorelaxation. Similarly, In rat 
mesenteric arteries the effects of AEA are not inhibited by CB2 
antagonism (O'Sullivan et al., 2004). 
AEA is an agonist at the TRPV1 receptor with a pECso value in 
the low to mid mlcromolar range (Ross et al., 2001), TRPV1 receptors 
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are expressed in human smooth muscle and endothelial cells (Fantozzi 
et al., 2003; Wang et al., 2008). In the rat mesenteric artery, 
AEA-induced vasorelaxation is inhibited by desensitisation of TRPVl 
(O'Sullivan et al., 2004). However, in this study AEA-induced 
vasorelaxation was not attributable to TRPVl activation. In chapter 
four, CBD-induced vasorelaxation was inhibited by TRPVl 
desensitisation, suggesting that TRPVl channels are present and able 
to induce vasorelaxation of human mesenteric arteries. It is reported 
that AEA activation of TRPVl can be altered depending on PKA and PKC 
activity (De Petrocellis et al., 2001), therefore the lack of TRPVl 
activity seen in this study may be associated with altered receptor 
function. It also been shown that activation of the TRPVl receptor by 
AEA requires facilitated transport across the cell membrane (De 
Petrocellis et al., 2001) and pharmacological inhibition of the proposed 
membrane transport has been shown to reduce AEA potency in the rat 
mesenteric "artery (Andersson et al., 2002). It is of note that when 
TRPVl receptors are desensitised in rat mesenteric arteries there is a 
similar remaining vasorelaxation to that observed in human mesenteric 
arteries (O'Sullivan et al., 2004). Therefore, it is possible that the 
reduced vasorelaxation to AEA in human mesenteric arteries is caused 
by failure of AEA to activate TRPVl channels in these arterial segments. 
Removal of the endothelium has been shown to inhibit 
AEA-Induced vasorelaxation in rat mesenteric arteries (O'Sullivan et al., 
2004; Poblete et al., 2005; Wheal and Randall 2009), rat pulmonary 
arteries (Baranowska-Kuczko et al., 2012), rabbit aortae 
(Mukhopadhyay et al., 2002) and bovine ophthalmic arteries (Romano 
and Lograno 2006). This study similarly shows that removal of the 
endothelium and inhibition of NO inhibits AEA responses in human 
mesenteric arteries. Further support for the ability of AEA to cause NO 
release has been shown in rat first order mesenteric arteries (Wheal 
and Randall 2009), rat renal arteries (Deutsch et al., 1997), rat 
pulmonary arteries (Baranowska-Kuczko et al., 2012) and bovine 
ophthalmic arteries (Romano and Lograno 2006). A further endothelial 
site known to mediate AEA induced vasorelaxation is the CBe receptor. 
AEA causes vasorelaxation through this receptor site in a variety of 
vascular beds (Jaral et al., 1999; Mukhopadhyay et al., 2002; Begg et 
al., 2003; Hoi and Hiley 2006). Furthermore this receptor site has been 
shown to mediate vasorelaxation to the endocannabinoid virodhamine 
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in the human pulmonary artery (Kozlowska et al., 2008). In the 
Kzolowska et al. (2008) study, arterial incubation with 0-1918 reduced 
the maximal response to virodhamine by almost half. Whereas In rat 
mesenteric arteries 0-1918 shifts the potency of AEA by ten-fold 
without reducing maximal response (O'Sullivan et al., 2004). In the 
present study 0-1918 caused a 3.3 fold rightward shift in the 
concentration response curve to AEA, without effecting maxiamal 
responses. This finding suggests a role for the CBe receptor in human 
mesenteric arteries. Furthermore, this finding suggests that activation 
of the CBe receptor by AEA In human mesenteric arteries is similar to 
that observed In rat mesenteric artereis, but not human pulmonary 
arteries. Both CB l and CBe receptor activation has previously been 
speculated to produce nitric oxide (Deutsch et al., 1997; 
Mukhopadhyay et al., 2002). Therefore, given the findings of this study 
it is likely that, in part, AEA activities either CB l or CBe receptors, which 
through unknown mechanisms result In endothelial nitric oxide release 
and subsequent vasorelaxation. 
This study reports that a 2-hour incubation with AEA causes 
vasorelaxation that gradually Increases and is significantly different to 
vehicle and previous time points. However, this effect is not inhibited 
by PPARy antagonism. In rat aortae, AEA and NADA cause 
time-dependent vasorelaxation that can be inhibited by PPARy 
antagonism (O'Sullivan et al., 2009). Despite this study showing the 
time-dependent effect of AEA is not Inhibited by PPARy antagonism, it 
does not rule out the potential effects of AEA at the PPARy receptor in 
human mesenteric arteries. The lack of PPARy mediated response could 
be on account of the arteries used. It has previously been shown that 
in G3 resistance arteries THC is unable to cause PPARy-mediated 
vasorelaxation (O'Sullivan et al., 2006), suggesting that PPARy 
mediated vascular responses may be restricted to particular arterial 
beds. 
The effects of AEA were not dependent on gender or correlated 
with age or bradykinin response, a finding that is surprising given that 
endothelial denudation inhibits vasorelaxation to AEA. 
This study shows that the vasorelaxation to AEA is Increased In 
patients with cancer compared to those with Inflammatory bowel 
disease. In colorectal cancer tumour tissues and surrounding mucosal 
tissue It Is reported that the levels of endocannabinolds are higher than 
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in non-cancer tissues (Ligresti et al., 2003), and it has previously been 
shown that co-administration of AEA with other endocannabinoids 
facilitates AEA-induced hypotension through CB1-sensitive mechanisms 
(Garcia Mdel et al., 2009). Therefore, even moderately increased 
endocannabinoid production may act by having a priming effect at the 
CB l receptor and potentiate the effects of CB l activation. However, in 
this case it would be reasonable that CBD responses were enhanced in 
cancer patients, however the results in chapter four show they were 
not. An alternative explanation may be that AEA responses are reduced 
in inflammatory bowel disease. Little is known about the 
endocannabinoid system in these conditions however, it is known that 
AEA levels are often altered in mucosal and submucosal tissues 
(Alhouayek and Muccioli 2012). 
This study has also shown that AEA-induced vasorelaxation is 
similar in patients with hypercholesterolaemia, diabetes and 
hypertension when compared to patients without the aforementioned 
characteristics. Interestingly, smoking had no effect on AEA-induced 
vasorelaxation. Increased cholesterol (Vanhoutte 1991), diabetes (De 
Vriese et al., 2000), hypertension (Vanhoutte 1996) and smoking 
(Vanhoutte et al., 2009) are all associated with endothelial dysfunction, 
reduced nitric oxide production and increased production of 
vasoconstrictor prostaglandins. However, AEA responses were 
unaltered in these conditions. 
The effects of AEA were reduced in patients with ischaemic heart 
disease and in patients with increased BMI. In rat mesenteric arteries, 
cardiac ischaemia and reperfusion were associated with decreased 
endothelium-dependent vasorelaxation, increased contractile responses 
and oxidative stress (Zhao et al., 2012). There is also a strong immune 
response associated with Ischaemlc heart attacks, whereby the immune 
system over-compensates the repair of damaged arteries reducing 
arterial compliance (Timmers et al., 2012). Therefore, in ischaemic 
heart disease, increased oxidative damage may lead to arterial re-
modelling and subsequent reduced vasorelaxation.· Interestingly, the 
effects of CBO were not reduced in patients with IHD, however the 
effects of both endocannabinolds (AEA and 2-AG) used in this study 
were reduced In patients with IHO. A further point of interest is that 
endocannabinoids are increased and associated with coronary 
Circulation dysfunction In ischaemic heart disease (Quercloli et al., 
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2011). Although the potential reason for this is untested, it is 
speculated that increased endocannabinoids may chronically stimulate 
CBl leading to increased atherosclerosis and reduced endothelial 
function. It is also to be noted that in this study all patients with 
ischaemic heart disease had other vascular co-morbidities including 
hypertension, diabetes and hypercholesterolaemia. Therefore, a 
potential explanation for the reduced responses to AEA might be 
through the extent of vascular damage caused by the summation of 
several disease states (although none alone affected AEA responses). 
This study also observed decreased vasorelaxation to AEA in 
patients with a BMI >25kg/m2• Interestingly a recent study has shown 
that AEA levels are increased in patients that are obese, and that this 
increase in AEA is directly proportional to endothelial dysfunction in 
coronary arteries (Quercioli et al., 2011) as discussed above. Given the 
finding of Quercioli et al. (2011), It should not be ruled out that the 
increase in endocannabinoid levels might have detrimental effects on 
the cardiovascular system. 
This study has shown that AEA-induced vasorelaxation is 
reduced in patients taking beta-blockers and in patients taking NSAID 
medication. Given that the effects of AEA are not dependent on COX 
metabOlism, the reduction observed may be caused by the disease 
states that these medications are used to treat. However, various 
NSAIDs have been shown to affect the endocannablnoid . system 
(Paunescu et al., 2011), with specific interactions observed between 
nimesullde, parecoxib and valdecoxib at the CB l receptor (Staniaszek et 
al., 2010; Schroder et al., 2011). Therefore, through as yet unknown 
mechanisms, the CB l mediated responses seen In this study might be 
altered In the presence of COX Inhibitors. Another explanation could be 
that NSAIDs are reported to inhibit PGh production and therefore 
contribute to an overall decline in vascular function (McGettigan and 
Henry 2011). 
In conclusion, this study has shown that In human mesenteric 
arteries, AEA Induces vasorelaxation that Is less efficacious than seen in 
animal models. Furthermore, the efficacy of AEA Is considerably less 
than 2-AG (Chapter 3). AEA-Induced vasorelaxation occurs through 
previously shown pathways, but does not activate TRPV1 channels. The 
reduced effects of AEA may be a result of lack of TRPV1 activity. 
AEA-induced vasorelaxatlon Is reduced in patients with IHD, increased 
148 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
8MI and those taking beta-blocker or NSAID medication. Taken 
together, this study suggests that AEA may act as regulator of vascular 
tone through known receptors and a potentially unknown 
uncharacterised receptor in human mesenteric arteries. Furthermore, 
the effects of AEA may be reduced in patients with cardiovascular 
disease or taking medication for cardiovascular disease. 
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6. GENERAL DISCUSSION 
Cannabinoids have been shown to cause vasorelaxation of a variety of 
animal vascular beds in a range of species (reviewed in Chapter 1). The 
extent of vasorelaxation and the mechanisms utilised often depend on 
the species, vascular bed or cannabinoid ligand studied. However, the 
effects of cannabinolds in the vasculature of humans have not been 
fully Investigated. To date there has been only four papers published 
that have investigated the vascular effects of cannabinoids in human 
arteries. These papers have looked at a limited range of cannabinoid 
ligands In vascular beds that have not been commonly tested in 
animals. Therefore, to fully understand the role or potential therapeutic 
role of cannabinolds or the endocannabinoid system in the modulation 
of vascular tone it is important more human work is carried out. The 
aim of this thesis was to assess the vascular effects of a range of 
cannabinoid ligands in human mesenteric arteries. Given that the 
mesenteric vascular bed is the most widely tested in previous 
cannablnoid studies, human work in this vascular bed enables 
comparisons to be made more easily between human and animal 
studies. Once initial screening studies were carried out, a second aim of 
this thesis was to Investigate the mechanisms of action of the most 
interesting cannabinoid ligands. A third aim of this thesis was to 
investigate the potential ability of cannabinoids to cause 
time-dependent PPARy mediated vasorelaxation of human mesenteric 
arteries. A final aim of this thesis was to investigate the often seen 
variability of cannablnoid responses between patients. 
6.1. Interpretation of Findings 
6.1.1. Cannabinold Screening Experiments 
Initial screening experiments probed six cannabinoid ligands in their 
potential vascular effects. The cannabinoid ligands chosen were 
CP55,940, HU308, AEA, 2-AG, ~ 9 - T H C C and CBO. All these ligands with 
the exceptions of CBO and HU308 have been shown to cause 
well-characterised vasorelaxation in animal arteries. Screening 
experiments revealed that the most efficacious cannabinoid tested was 
the highly potent, highly efficacious CBdCB2 receptor agonist 
CP55,940. However the CB2 specific agonist, HU308, was unable to 
cause vasorelaxation. This finding may suggest that in human arteries 
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there is a role for the CB1 receptor but not the CB2 receptor in causing 
vasorelaxation. It is also suggestive that any such role for the CB1 
receptor may be modest, as CP55,940 caused ::::50% reduction in 
pre-imposed tone. Although this study did not probe the mechanisms 
of action of CP55,940 further support to the speculation for a modest 
role of the CB1 receptor can be found in Chapter 5 of this thesis 
whereby the effects of AEA, a partial agonist at the CB1 receptor, were 
in part inhibited by antagonism of the CB t receptor. However, 
confirmation of this theory would be found in further experiments 
carrying out CP55,940 concentration response curves in the presence 
of a CB t antagonist. Other work could then use other cannabinoid 
ligands with high CB1 efficacy such as HU210 to see if a similar level of 
vasorelaxation was observed to that of CP55,940. 
Screening experiments also revealed that 2-AG was the most 
efficacious endocannabinoid tested. This finding, in human mesenteric 
arteries, contrasts findings in rat mesenteric arteries where both AEA 
and 2-AG cause maximal vasorelaxation (Ho and Randa" 2007). 
Therefore the finding that 2-AG causes greater vasorelaxation than that 
of AEA may be a finding that is specific to the human mesenteric 
vascular bed, and may suggest that in this vascular bed 2-AG has the 
ability to regulate vascular tone more than that of AEA. Indeed, In 
human plasma samples from healthy patients 2-AG concentrations are 
found to be higher than that of AEA (Quercioli et al., 2011), suggesting 
that 2-AG is more readily produced than AEA. However the previous 
study also' reported that increased endocannabinoid levels seen in 
obesity were associated with decreased coronary blood flow (Quercioli 
et al., 2011). Therefore, to fully understand the role endocannabinoids 
might play in vascular tone, further studies should address a range of 
vascular beds and should take arteries from a greater number of 
patients with and without vascular disease or disease risk factors. Such 
a study should measure patient plasma and vascular tissue 
endocannabinoid levels along with the effects of each endocannabinoid 
in a range of vascular tissues. Such a study should also Investigate 
how specific diseases affected the plasma and tissue endocannabinoid 
levels along with vascular responses to endocannabinoids. This would 
aid in developing a broader picture of any potential roles for 
endocannabinoids in the modulation of vascular tone under both 
healthy and diseased conditions. 
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Screening experiments into the effects of two phytocannabinoids 
(CBO and ~ 9 I H C ) ) showed that CBO (a cannabinoid previously 
uncharacterised in any vascular bed) caused significantly greater 
vasorelaxation than that of ~ 9 I H C . . In third order mesenteric arteries 
THC causes half maximal vasorelaxation (O'Sullivan et al., 2005), 
whilst In rat mesenteric arteries CBO causes maximal vasorelaxation 
(Offertaler et al., 2003). Therefore the finding that In humans CBO has 
a greater maximal effect than ~ 9 I H C C is In keeping with findings in rat 
mesenteric arteries. However, the maximal effects of each compound in 
human mesenteric arteries are lower than those observed in the rat 
mesenteric arteries. 
The main finding of the screening study reported in Chapter 3 
was that cannabinoids cause vasorelaxation of human mesenteric 
arteries. However, striking differences were observed in the maximal 
effects of cannabinoid ligands used in this study. The differences 
observed might be associated with the patients that these arteries were 
taken from, as many of the patients used in this study were advanced 
in age and presented with several diseases that have a direct impact on 
vascular function. Although vasorelaxation was validated in this study 
using bradykinin, this particular vasorelaxant has been shown to be 
more resistant than other vasorelaxants to vascular decline associated 
with age or disease (Hatake et al., 1990; DeSouza et al., 2002; Van 
Guilder et al., 2006; MacKenzie et al., 2008). Indeed, it has been 
shown that bradykinin produces vasorelaxation of over 70% in older 
adults and adults with cardiovascular risk factors (Angulo et al., 2012). 
These findings may suggest that the efficacy of cannabinoid-induced 
vasorelaxatlon Is more susceptible to vascular decline than that of 
bradykinin. This might explain why It was often seen that cannabinoid 
responses might be reduced with responses to bradykinin were 
unaltered. A further explanation for reduced cannabinoid responses 
could be accredited to the contractile agent used in this study. In the 
rat mesenteric vasculature methoxamine is often the contractile agent 
used (Randall et al., 1997; White and Hiley 1998; O'Sullivan et al., 
2004), whilst the present study used U46619. At mid mlcromolar 
concentrations (often used in rat mesenteric studies) methoxamine has 
relatively few off target effects with, to the best of my knowledge, only 
one paper showing off target actions of methoxamine and that was 
inhibition of KArp channels (Haruna et al., 2002). However, at similar 
152 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
concentrations to those used in this study, U46619 through activation 
of the TP receptor, has been shown to inhibit BKca and Kv channels 
(Cogolludo et al., 2003; Li et al., 2010). Therefore, the choice of 
contractile agent may have Influenced the magnitude of 
cannabinoid-induced vasorelaxation in this study. 
In summary, with the exception of the CB2 specific ligand, all 
cannabinoids tested caused vasorelaxation of human mesenteric 
arteries. However, the maximal effect of cannabinoid-induced 
vasorelaxation is often less than reported in rat mesenteric arteries. 
The reduced maximal effect of cannabinoids in humans may be 
attributed to the patient population from which samples were taken, 
differences in the methodology, or may simply be attributed to species 
differences. Finally, although cannabinoid responses in human 
mesenteric arteries were modest this should not rule out targeting the 
endocannabinoid system as a potential therapeutic target in the 
modulation of vascular tone in health and disease. Given that, the 
regulation of vascular tone is often multifactorial, the endocannabinoid 
system in this should not be overlooked. 
6.1.2. Cannabinoid Mechanisms of Action 
The first cannabinoid to be probed for mechanisms of action was the 
endocannabinoid 2-AG (Chapter 3). These experiments revealed that 
2-AG Induced-vasorelaxation was distinct from the effects of 2-AG in 
rat mesenteric arteries. The distinction being that 2-AG-lnduced 
vasorelaxation, in rat mesenteric arteries, is limited by metabolism (Ho 
and Randall 2007). However, in humans, similar to bovine coronary 
arteries (Gauthier et al., 2005), metabolism mediates 2-AG-induced 
vasorelaxation. Gauthier et al. (2005) report that 2-AG-lnduced 
vasorelaxation is dependent on MAGL and FAAH hydrolysis of 2-AG to 
arachidonic acid and then subsequent metabolism by COX. In human 
mesenteric arteries the MAGL and FAAH inhibitors JZL184 and URB597 
had no effect on 2-AG-induced vasorelaxation. This suggests that 2-AG 
was directly metabolised by COX. Further experiments to find the 
particular COX Isoform Involved in 2-AG-lnduced vasorelaxation 
revealed that the COX-2 specific inhibitor nimesulide had no effect on 
vasorelaxation, whereas the COX-1 favourable inhibitor flurbiprofen 
reduced 2-AG-induced vasorelaxation. This finding is in contention with 
research showing COX-1 and COX-2 binding affinities for 2-AG (Kozak 
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et al., 2001). Work suggests that COX-1 lacks 2-AG affinity due to the 
amino acids present in residue 513 of the side pocket-binding region. 
In this residue COX-1 has a histidine amino acid whereas COX-2 has an 
arginine. Mutations in Arg-S13 significantly reduce COX-2 affinity for 
2-AG (Kozak et al., 2001). Given that Kozak et al. (2001) use human 
COX-1 and COX-2 in their work, it is likely that there are potential 
issues in the pharmacology of the cox inhibitors used in Chapter 3. For 
Instance, It has been shown that the main amino acid residue Involved 
in the specific binding of COX-2 inhibitors Is that of valine 523, and that 
some COX-2 inhibitors, depending on chemical structure, do not bind to 
Arg-513 (DeWitt 1999). Further work should look at the effects of a 
range of COX-2 inhibitors on the effects of 2-AG-induced 
vasorelaxation. Such studies would be of therapeutic interest in that 
they might allow 2-AG access to Its site of metabolism on COX-2 that 
may elicit vasorelaxation, yet also reduce the detrimental effects of 
COX-2 metabolism of arachidonic acid. A further finding of interest was 
that 2-AG-induced vasorelaxatlon was enhanced in the presence of 
AH6809 (an antagonist at both contractile and vasorelaxant prostanoid 
receptors). This may suggest that 2-AG metabolism produces both 
vasorelaxant and vasoconstrictor prostanoids, which may also provide a 
potential therapeutic pathway, in that antagonism of vasoconstrictor 
prostanoid receptors may enhance vasorelaxation not only to 
endocannabinoids but also to arachidonic acid metabolites. 
In Chapter 5 this thesis explored the effects of metabolism on 
AEA-Induced vasorelaxation. Previous studies in the rat mesenteric 
artery showed that the effects of both 2-AG and AEA were limited by 
their metabolism (Ho and Randall 2007). However, Chapter 5 revealed 
that Inhibition of FAAH or COX had no effect on AEA-Induced 
vasorelaxation. Further work to explore the mechanisms of 
AEA-Induced vasorelaxation revealed that AEA-induced vasorelaxatlon 
was Inhibited by CB l and CBe receptor antagonism. Given that AEA is a 
partial agonist at the CB l receptor this may add strength to the 
previous argument concerning the speculation to the modest role the 
CB l receptor may play In the regulation of vascular tone. Interestingly, 
similar to vasorelaxation In the rat kidney (Deutsch et al., 1997) and 
rabbit aortic ring (Mukhopadhyay et al., 2002), AEA-Induced 
vasorelaxation could be inhibited by antagonism of CBt/CBe 
(Gllo-coupled) receptors and was also dependent on nitric oxide. 
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Suggesting a potential link between these receptors and the production 
of nitric oxide. Indeed, later work has gone on to show that the 
metabolically stable synthetic analogue of AEA, methanandamide, 
stimulates nitric oxide production in endothelial cells through 
Gi/o-coupled receptor activation of the phosphatidylinositide 3-kinase 
protein kinase B pathway (McCollum et al., 2007). Further support for 
the potential role of the CB l receptor signalling to release nitric oxide in 
the human mesenteric arteries came in Chapter 4 whereby 
CBO-induced vasorelaxation could be inhibited using AM2S1, LY32013S 
and L-NAME. Given that both AEA and CBO implicate a role for the CB l 
receptor and that both ligands are also inhibited by L-NAME this offers 
a strong suggestion of the presence of a CB l receptor in human 
mesenteriC arteries and that this receptor may be coupled to nitric 
oxide release. Therefore, although the vasorelaxatlon through this 
receptor appears modest, this makes the CB l receptor a potential 
therapeutic target of interest given that both these ligands are weak or 
partial agonists at this receptor. Future studies should investigate the 
effects of cannabinoids with increased efficacy at this receptor such as 
CPSS,940 and HU210. However, it should be noted that such a 
therapeutic strategy might have complicated risks. The CB l receptor is 
expressed widely throughout the cardiovascular system, therefore 
administration of a highly potent, highly efficacious agonist at such a 
receptor may have detrimental effects. For example, CB l antagonism in 
the cardiovascular system has been shown to reduce myocardial 
apoptosis (Mukhopadhyay et al., 2007), reduce atherosclerotic lesions 
(Sugamura et al., 2010) and reduce cell death of human coronary 
artery endothelial cells (Rajesh et al., 2010). Therefore if such a 
therapeutic tool were going to be used, careful consideration would 
need to be paid to several factors Including, but not limiting, to the 
dose, the route of administration and the circumstances leading to 
administration. 
Studies probing the effects of AEA also highlighted the 
involvement of the putative CBe receptor. The involvement of this 
receptor has previously been implicated in other human arteries. In the 
human pulmonary artery virodhamine and Abn-CBO both cause 
maximal vasorelaxation that is reduced in the presence of the CBe 
antagonist 0-1918 (Kozlowska et al., 2007; Kozlowska et al., 2008). 
However, there is much still unknown about this receptor and its 
155 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
identification and full characterisation would need to be carried out 
before considering it therapeutically. The most recent speculation as to 
the Identity of the CBe receptor comes from the Bradshaw laboratory, 
whereby it has been shown that the novel GPR18 receptor shares a 
similar pharmacological profile as the CBe receptor (McHugh et al., 
2012). The isolation and complete characterisation of the CBe receptor 
may offer a potentially exciting and therapeutic target in the 
vasculature given its known vasorelaxant effects with, as yet, no known 
detrimental effects. 
A finding of particular Interest was the finding that AEA-induced 
vasorelaxation was unaffected by desensitisation of the TRPVl receptor 
using capsaicin. Confirmation of a role for this receptor was shown in 
Chapter 4 whereby CBD-induced vasorelaxation was inhibited by 1 hour 
pre-treatment with capsaicin. Therefore, the lack of role for TRPV1 in 
AEA-induced vasorelaxation appears to be specific to AEA, and could 
account for the reduced efficacy seen to AEA in human mesenteric 
arteries. O'Sullivan et al. (2004) reported that, in rat third order 
mesenteric arteries, desensitisation of the TRPVl receptor reduced the 
maximal effect of AEA from 100% reduction in pre-Imposed tone to 
50% reduction in pre-Imposed tone. The lack of a TRPV1-mediated role 
In AEA-Induced vasorelaxation might be specific to humans. Indeed, 
AEA activation of the TRPVl receptor is reported to be dependent on 
the presence of an Intracellular transporter (De Petrocellis et al., 2001), 
the phosphorylation state of the TRPV1 receptor (De Petrocellis et al., 
2001) and the temperature at which the experiment is carried out 
(Sprague et al., 2001). Further studies could specifically probe the 
effects of AEA at the TRPV1 receptor by carrying out concentration 
response curves to capsaicin to firstly confirm the presence of the 
TRPV1 receptor. Then investigations Into AEA-TRPVl interactions could 
look at the effects of temperature, receptor phosphorylation state and 
voltage state. This could be done using myography and altering 
parameters such as temperature settings and buffer solutions. 
Investigations Into the role of an intracellular transport protein In the 
transportation of AEA is an issue of contention, however It has been 
suggested recently that fatty acid binding proteins and heat shock 
proteins may act as such transporters and allow AEA uptake (reviewed 
In Fowler 2012). Experiments to probe the effects of fatty acid binding 
proteins and heat shock proteins in humans would be difficult. 
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However, human mesenteric arteries could be assessed for content of 
fatty acid binding proteins (FABP5 and FABP7) and heat shock protein 
(Hsp70), all of which have been shown to increase AEA uptake in cell 
culture (reviewed in Fowler 2012). Such studies may have revealed 
reduced levels of these proteins in this tissue and therefore may 
explain the lack of TRPV1 involvement in AEA-induced vasorelaxation. 
Pharmacologically targeting TRPV1 sensitivity to AEA activation may 
prove a useful therapeutic as it would enhance the effects of AEA, 
whilst avoiding any potential detrimental effects of increased levels of 
AEA. 
A third aim of this study was to assess the potential for 
cannabinoids to cause time-dependent PPARy-induced vasorelaxation. 
This novel mechanism of cannabinoid-induced vasorelaxation was 
shown using 6 9-THC in the rat aorta (O'Sullivan et al., 2005), since this 
paper it has been shown that CBD, AEA and NADA all cause 
vasorelaxation through PPARy activation (O'Sullivan et al., 2009; 
O'Sullivan et al., 2009). Although these effects are not just limited to 
the aorta they have been shown to be present in conduit arteries as 
opposed to resistance arteries (O'Sullivan et al., 2006). Therefore 
experiments were undertaken in the largest human arteries available to 
see if these effects were present in human mesenteric arteries. These 
experiments revealed that although CBD and AEA did cause 
vasorelaxation that significantly Increased over a two-hour period, it 
could not be antagonised using an antagonist of the PPARy receptor. 
Whilst there is the possibility that this time-dependent vasorelaxation 
may have occurred via a different PPAR receptor isoform, such as 
PPARa (Romano and Lograno 2012), time-dependent vasorelaxation 
may have occurred through an already identified pathway. For 
example, CBl receptor stimulation with highly potent, highly efficacious 
ligands leads to rapid internalisation of the receptor often within 
20 minutes and at picomolar concentrations (HSieh et al., 1999; 
Grimsey et al., 2010). However, when stimulated with less efficacious 
agonists such as 6 9-THC and methanandamide have been shown to still 
have receptors present and signalling on cell surface membranes after 
half an hour (Hsieh et al., 1999). Suggesting that receptor 
internalisation is dependent on maximal or near maximal receptor 
activation. Therefore given that AEA and CBD are both partial/weak 
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agonists at the CB 1 receptor this may stop the CB 1 receptor 
internalising and may allow for a continued vasorelaxation. 
In summary cannabinoid-induced vasorelaxation occurs through 
both receptor and metabolism mediated pathways (see Figure 6.1). 
With AEA sharing similar vasorelaxation pathways to that of the 
phytocannabinoid CBD, potentially due to it being a more stable 
compound than 2-AG. This thesis has shown some differences in the 
mechanisms of cannabinoid-induced vasorelaxation, with these 
differences potentially explaining the reduced efficacy to AEA. However, 
the main finding of these studies is that the endocannabinoid system 
through receptor activation and metabolism is capable of causing 
vasorelaxation in human mesenteric arteries. 
AEA 
~ I I - - - -
CBD 
............. ... 
2-AG 
c 
Figure 6.1 Schematic representation of cannabinoid-induced 
vasorelaxation in human mesenteric arteries 
6.1.3. Bearing of Patient Characteristics on Cannabinoid Responses 
Cannabinoid responses showed varied degrees of vasorelaxation at the 
highest cannabinoid concentration used. 2-AG responses ranged from 
0-103% reduction in pre-imposed tone (Chapter 3), CSD responses 
ranged from 22-75% reduction in pre-imposed tone (Chapter 4) and 
AEA responses ranged from -4.8-83.1 % reduction in pre-imposed tone 
(Chapter 5). In an attempt to understand some of the potential 
differences in these responses post-hoc analysis of patient medical 
notes were performed. Patient medical notes were assessed for 
cardiovascular disease or cardiovascular disease risk factors, a 
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summary of these findings can be seen in table 6.1. The most common 
reduction in response was in patients taking NSAIO medication with 
2-AG, AEA and CBO (Chapters 3, 4 and 5) all being reduced. In the 
studies conducted in this thesis, NSAIDs were the most commonly 
prescribed drug with a third of patients taking NSAIDs for a range of 
cardiovascular diseases or cardiovascular disease risk factors. 
Therefore, the reduced responses observed could be on account of the 
variety of underlying diseases that the NSAIDs were used to treat. 
However, NSAIDs have been shown to affect levels of PGI2 (McGettigan 
and Henry 2011) and affect binding at the CB1 receptor (Staniaszek et 
al., 2010) which are two major pathways of cannabinoid-induced 
vasorelaxation in human mesenteric arteries. The finding that 
ischaemic heart disease reduced responses only to the 
endocannabinoids tested in this theSiS, is a finding of interest given 
that 2-AG and AEA did not share common vasorelaxation pathways 
(Chapter 3 and 5). However, recent reports have suggested that raised 
endocannabinoid levels are associated with coronary dysfunction in 
obesity (Quercioli et al., 2011). Given the findings shown in this thesis 
it is possible to suggest that the raised endocannabinoids seen by 
Quercioli et al. (2011) might be caused by loss of endocannabinoid 
sensitivity in the vasculature. However it is also likely that high 
circulating levels of endocannabinoids desensitise the vascular 
responses to endocannabinoids. Hypercholesterolaemia and type two 
diabetes caused reductions in cannabinoid sensitivity to both 2-AG and 
CBO (Chapters 3 and 4). The possible reasons for these reduced 
responses may lay in the altered prostaglandin functions and 
endothelial dysfunction associated with these disease states (Vanhoutte 
et al., 2009). However, it is of interest that the responses to AEA were 
not inhibited in such patients (Chapter 5). In hypertensive models the 
vasorelaxant effects of cannabinoids can be enhanced (see introduction 
section), however this thesis has shown that responses to 2-AG 
(Chapter 3) and AEA (Chapter 5) were unaltered, yet responses to CBO 
(Chapter 4) were reduced in hypertension. Given that the TRPV1 
receptor mediated vasorelaxation to CBO but not 2-AG and AEA, and 
that TRPV1 receptor expression is reduced in models of hypertension 
(Wang and Wang 2006), this might explain the exclusivity of this 
finding. 
159 
AN INVESTIGATION INTO THE PHARMACOLOGICAL EFFECTS OF 
PHYTOCANNABINOIDS AND ENDOCANNABINOIDS IN HUMAN MESENTERIC 
ARTERIES 
Although cannabinoid responses were often significantly reduced 
in patients with cardiovascular disease, cardiovascular disease risk 
factors or In patients taking various medications, some of these 
findings might have little biological relevance. Indeed, Thompson 
(2002) argues that statistical significance (P<O.OS) does not relate to 
biological significance, as studies are able to manipulate statistical 
significance to make small effects significant given a large enough 
sample size. Therefore, to test biological significance, effect sizes must 
be reported (tables 6.2, 6.3 and 6.4). In assessing the effect size the 
s.e.m should be viewed more critically, and it is suggested that 
biological significance would not occur unless the mean of one variable 
was at least several orders of s.e.m different to the mean of the other 
variable (Thompson 2002). Given this argument, if the data in tables 
6.2, 6.3 and 6.4 were assessed to have biological significance providing 
that there was greater than two s.e.m between each mean value, there 
would be no significant differences in cannabinoid potency. However, it 
would be expected that there was biologically relevant reductions In 
vasorelaxation to the maximal effects of 2-AG and AEA in patients with 
heart disease and patients taking NSAID medication (2-AG responses 
would also be reduced in patients taking hypoglycaemic and statin 
medication). Furthermore, CaD responses would only be reduced in 
those with diabetes or on diabetic medication. 
In summary the interpretation of the effects of patient disease 
state on cannabinoid responses should be carried out with caution. 
There is a clear distinction between statistical significance and 
biological significance. However, the finding that cannabinoid responses 
are often extremely variable In humans deserves greater attention. 
Understanding these variances and the endocannabinoid system in 
health and disease might provide future therapeutic strategies. Further 
studies should look at the vascular· effects of endocannabinoids in 
healthy and diseased patients, but they should have strict inclusion and 
exclusion criteria to limit the potential confounding factors such as 
multiple diseases or multiple medication. Also, such studies should 
approach reporting findings with caution and pay considerable attention 
to statistical tests used In reporting findings. 
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Table 6.1 The effects of patient disease state on vasorelaxant 
responses to 2-AG, CBD and AEA in human mesenteric arteries 
Table 6.2 Patient disease states in 2-AG study, alterations in pECso and 
Rmax values. Data given as mean ± s.e.m with n equal to the number of 
patients 
Patient c:haraderlstle Effeds 01"1 2 ~ ~ ( l ~ l n d l j e e d d vasorelaxiiltlon 
P resenting Absence of 
characteristic cha racteristic 
mean ± s.e.m n mean ± s.e.m 
pECso S.1±O.2 9 S.6±O.1 Heart disease Rmax 49.7±3.9 76.3±3.3 
Hypercholesterolaemia pECso S.4±O.2 16 S.6±O.1 
Rmax 65.4±S.O 7S.S±3.8 
Type-2 diabetes pECso S.4±O.3 10 S.S±O.1 
Rmax 58±7.1 76.3±3.0 
Hypertensive pECso 
5.5±O.2 16 S.5±0.1 
Rmax 65±4.1 73±4.1 
BMI ~ 2 5 k g / m 2 2 pECso 5.4±0.2 13 5.6±0.1 
Rmax 72.5±5.9 70.1±3.7 
161 
n 
32 
25 
31 
25 
28 
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Smoker ~ E C s o o s.2±0.2 11 s.6±0.1 
Rmax 78.0±6.3 68.8±3.S 
NSAID ~ E C s o o S.2±0.2 14 s.6±0.1 
Rmax s1.1±s.0 81.1±3.1 
Statin pECso s.3±0.2 16 s.6±0.1 
Rmax s7.6±s.0 77.4±3.3 
Hypoglycaemic pECso s.1±0.3 6 s.s±O.l 
Rmax 43.2±s.8 74.8±3.0 
Beta blocker pECso s.3±0.2 8 s.6±0.1 
Rmax 6s.1±4.8 69.9±3.s 
ACE Inhibitor pECso s.s±0.3 6 s.s±O.l 
Rmax 6s.4±6.8 70.7±3.3 
Table 6.3 Patient disease states In CBD study, alterations In pECso and 
Rmax values. Data given as mean ± s.e.m with n equal to the number of 
patients 
Heart disease 
Hypercholesterolaemla 15 
Type-2 diabetes 10 
Hypertensive 
BMI ~ 2 s k g / m 2 2 24 
Smoker 
NSAID 
Stat!n 14 
Hypoglycaemlc 
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Beta blocker pECso s.4±0.3 6 s.s±O.l 
Rmax 35.3 ±S.O 4s.0±2.0 
ACE inhibitor DECso s.s±0.3 7 s.S±O.l 
Rmax 40.0±s.0 44.2±2.0 
Table 6.4 Patient disease states in AEA study, alterations in pECso and 
Rmax values. Data given as mean ± s.e.m with n equal to the number of 
patients 
Patient characteristic Effects on AEA"lnduced vasot·elaxatlon 
Presenting Absence of 
cha racteristic characteristic 
mean ± s.e.m n mean ± s.e.m 
Heart disease DECso 6.0±0.S 6 S.9±0.2 
Rmax 24.3±3.1 3s.7±2.0 
Hypercholesterolaem ia DECso 6.0±0.3 14 S.9±0.2 
Rmax 3S.7±2.8 30.8±2.1 
Type-2 diabetes DECso S.9±0.4 8 S.9±0.2 
Rmax 38.1±4.S 31.3±1.7 
Hypertensive pECso s.9±0.3 16 S.9±0.3 Rmax 34.0±2.6 32.2±2.4 
BMI ~ 2 s k g / m 2 2 DECso S.9±0.2 19 6.0±0.2 
Rmax 30.6±2.3 38.9±2.S 
DECso 6.1±0.4 6 s.9±0.2 Smoker Rmax 27.1±2.4 34.9±2.2 
pECso 6.2±0.4 13 s.7±0.2 NSAID Rmax 27.S±2.8 38.9±2.1 
DEeso 6.0±0.3 lS s.9±0.3 Statin Rmax 3S.2±2.7 31.1±2.3 
DECso S.S±O.4 S 6.0±0.2 Hypoglycaemic Rmax 30.8±4.7 33.9±1.9 
Beta blocker DECso 
6.1±0.4 5 S.9±0.2 
Rmax 2S.2 ±3.1 3S.1±2.1 
ACE inhibitor DECso 
S.9±0.3 7 S.9±0.2 
Rmax 31.7±3.1 34.6±2.1 
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6.2. Limitations and future work 
The focus of this study was to investigate the pharmacological effects 
of cannabinoids in human mesenteric arteries. To do this, this study 
utilised mesenteric arteries from patients undergoing colorectal surgery 
for colorectal cancer or inflammatory bowel disorders. Arteries were 
then probed pharmacologically whilst mounted on a wire myograph. 
One of the major limitations of this study was the single 
technique used to carry out investigations. Wire myography is often 
used to characterise vascular function and pharmacological responses, 
and is an extremely useful tool in that many compounds can be 
screened concurrently. However, wire myography does not exactly 
replicate physiology. In studies comparing both wire and pressure 
myography it has been shown that arteries mounted on a wire 
myograph often have decreased sensitivity to exogenously applied 
vasoconstrictors (Buus et al., 1994; Dunn et al., 1994; Falloon et al., 
1995), and decreased sensitivity to vasorelaxant agents (Lu and 
Kassab 2011). Whilst morphological changes in endothelial cells and 
smooth muscle cells were suggested to be minor (Falloon et al., 1995), 
wires used In wire myography are associated with a small amount of 
endothelial injury (Dunn et al., 1994). These alterations in sensitivity to 
pharmacological agents may be associated with arterial damage caused 
when using wire myography, or may be due to the comparative lack of 
physiological relevance of wire myography compared to pressure 
myography. To date only one study has looked at the effects of 
cannabinoids using pressure myography. Kenny et al. (2005) report 
that, in human myometrial arteries, AEA was unable to cause 
vasorelaxation. Given that the effects of cannabinoids have not 
previously been reported In myometrial arteries it is hard to draw any 
meaningful comparative conclusion from this study. However, to take 
cannabinoid-induced vasorelaxation research a step closer to the 
physiological setting, future research should investigate the effects of 
cannabinoids in perfused arteries. 
A further limitation of wire myography is that it relies on the use 
of pharmacological antagonists and inhibitors, many of which have 
actions that are beyond their target receptor or enzyme (Pertwee 
2005; Fowler 2007). Although controls for this activity were put In 
place by using different analogues to inhibit the same target site and 
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by using concentrations that avoid off target actions, this thesis has 
shown several novel findings that need to be further substantiated 
using molecular pharmacological techniques or immunochemical 
techniques. In Chapter 3, the finding that 2-AG appears to be 
metabolised by COX-1 with subsequent prostanoid receptor activity 
could be further probed. Firstly ELISA techniques could be used to 
measure COX activity in explanted human mesenteric artery 
endothelial and smooth muscle cells after exposure to 2-AG. Using 
similar explanted cells and ELISA technique it would also be possible to 
assess prostanoid production. Given rapid hydrolysis of prostaglandin 
glycerol esters, assessment of their formation may prove difficult. 
However, other studies have incubated 2-AG with cell lines and 
characterised prostaglandin glycerol ester production using mass 
spectrometry. Therefore arterial cells could be explanted and incubated 
with 2-AG and be assessed in the same way. Alternately it is now 
possible to purchase synthetic, stable, glycerol esters that could be 
used in conjunction with a wire myograph to assess their potential 
vasorelaxant effects in human arteries. 
Chapter 4 of this thesis describes CBD induced vasorelaxation 
through CB l dependent pathways. Given that binding and activation of 
CB l by CBD is controversial, expression of CB l receptors using RT-PCR 
and radioligand binding of CBD to CB l receptors in explanted 
endothelial or smooth muscle cells would have added strength to this 
argument. CSD was also inhibited by capsaicin pre-treatment. Whilst 
CBD has previously been shown to activate TRPV1 channels in other 
studies, the present study could have confirmed this In human smooth 
muscle or endothelial cells using patch clamp techniques similar to 
those of Zygmunt et al. (1999). 
Chapter 5 showed that the effects of AEA are not mediated by 
the TRPV1 receptor. Therefore, despite the findings of CBD, carrying 
out concentration-response curves to capsaicin would aid in showing 
the functional role of this receptor in human mesenteric arteries. Also, 
investigations into optimal conditions for AEA-Induced activation of the 
TRPV1 receptor as outlined In section 6.1.2 would aid in understanding 
the physiological relevance of AEA's interactions with TRPV1 or lack 
thereof in the human mesenteric arteries. 
Both 2-AG and CBD-induced vasorelaxation was dependent on 
potassium-mediated hyperpolarisation (thiS mechanism was not probed 
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in AEA-induced vasorelaxation). Further characterisation of this could 
be achieved using explanted smooth muscle or endothelial cells in 
conjunction with patch clamp techniques or pharmacologically using a 
range of potassium channel blockers including iberlotoxin, apamin, 
TRAM 34 and glibenclamide. By doing this it could first be shown what 
channels were activated and secondly, if the activation was caused 
directly or via receptor/metabolism mediated pathways. 
Finally, the studies conducted In this thesis found that the 
cannabinoids CBD (chapter 4) and AEA (chapter 5) caused 
time-dependent vasorelaxation of human mesenteric arteries. 
However, this effect could not be inhibited using a PPARy antagonist. 
The potential reason for this lack of responses could be that the 
arteries used in this study were not big enough. To further probe this 
finding similar experiments using a known PPARy agonist such as 
pioglitazone could be carried out in the presence or absence of a PPARy 
antagonist. This would clarify the potential role for PPARy in human 
mesenteric arteries. However, as discussed in section 6.1.2, it might be 
that CBD and AEA exerted time dependent vasorelaxation through 
stimulation of the CBl receptor. To probe this similar methods as those 
used In Grimsey et al. (2010) could be used. In brief the previous study 
labelled CBl receptors In CBl receptor expressing cells and stimulated 
the receptor with a range of compounds until the receptor could no 
longer be seen on the cell membrane, membranes were then assessed 
to see if CBl receptors were recycled. Carrying out such an experiment 
would offer inSight Into cannabinoid receptor stability and signalling in 
the vasculature. 
The Influence of patient characteristics may have had significant 
affects on the findings of this thesis. The acquisition of mesenteric 
arteries from patients without prior ill health and lower age would have 
been preferable, however choice was limited by availability. In future 
studies, peripheral arteries could be sought from healthy patients 
undergoing surgery for procedures such as hernia repair, open muscle 
biopsies, caesarean sections and breast reconstructive surgery. These 
studies would be able to fully probe the effects of a range of 
cannabinoids in otherwise healthy patients. In such studies it would 
also be of benefit to assess the levels of endocannabinoids and receptor 
expression, this would therefore enhance the understanding of 
physiological expression and function of the endocannablnoid system. 
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The studies carried out in this thesis have shown that the effects 
of cannabinoids might be reduced in patients with cardiovascular 
disease or cardiovascular disease risk factors. Therefore, to fully 
understand the effect these conditions have on cannabinoid-induced 
vasorelaxation future work should specifically address individual 
disease states, which could be done in different ways. One way would 
be to take arteries from patients having surgery that was not directed 
at curing or treating an underlying disease such as previously detailed. 
Given that some of these patients will naturally have cardiovascular 
disease or cardiovascular disease risk factors, and other patients will be 
apparently healthy direct comparisons can be made between a range of 
cannabinoids and disease states. A further way to investigate the role 
of disease on the effects of cannabinoids would be to take samples 
from patients with a known disease risk factor such as barlatric 
patients. In these patients a common disease risk factor will be present 
however the extent of co-morbidities will differ. Therefore, correlations 
can be made between the impact of co-morbidities on selected 
cannabinoids and vascular function. In both these routes of 
investigation pharmacological characterisation of cannabinoid function 
could be carried out and there could also be characterisation of 
receptor expression, enzyme expression and endocannabinoid plasma 
or whole blood levels, which would further increase the understanding 
of the role of the endocannabinoid system In vascular disease. 
Finally cannabinoids are being Increasingly used as therapeutics 
and also studies suggest that some cannabinoids such as CBO can be 
tolerated well in humans (Bergamaschi et al., 2011). Therefore 
cardiovascular parameters could be monitored In patients currently 
taking cannabinoid-based medication to see if there was any favourable 
effect. Furthermore non-psychoactive cannabinoids could be 
administered either systemically or locally to see if cannabinoids cause 
vasorelaxation or hypotension in vivo In humans. Another potential 
therapeutic option would be the administration of FAAH inhibitors to 
patients. Such a treatment may increase the amount of free AEA, which 
could potentially have a systemic hypotensive effect. A final therapeutic 
strategy could also be to manipulate the metabolism of 2-AG. As 
Chapter 3 showed, antagonism of contractile prostaglandin receptors 
enhanced 2-AG vasorelaxation, therefore administration of contractile 
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prostanoid receptor antagonists to patients may enhance 2-AG induced 
vasorelaxation. 
6.3. Final conclusion 
The primary aim of this project was to screen and characterise the 
pharmacological effects of cannabinoids In human mesenteric arteries. 
A secondary aim of this study was then to characterise the effects of he 
most interesting cannabinoids seen in screening experiments. A third 
aim was to investigate the possibility of cannabinoids causing 
time-dependent PPARy-mediated vasorelaxation in human arteries. A 
final aim, based on the variability of cannabinoid responses in human 
mesenteric arteries, became the analysis of cannabinoid responses 
based on patient characteristics. This study shows for the first time that 
phytocannabinoids, synthetiC cannabinoids and endogenous 
cannabinoids cause vasorelaxation of human mesenteric arteries. This 
study also shows that differences exist between human mesenteric and 
animal arteries In the extent of cannabinoid-induced vasorelaxation and 
the pathways utilised. The vasorelaxation observed in this study was 
through the specific cannabinoid receptors (CB1, CBe,) endovanilloid 
receptor (TRPV1) and well-established vasomodulators (COX, NO, ion 
channel modulation). Therefore, it is likely that, in human mesenteric 
arteries, the endocannabinoid system plays a role in the modulation of 
vascular tone, which may be susceptible to decline In disease states. 
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